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Abstract 
Cancers exist within complex microenvironments formed by heterogeneous cell types. 
This diversity creates significant challenges for detection, diagnosis and treatment. 
Mass spectrometry-based proteomics is a powerful approach capable of 
characterizing complex biological systems which are characteristic of cancer biology. 
In this thesis, proteomics was utilized to answer several questions related to ovarian 
cancer diagnosis and detection, and the effects of NODAL, an embryonic morphogen, 
on the breast cancer secretome and stromal cell recruitment. First, I compared 
multiple sample preparation techniques and found high-pH/low-pH fractionation to 
yield the greatest proteome coverage over commonly used approaches. Second, I 
compared the proteomes from two ovarian cancer subtypes (high-grade serous and 
endometrioid) for which histological discrimination remains difficult in a proportion of 
cases. I documented several unknown proteins, including KIAA1324, which were 
validated and confirmed to improve the differential diagnosis of endometrial ovarian 
cancer. Third, I extensively characterized extracellular vesicle proteomes from 
biological fluids (conditioned media, plasma and ascites) to catalogue potential 
biomarkers associated with malignant ovarian cancer. I detected many factors 
associated with advanced stage, high-grade serous ovarian cancer including CFHR4, 
MUC1, APCS and PZP that may be useful for early detection. Last, I characterized 
the global effects of the Transforming Growth Factor-β superfamily member NODAL 
on the breast cancer secretome and stromal cell recruitment in vitro. I found a 
previously unknown role for NODAL in modulating pro-inflammatory factors, including 
CXCL1 and IL6 that were correlated with multipotent stromal cell recruitment. In 
summary, this work represents a significant contribution to the histological 
assessment and detection of ovarian cancer and our understanding of the malignant 
properties of NODAL within the breast cancer microenvironment. 
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Chapter 1  
1 Introduction 
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1.1 General introduction 
Cancer is a complex and heterogeneous group of diseases characterized by 
dysregulated cell growth, metastatic dissemination and the disruption of healthy 
tissue and organ function. The lifetime risk of developing cancer in the US is 38.4% 
with an average 5-year survival of 66.9% [1]. In Canada, this risk is even greater 
with 49% of males and 45% of females expected to develop cancer in their lifetime 
[2]. Cancer initiation and development is linked to genomic alterations incurred by 
normal cells during replication and exposure to environmental stresses. 
Prerequisites or “hallmarks” underlying malignant transformation include 
perturbations in carefully regulated cellular processes involving replicative 
immortality, Epithelial-Mesenchymal Transition (EMT), and sustained 
angiogenesis [3]. While these intrinsic alterations are critical for cancer initiation, 
extrinsic factors are similarly essential for tumour progression by mediating 
communication between cancerous and non-transformed host cells within the 
tumour microenvironment (TME) [4]. Characterizing the TME may lead to improved 
diagnostics and therapeutics, however this task is not trivial given the complexity. 
High resolution mass spectrometry (MS)-based proteomics is a powerful technique 
which can achieve quantitative information on thousands of proteins and provide 
insight into biological systems. In this thesis, I employed MS-based proteomics to 
improve the differential diagnosis of endometrioid and high grade serous ovarian 
cancer subtypes, to discover biomarkers for detecting high grade serous ovarian 
cancer in bio-fluids, and to characterize the role of NODAL in multipotent stromal 
cell (MSC) recruitment in breast cancer. 
1.2 Ovarian cancer  
Collectively, ovarian cancer (OC) is a broad and diverse group of diseases with 
disparate origins traced to sex organs of the female reproductive system [5]. In the 
United States (US), OC is the 5th most lethal female cancer and most lethal 
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gynecological disease. Although the lifetime risk of developing OC is low (1.27%), 
the 5-year survival is relatively poor (46.5%) [1]. Endometrial cancer (cancer of the 
uterine corpus), for comparison, is the most common gynecological cancer in the 
US with a lifetime risk developing of 2.86% but 5-year overall survival of 81.1% [1]. 
Cervical cancer, however, comprises the greatest disease burden worldwide 
(incidence and total deaths) of all gynecological cancers [6]. This is largely 
attributed to the limited resources of low- to middle-income countries for prevention 
and early detection that is routinely practiced in health care systems of developed 
regions. Unfortunately, regardless of region, there is currently an unmet need for 
better detection and treatment of OC globally.  
 Basic anatomy of the female reproductive system  
The female reproductive system is comprised of several internal and external sex 
organs which function in concert to regulate oocyte production, maturation and 
fertilization, and support embryonic (fetal) development [7]. The internal sex 
organs, located within the lower abdomen (intraperitoneal cavity), are comprised 
of two ovaries (left and right sides) connected to the uterus by separate fallopian 
tubes (Figure 1.1) [7]. The ovaries are surround by an epithelium and contain an 
inner mass made up of stromal cells and follicles [7]. Within each ovary, there are 
a finite number of follicles made up of a centrally located oocyte (egg) surrounded 
by cumulus cells, granulosa cells and an outer layer of theca cells [8]. 
Approximately once every month, until menopause, a mature follicle will rupture 
from the ovarian surface epithelium (OSE) and release (ovulate) an oocyte [7]. At 
the end of the fallopian tube, finger like projections (fimbriae) grasp the ovary and 
capture ovulated oocytes. Once captured, oocytes are transported to the uterus 
through the fallopian tube which is comprised of several cell types with specialized 
functions. The inner fallopian tube epithelium is lined with ciliated and secretory 
(glandular) cells which support egg transport and tubal fluid synthesis, respectively 
[5]. Stromal and contractile smooth muscle cells make up the inner region and 
outer layer of the fallopian tube, respectively. If an egg becomes fertilized (zygote) 
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during the journey through the fallopian tube over several days, it will implant into 
uterine wall (endometrium) and begin developing into a fetus [7]. The endometrium 
is a specialized organ comprised of epithelial cells, stromal cells and blood vessels 
and is part of the  maternal-fetal interface (placenta) which is critical for exchange 
of nutrients and waste to and from developing fetus [9]. While these organs are 
integral for reproduction, perturbations within various cells types can lead to the 
development of abnormal lesions and ovarian malignancies [5,7]. 
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Figure 1.1 Anatomy of female reproductive system 
The female sex organs are comprised of the ovaries (b), fallopian tubes (a) and 
uterus (c). Each organ contains specialized cell types which facilitate reproduction. 
(a and b) During ovulation, a follicle will rupture form the ovarian surface epithelium 
(OSE) and be captured by fimbrae connected to the fallopian tube. Ciliated and 
secretory epithelial cells lining the fallopian tube are important for egg 
transportation and fertilization. (c) If an egg becomes fertilized during this journey, 
the zygote will implant into the uterine wall or endometrium. EME endometrial 
epithelium, EMS endometrial stroma. Adapted by permission from RightsLink 
Permissions Springer Customer Service Centre GmbH: Springer Nature. Nature 
Reviews Cancer. The disparate origins of ovarian cancers: pathogenesis and 
prevention strategies, Anthony N. Karnezis, Kathleen R. Cho, C. Blake Gilks, 
Celeste Leigh Pearce, David G. Huntsman (2016) 1:65-74. 
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 Staging 
Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer and 
accounts for approximately 90% of all diagnoses in developed countries [16]. 
During ovarian cancer progression, tumours may spread to neighboring organs 
through direct contact or passively disseminate as single cells or spheroids via fluid 
known as ascites within the intraperitoneal cavity [10]. The intraperitoneal wall 
(peritoneum) and omentum are the most common sites affected by metastatic 
ovarian cancer followed by the colon, liver, and kidneys. In rare cases, ovarian 
cancer metastasizes to the lungs, brain, skin, spleen and lymph nodes [11].  
Staging is critical part of all cancer care and involves documenting the extent of 
cancer progression to better predict patient prognosis and guide treatment 
decisions [12]. For ovarian cancers, two systems are used for staging; the 
International Federation of Gynecology and Obstetrics (FIGO) and the American 
Joint Committee on Cancer (AJCC) Tumour Node Metastasis (TNM) [13]. The 
FIGO staging system is more widely adopted and recognized worldwide but shares 
a number of similarities with TNM staging.  
Individual components monitored by the TNM scoring system include tumour (T) 
size and spread, the presence of cancer cells in the lymph nodes (N), and 
metastasis (M) to distant organs. A cancer patient’s overall stage is comprised of 
the number and/or letter assigned to each TNM component. Higher TNM 
values/letters are associated with later stages and therefore greater disease 
burden. In patients with stage I ovarian cancer, tumours are confined to the 
ovary(ies) and/or fallopian tube(s). During stage II disease, tumour growth has 
spread or invaded into adjacent organs such as the bladder, uterus, colon and/or 
formed primary peritoneal cancer. At stage III, small cancer growths (<2cm) are 
present on the surface of organs beyond the pelvic region such as the spleen or 
liver and cancer cells may also be found in the lymph nodes. In patients with stage 
IV cancer, the last and most deadly stage, cancer cells can be detected in fluid 
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surrounding the lungs (pleural effusions) and/or tumours have formed in distant 
organs such as the liver, lungs, skin, brain, spleen, lymph nodes and in rare cases, 
bone [11]. Patients with early stage invasive EOC (I and II) have much better 
prognosis with 5-year overall survival rates ranging from 70-90% [14]. 
Unfortunately, most invasive EOCs are detected during later stages for which the 
5-year overall survival drops significantly (39-59% for stage III and 17% for stage 
IV). While lifetime risk of developing ovarian cancer is low, the risk of dying, in 
absolute terms, is quite high at 0.93% [1].  
 Subtypes 
In addition to staging, subtype classification based on morphological and molecular 
features is another important factor for diagnosing and treating cancer [15]. There 
are 5 major histotypes of invasive EOC and two histotypes of borderline disease 
(serous and mucinous) [17]. The 5 invasive EOC subtypes are high grade serous, 
low grade serous, endometrioid, clear cell and mucinous (Table 1.1) [18]. Up to 
30% of all EOC cases are diagnosed as endometrioid, clear cell or mucinous. 
These cancers are generally benign or slow growing with intermediate to 
favourable prognosis and are also referred to as type I tumours [15]. Unfortunately, 
the majority of patients (~70%) are diagnosed with high grade serous ovarian 
cancer (HGSC) or type II tumours which comprise the most aggressive and 
deadliest form(s) of EOC. Notably, mutations in TP53 are prevalent in 95% of 
HGSC given the central role in dictating cell cycle arrest and apoptosis [19–22]. 
Indeed, TP53 is the most frequently mutated gene in cancer. Diagnosis and 
subtype identification of tumour samples is initially determined by a pathologist 
however, in ~10% of cases, EOC may be misclassified due to similarities in 
histology [23]. Of note, this is particularly problematic when differentiating (high-
grade) endometrioid ovarian cancer (EC) from HGSC and low grade serous 
ovarian cancer (LGSC) from HSGC [23,24]. 
9 
 
 
 
 Pathogenesis 
In terms of pathogenesis, histopathological and genetic profiling has recently 
identified distinct precursor lesions for type I and type II tumours [15]. Until recently, 
EOC was predominately believed to arise through invagination and neoplastic 
transformation of ovarian surface epithelial (OSE) cells following repeated 
ovulation. However, the incessant-ovulation hypothesis is less favoured with new 
evidence tracing the origins of EOC to the fallopian tube and endometrial 
epithelium [5]. Indeed, the majority of HGSC are associated with Serous Tubal 
Intraepithelial Carcinomas (STICs) primarily located within fimbriae (Figure 1.2) 
[25]. STICs are derived from fallopian tubal epithelial cells (FTECs) and 
importantly, frequently share identical TP53 mutations with their HGSC 
counterparts [26,27]. Moreover, HGSC may arise from ectopic ciliated and/or 
secretory fallopian tube epithelium (endosalpingiosis) or cortical inclusion cysts 
(CICs) of the ovary. Endosalpingiosis and CICs are believed to arise due to 
invagination of the OSE or tubal-type epithelium following ovulation [28]. The rarer 
and less aggressive LGSC and serous borderline tumours may also originate from 
CICs. However, unlike HGSC, these tumours are characterized by intact and wild-
type TP53 expression and patchy CDKN2A staining [29]. EC and clear cell 
carcinoma (CCC), in contrast, are associated with atypical endometriosis 
(endometriomas) of the ovary [30–33]. Endometriomas, like endosalpingiosis, are 
ecotopic endometrial tissue derived from ciliated and/or secretory cells. 
Retrograde menstruation, and possibly endometrial remnants, are thought to be 
the primary source of endometriomas. Moreover, recent work by Cochrane et al. 
suggests EC and CCC may be derived from secretory and ciliated endometrial 
epithelial cells, respectively [33]. Interestingly, whereas STICs give rise to HGSC, 
fallopian tube cancers are extremely rare. Hence, genotoxicity of the fallopian tube 
is theorized to prevent ectopic implantation of embryos and coincidentally, tumour 
growth [5]. Conversely, the ovary has been suggested to contain supportive 
stromal cells and factors which can promote tumour growth [5]. Indeed, metastasis 
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to the ovary has been linked to breast, colon, stomach and appendiceal cancers 
[34]. How EOC preferentially co-opts the ovaries during progression is not 
understood and improved characterization of this close association may reveal 
targets for inhibiting tumour growth. 
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Table 1.1 Features of main epithelial ovarian cancer (EOC) subtypes 
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Figure 1.2 Anatomical overview of cell types and precursor lesions which 
give rise to EOC subtypes. 
(a) Cells from different origins of the female reproductive system give rise to 
ovarian cancer. Precursor lesions and signalling pathways underlying progression 
of individual EOC subtypes are shown. (b) Proposed roles of ovarian and fallopian 
tube stromal cells on ovarian cancer progression.  Adapted by permission from 
RightsLink Permissions Springer Customer Service Centre GmbH: Springer 
Nature. Nature Reviews Cancer. The disparate origins of ovarian cancers: 
pathogenesis and prevention strategies, Anthony N. Karnezis, Kathleen R. Cho, 
C. Blake Gilks, Celeste Leigh Pearce, David G. Huntsman (2016) 1:65-74. 
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 Treatments 
HGSC accounts for ~70% of all EOC cases and ~90% of advanced (stage III/IV) 
disease [35]. First line treatments for advanced ovarian cancer remain limited and 
require aggressive surgery combined with chemotherapy [36]. Surgery should be 
performed by a gynecological oncologist and generally involves tumour debulking, 
hysterectomy (removal of the uterus), bilateral salpingo-oophorectomy (removal of 
the ovaries and fallopian tubes), and omentectomy [37]. When tumour debulking 
is not feasible due to risk of patient morbidity associated with extensive surgery, 
neoadjuvant (preoperative) chemotherapy may be administered followed by 
interval debulking [37]. Taxanes (i.e. paclitaxel, docetaxol) and platinum based 
compounds (i.e. carboplatin, cisplatin) are standard chemotherapeutics 
administered following surgery. These drugs inhibit cellular proliferation by 
stabilizing microtubules (taxanes) and crosslinking DNA to inhibit repair and 
replication (platinum based compounds) [38,39]. While short term responses are 
often achieved with aggressive treatment, tumours often develop resistance [40].  
Accurate molecular and  histotype classification is becoming increasingly relevant 
for the management and treatment of EOC [15]. For example, germline mutations 
in breast cancer susceptibility type 1 and/or 2 (BRCA1/2)  are currently the single 
best predictors of developing ovarian and breast cancer [41]. Indeed, BRCA1 and 
BRCA2 mutations increase the likelihood of developing ovarian cancer by 44% 
and 17% respectively. In breast cancer, the risk is even greater at 72% for BRCA1 
and 69% for BRCA2 carriers [42]. Therefore, females bearing germline BRCA1/2 
mutations may undergo risk reducing prophylactic salpingo-oophorectomy and/or 
mastectomy (removal of the breasts) to prevent ovarian and breast cancer, 
respectively. Moreover, up to 33% of HGSC cases are estimated to exhibit 
alterations in BRCA1/2 due to germline and somatic mutations or epigenetic 
silencing [37]. Notably, both BRCA1/2 and Poly (ADP-ribose) polymerase (PARP) 
PARP carry out homologous recombination mediated DNA repair and maintain 
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genome integrity [43,44]. Together, these findings have led to the clinical use of 
PARP inhibitors in BRCA1/2 defective cancers like HGSC by exploiting the 
concept of synthetic lethality [45]. In essence, the combination of BRCA1/2 defects 
and PARP inhibition impairs cancer cells ability to repair DNA damage and results 
in cell death. In contrast, healthy cells without DNA damage are largely spared. 
Indeed, clinical trials investigating PARP inhibitors in HGSC have demonstrated 
impressive increases in progression free survival (PFS) with few significant side 
effects [46]. However, significant increases in PFS with PARP inhibitors such as 
Olaparib did not translate into overall survival (OS) but combination therapies, 
dosing and stratification of patient subgroups are still be explored to realize their 
full potential. 
Alternatively, the PI3K/AKT/mTOR pathway is frequently activated in EC and CCC  
and may be potential target when cancers do not respond to chemotherapy [44]. 
Furthermore, estrogen receptor (ER) and/or progesterone receptor (PR) 
expression has been reported in EOC, in particular EC and HGSC. High ER and 
PR expression was highest in EC and associated with increased disease free 
survival [47]. Unfortunately, clinical studies targeting PR in EC are lacking, in part 
due to side effects and poor specificity of progesterone receptor modulators [48]. 
Given the limited treatment options for EOC, additional studies focused on 
hormonal therapy may improve patient outcomes. 
 Detection and diagnosis 
According to the National Institutes of Health Biomarkers Definitions Working 
Group, a biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention” [49]. In terms of 
biomarkers used for detecting or diagnosing diseases like cancer, sensitivity and 
specificity are standard metrics used to assess their performance. Sensitivity 
corresponds to the true positive rate or percentage of individuals within the 
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diseased population which test positive for a given biomarker. Alternatively, the 
specificity of biomarker indicates the percentage individuals which correctly test 
negative for the disease in question. 
In the context of ovarian cancer, early stage disease is often asymptomatic and 
therefore difficult to detect. Moreover, symptoms associated with disease 
progression are generally non-specific and primarily include abdominal pain and 
discomfort due to accumulation of ascites within the intraperitoneal cavity and/or 
malignant transformation of the fat pad (omentum) covering the bowel and 
abdominal cavity [10].  
Currently, there are no FDA approved biomarkers for ovarian cancer screening; 
however cancer antigen 125 (CA-125) levels in the blood are widely used to aid in 
diagnosis, monitor disease progression and treatment response [50]. CA-125 is 
derived from the transmembrane glycoprotein Mucin 16 (MUC16), and is typically 
elevated in ~83% of EOC cases [50]. Unfortunately, several issues primarily 
related to sensitivity and specificity make CA-125 unsuitable as a single agent for 
early screening [50]. Firstly, CA-125 is only elevated in ~67% of patients with stage 
I disease when using a less stringent cut-off of 30 U/mL [51]. Secondly, non-
malignant/benign gynecological conditions can increase CA-125 levels 
necessitating the need for surgical follow-up [51]. Lastly, CA-125 levels fluctuate 
between post-menopausal women depending on race/ethnicity, age, 
hysterectomy, smoking history and obesity and thus confound the use of a set cut-
off to establish disease status [52]. For example, CA-125 significantly increases 
with age and is higher in Caucasians compared to African Americans and other 
minorities. 
In addition to CA-125, highly sensitive imaging methods like transvaginal 
ultrasound (TVUS) can detect abnormal ovarian masses/features. However, 
invasive follow-up surgeries/biopsies associated with significant patient discomfort 
remain essential for accurate diagnosis by a pathologist. Moreover, the majority of 
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these surgeries do not reveal malignant disease with the ratio of surgeries to the 
number of cancers detected by TVUS being ~19:1 [53]. For reference, two large 
scale trials, the Prostate, Lung, Colorectal, Ovarian cancer screening trial (PLCO) 
in the US and UK Collaborative Trial of Ovarian Cancer Screening trial 
(UKCTOCS) evaluated the role CA-125 and TVUS screening on reducing ovarian 
cancer deaths [54,55]. Both trials monitored tens of thousands of females over a 
number of years. Unfortunately, results from these trials did not achieve a 
significant reduction in overall mortality based on their initial analyses. In the PLCO 
trial, a substantial number of false-positive screening results were reported in the 
intervention group (CA-125 plus TVUS) that were later associated with follow-up 
surgery related complications [55]. Surprisingly, the authors did not observe a 
stage shift in detecting early ovarian cancer in the intervention group compared to 
usual care. The UKCTOCS trial, on the other hand, noted a significantly higher 
proportion of cases with low volume disease (stage I, II, IIIa) in the multimodal 
screening group (CA-125 plus TVUS) compared to no screening (40% versus 
26%) [54]. Initially, the authors reported a small but insignificant mortality reduction 
in the screening groups (CA-125 plus TVUS or TVUS only) compared to standard 
care (no screening) [54]. However, an overall mortality reduction of 20% (between 
years 0 to 14 after screening) in favour of multimodal screening (CA-125 plus 
TVUS) was reached when subgroup analysis was performed excluding prevalent 
cases (females likely harbouring ovarian cancer prior to enrolment). Together, 
these studies highlight the limitations associated with CA-125 and TVUS screening 
modalities and suggest that longer follow-up studies may be needed to achieve 
significant reductions in mortality. 
Consequently, the lack of clinically available screening strategies remains a major 
bottleneck for improving survival of ovarian cancer patients.  Given the absence or 
limited number of biomarkers for EOC screening and diagnosis, a substantial 
amount of research effort is focused on identifying/developing new or improved 
markers. For example, human epididymis protein 4 (HE4) is another clinically 
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approved marker with sensitivity and specificity similar to CA-125 but has not been 
widely implemented [56]. Moreover, Cramer et al. surveyed 49 markers in a large 
cohort of malignant and non-malignant plasma samples from the PLCO trial [57]. 
When using a sensitivity cut-off of 95%, CA-125 followed by HE4 were the best 
predictors of disease status with specificities of 0.73 and 0.54, respectively. In 
addition to single biomarkers, several assays have been developed which monitor 
a panel of plasma proteins and achieve greater performance than CA-125 or HE4 
alone. These products include OvaSure, OVA1 and OvPlex and can aid in the 
diagnosis of EOC such that patients may not have to undergo surgeries for benign 
conditions [56]. Very recently, a study published in the journal Science reported a 
multi-analyte blood test capable of achieving very high detection rates for 8 
different cancers [58]. This test, called CancerSEEK, monitors ~60 amplicons in 
cell-free DNA and several proteins in the blood. Impressively, CancerSEEK 
achieved sensitivities ranging from 69-98% (98% for ovarian cancer) at a 
specificity >99% and could also predict the anatomical location of cancers. Studies 
like this highlight the significant challenges associated with low signal to noise in 
detecting tumour-derived products that are present in minute quantities. However, 
sensitive assays which monitor multiple biomarkers may hold the future of 
screening tools. 
1.3 Breast cancer  
Breast cancer is second leading cause of cancer related deaths in females with a 
lifetime risk of developing breast cancer (invasive and ductal carcinoma in situ) of 
14.73% (12.41% for invasive disease only) [1]. Although the incidence of breast 
cancer is high in the US, 89.5% of patients are alive after 5-years. In absolute 
terms, the lifetime risk of dying from breast cancer for females in the US is 2.62%. 
Screening strategies have significantly improved early detection and treatment, 
however metastatic disease remains difficult to cure. In terms of risk factors, both 
breast and ovarian cancers have several in common even though they originate in 
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anatomically different locations. For example, early age of first menarche 
(menstruation), non-parous (non-child bearing) females, and delayed menopause 
are all associated with increased risk of developing breast and ovarian cancer. 
Conversely, early age of first childbirth and breastfeeding are protective against 
breast cancer and long term oral contraceptive use are protective against 
developing EOC [59–61]. Intriguingly, the most aggressive forms of breast and 
ovarian cancer share similar genetic profiles [19]. 
 Basic anatomy of the breast 
The breasts contain a branching of network glandular structures (mammary 
glands) within a vascularized layer of fatty tissue that is externally supported by 
connective tissue (Figure 1.3) [62]. The primary function of the breasts (mammary 
glands) are milk production (lactation) to support newborns. These organs are 
unique to mammals and undergo extensive morphogenesis/remodelling 
throughout embryonic development, puberty, and pregnancy [63]. Within each 
breast, the mammary gland forms a hollow tree like network of ~15-20 lobes or 
terminal end buds (TEBs) which radiate outward from the nipple. These tubular 
structures (mammary ducts) are made up of a bilayer of inner luminal and outer 
basal epithelial cells that arise through proliferation and elongation into the fat pad 
throughout puberty [63,64]. During pregnancy, the TEB luminal epithelium 
proliferates and differentiates into secretory (milk producing) cells comprised of 10-
100 alveoli. While breastfeeding, basal myoepithelial cells surrounding alveoli 
contract to expel milk into the ducts. After breastfeeding is no longer required, 
alveoli undergo massive apoptosis to remove up to 80% of the epithelium [64]. 
Strikingly, this dynamic cycle of proliferation, differentiation and apoptosis is tightly 
regulated by a number of extracellular factors and can be repeated many times 
over several decades [64].   
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Figure 1.3 Anatomy of the breast. 
The breast is comprised a branching network of ducts which terminate into 
lobular units surrounded by stromal and adipose tissue. Each lobular unit 
(mammary gland) contains an inner and outer layer of luminal epithelial and 
myoepithelial cells, respectively.  Adapted from the McMaster Pathophysiology 
Review (MPR) website: http://www.pathophys.org/breast-cancer/. 
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 Staging 
Cancer staging is a critical component of patient management. Similar to ovarian 
cancer, breast cancer staging is also based upon the AJCC TNM system with TNM 
components assigned a value/letter corresponding to disease progression at 
diagnosis [60]. For example, T1 corresponds to the presence of a tumour <2 cm 
across while a score of T4 includes tumours of any size that have grown into the 
chest wall or skin. In addition, the AJCC TNM staging system was recently updated 
to include tumour grade and estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor 2 (HER2) expression status [65]. Tumour grade is 
based on how normal and or undifferentiated the cancer cells appear with less 
differentiated cells often associated with advanced disease. 
 Subtypes 
Breast cancer is primarily comprised of 4 intrinsic subtypes: luminal A, luminal B, 
HER2-enriched and triple negative breast cancer (TNBC) (Table 1.2) [66]. Luminal 
breast cancers express ER and PR and accordingly, are classified as hormone 
receptor (HR) positive. Of note, luminal A breast cancers are HER2- while luminal 
B can be either HER2- or HER2+. For reference,  the Surveillance, Epidemiology, 
and End Results (SEER) breast cancer registry in the US population revealed 83% 
of all breast cancers diagnosed are HR+ [67]. When accounting for HER2 
expression, 72.7% and 10.3% of HR+ breast cancers were HER2- and HER2+, 
respectively. A similar report by the North American Association of Central Cancer 
Registries found 72.1% and 10.3% of all HR+ breast cancer to be HER2- and 
HER2+, respectively [68]. From these findings, the luminal A subtype is the most 
predominate and fortunately, exhibits the highest OS of all invasive breast cancers. 
Luminal B cancers, in contrast, are less frequent, characterized by high levels of 
proliferating Ki67+ cells and have a worse prognosis [69–71]. Compared to luminal 
cancers, HER2-enriched tumours are rarer and account for ~4.6% of cases [67]. 
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This subtype typically lacks ER and PR, is highly aggressive and associated with 
low OS. The last main subtype, TNBC, lacks ER, PR, and HER2 and comprises 
the most heterogeneous form of breast cancer. TNBC  accounts for ~12.2% of all 
cases and based on molecular profiling, can be divided into two subgroups, basal 
A and basal B (or claudin-low) [67,72]. Like HGSC, TP53 mutations are found in 
up to 84% of all TNBCs [73]. Of note, inflammatory breast cancer is another form 
that is extremely rare but highly proliferative and aggressive [74]. It is characterized 
by swelling and redness of breasts and associated with a higher rate of recurrence 
and worse OS compared to non-inflammatory locally advanced breast cancer 
(Stages IIB, IIIB,IIIA) [75]. 
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Table 1.2 Features of main invasive breast cancer subtypes 
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 Pathogenesis 
Ductal Carcinoma In Situ (DCIS) accounts for about 1 in 5 of all breast cancers 
diagnosed and is the precursor to invasive breast cancer (IBC) [82]. DCIS is 
characterized by confined hyperplasia of ductal epithelial cells and when detected, 
5-year survival rates are nearly 100%. Alternatively, Lobular Carcinoma In Situ 
(LCIS) is a more rare form of breast cancer that involves neoplasia of the secretory 
cells lining the mammary glands. DCIS which proceeds to invade through the 
myoepithelium and breach the basement membrane is termed Invasive Ductal 
Carcinoma (IDC). IDC accounts for the majority of breast cancer cases and is 
typically detected when localized to the breast and axillary lymph nodes, chest wall 
and skin of the breast [2]. Metastatic breast cancer (mBC) is the rarest and most 
aggressive form which occurs when cancer cells travel through the bloodstream or 
lymphatic system and form secondary tumours at distant sites. Bone, liver, lungs 
and brain are the main organs of breast cancer metastasis [82]. Patients with 
metastasis to the bone have better prognosis compared to those with lung and 
liver and brain metastases are the least frequent but most lethal [76]. In terms of 
origin, gene expression patterns for luminal and TNBC subtypes more closely 
resemble those of ductal and myoepithelial cells, respectively, however EpCAM+ 
luminal epithelial cells are main progenitors from which most breast carcinomas 
arise [77–79].  
 Detection and diagnostics 
In contrast to ovarian cancer, breast cancer screening has had a significant impact 
on patient mortality and is performed via routine mammograms in females aged 
50-55 or older [80]. Even more so, the advent of 3D mammography (breast 
tomosynthesis) has further increased detection rates while reducing the false 
positives associated with 2D mammography [80]. Self-examination of the breast 
for masses, irritation and discoloration can also aid in early detection.  Taken 
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together, breast cancer screening has significantly reduced breast cancer mortality 
and rates of stage II disease or higher [81]. A number of gene-expression assays 
are also clinically available to aid predicting recurrence and response to therapy 
for breast cancer. For example, OncotypeDx™ – a genomic test which measures 
the expression of a panel of 21 genes – prognosticates the likelihood of recurrence 
and predicts the likelihood of benefit from chemotherapy in patients with node-
negative, early-stage, ER positive breast cancer treated with surgery and/or 
hormonal therapy [66]. 
 Treatments 
In cases of DCIS, females may opt for breast conserving surgery or mastectomy 
depending on the tumour size and spread [82]. Lymph node removal may be 
required depending on sentinel lymph node biopsy results and radiation and/or 
adjuvant hormone therapy may be administered. Although luminal breast cancers 
are HR positive, hormone therapy including selective estrogen receptor 
modulators (SERMs, i.e. tamoxifen) and aromatase inhibitors are largely 
ineffective in Luminal B cancers for which chemotherapy may be appropriate. 
Surgery plus chemotherapy is standard treatment for TNBC, inflammatory breast 
cancer and HER2-enriched tumours. However, the monoclonal antibody 
(trastuzumAb/Herceptin™) which targets the HER2 receptor is therapeutically 
effective in HER2-enriched subtypes when combined with chemotherapy but 
relapse rates are high [83]. TNBC lack HR and HER2 expression and consequently 
are the most difficult to target. Coincidentally, TNBCs are frequently BRCA1/2 
defective and therefore susceptible to PARP inhibitors like HGSC. Indeed, ongoing 
and recently completed trials exploring the potential of PARP inhibitors as a 
monotherapy or combination therapy have shown positive increases in PFS [84].  
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1.4 Breast cancer plasticity 
Cellular plasticity exists throughout embryonic development and refers to the ability 
of cells to adapt to and modulate their surrounding microenvironment [85]. Cellular 
plasticity is also characterized by the capacity for stem cells to undergo self-
renewal and multi-lineage differentiation and remains important for tissue 
repair/homeostasis. However, during development and in adult tissues, cellular 
plasticity becomes increasingly restricted [86]. For example, during mammary 
gland development, mammary stem cells (MaSCs) within differentiate into luminal 
and basal epithelial cells which subsequently undergo rapid expansion and 
apoptosis throughout and following pregnancy, respectively [63]. Although cellular 
plasticity is tightly regulated, during (breast) cancer progression, terminally 
differentiated cells can acquire plastic, stem-like phenotypes through genetic, 
epigenetic and microenvironmental mechanisms which in turn confer selective 
advantages to intrinsic and extrinsic stresses such as TP53 inactivation and low 
oxygen (hypoxia) [86]. For instance, in transgenic mouse models, oncogenic 
PIK3CAH1047R expression in luminal cells permitted multi-lineage luminal-to-basal 
differentiation and recapitulation of all main breast cancer subtypes (luminal, HER2 
and basal-like) in mouse xenografts [87]. In basal cells, although oncogenic 
PIK3CAH1047R expression promoted basal-to-luminal differentiation, oncogenic 
PIK3CAH1047R expression combined with TP53 deletion was required to form breast 
tumours with characteristics of the most aggressive subtypes (basal-like TNBC). 
Currently, it is not clear whether stem-like breast cancer cells arise from tissue 
resident progenitors or differentiated ductal cells [85,88]. Regardless, stem-like 
breast cancer cells have been implicated in cancer initiation, metastasis and 
secondary tumour formation and are often demarcated based on CD44+/CD24- 
and/or ALDH1 expression [85,89]. Remarkably, stem-like breast cancer cells 
constitute a small fraction of the overall tumour mass but when purified/sorted, 
efficiently recapitulate entire tumours in limiting dilution assays with as little as 
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1000 cells [90]. Moreover, CD44+/ALDHhi breast cancer cells were also found to 
be more resistant to chemotherapy and radiation [91]. However, the association 
between CD44+/CD24- breast cancers, patient survival and prognosis is not 
entirely clear [92,93]. For instance, a meta-analysis of 16 studies found CD24 
expression to be a prognostic indicator of worse prognosis and no significant 
association was found for CD44+ and CD44+/CD24- breast cancers [93]. In this 
meta-analysis, subtype specific expression of CD44/CD24 was not available which 
may influence prognostic value. Other properties of stem-like cancer cells include 
anchorage independent  growth and expression of embryonic signalling pathways 
[94]. For example, human embryonic stem cell transcription factors OCT-4 
(POU5F1), NANOG, SOX2, MYC and their target genes, are enriched in poorly 
differentiated cancers, in particular, ER-/basal-like breast tumours [95]. However, 
embryonic signatures were not associated with CD44+/CD24- expression in this 
study, suggesting that different markers may be used to identify populations of 
stem-like breast cancer cells. In another study by Spike et al., HER2-enriched and 
basal breast cancer subtypes were found to exhibit similar gene expression 
patterns characteristic of mouse fetal MaSC (fMaSC) [96]. Ultimately, a number of 
embryonic signalling pathways have been implicated promoting plasticity in breast 
cancer including WNT, NOTCH and recently, NODAL [95,97–99].  
1.5 The embryonic morphogen NODAL 
NODAL is an embryonic morphogen which has been shown to regulate plasticity 
in a variety embryonic and tumourigenic settings [100]. NODAL belongs to the 
Transforming Growth Factor-beta  (TGF-β) superfamily and is widely regarded for 
its roles in patterning left-right asymmetry during embryonic development, meso-
endoderm induction and maintaining human embryonic stem cell (hESC) 
pluripotency [101]. NODAL is synthesized as a homodimeric pro-protein which 
requires cleavage by PACE4 and/or FURIN to generate mature NODAL (Figure 4) 
[99]. Mature NODAL ligands signal through a receptor complex involving the type 
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I ACTIVIN receptor-like-kinase (ALK4/7), the ACTIVIN type IIB receptor (ActRIIB) 
and the co-receptor CRIPTO. Phosphorylation of downstream SMAD2/3 signalling 
proteins by the ALK4/7-ActRIIB receptor complex leads to the formation and 
translocation of SMAD2/3 dimers with SMAD4 into the nucleus. SMAD2/3-SMAD4 
complexes associate with several transcription factors such as FOXH1 to regulate 
gene expression for a number of targets including NODAL and the endogenous 
inhibitor Lefty1/2. NODAL has also been shown to induce ERK1/2 activation in 
non-canonical manner in breast cancer cell lines [102].  
During early murine embryonic development, NODAL expression is proximally 
concentrated and regulated at the extraembryonic ectoderm-epiblast interface 
[86]. Diffusion of NODAL towards the distal region induces expression of its 
endogenous inhibitor Lefty at dorsal visceral endoderm (DVE) to generate a 
proximal distal (PD) gradient. The anterior posterior (AP) axis is formed when the 
DVE rotates anteriorly to become the anterior visceral endoderm (AVE). NODAL 
expression subsequently localizes posteriorly during formation of the germ layers 
and primitive streak (early gastrulation). NODAL expression eventually reaches 
the Node located distally where its activity becomes restricted to the left 
hemisphere of the developing embryo due to inhibition by Lefty in the right 
hemisphere. In hESCs, the addition of recombinant ACTIVIN and/or NODAL with 
FGF can maintain expression of pluripotency markers (POU5F1, SSEA3, SSEA4, 
Tra-1-60[PODXL]) over prolonged culture in feeder free conditions [103]. 
ACTIVIN/NODAL signalling drives NANOG transcription in hESCs via SMAD2/3 
binding within the NANOG promoter [104]. Nanog expression in turn prevents 
neuroectoderm differentiation by inhibiting FGF signalling, which is also required 
for pluripotency, and blocking transcription of ACTIVIN/NODAL in a negative 
feedback loop [104]. Conversely, targeting ALK4/5/7 with the small molecule 
inhibitor SB431542 accelerates hESC neuroectoderm differentiation [104]. Thus, 
NODAL contributes to a complex network of signalling pathways which can 
regulate pluripotency and differentiation. 
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Figure 1.4 NODAL signalling pathway 
NODAL is a secreted pro-protein that is cleaved by the convertases PACE4 and 
Furin to generate mature NODAL ligands. Mature NODAL homodimers induce 
phosphoryation of SMAD2/3 proteins via binding to the receptor complex invloving 
the type I ACTIVIN Like Kinase (ALK4/7), ACTIVIN type IIB receptor (ActRIIB) and 
co-repector CRIPTO. Phosphorylated SMAD2/3 dimers associate with SMAD4 
which together, translocate into the nucleus to regulate target gene expression by 
associating with transcription factors including FOXH1. NODAL signalling can 
promote expression of itself as well as the endogenous inhibitor LEFTY. 
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Intriguingly, NODAL is silenced in most adult tissues but aberrantly expressed and 
promotes malignant phenotypes in a variety of cancers including melanoma, 
breast, prostate, pancreatic and glioma [86]. Fascinatingly, early work by 
Topczewska et al. found aggressive C8161 melanoma cells transplanted into 
zebrafish embryos could induce ectopic outgrowths and body axis duplication 
which is a unique phenotype of NODAL signalling [100]. NODAL expression was 
further found to be positively correlated with metastatic melanoma in patient 
samples [100]. In a subsequent study, hESC conditioned Matrigel™ was shown to 
suppress NODAL signalling in aggressive melanoma cells via hESC derived Lefty. 
Importantly, inhibition of NODAL signalling could differentiate aggressive 
melanoma cells into a pigment producing melanocytic phenotype [105]. In breast 
cancer models, NODAL was recently found to positively regulate stem cell markers 
and promote stem cell phenotypes in claudin-low TNBC (MDA-MB-231) and 
luminal breast cancer (MCF-7) cell lines [98]. In addition to NODAL, its co-receptor 
Cripto-1 and family members TGF-β and ACTIVIN are frequently dysregulated in 
cancer [106–108]. Together, these studies and others highlight the dominant role 
NODAL signalling plays in promoting embryonic and plastic phenotypes in cancer.  
Recent work by our lab and others has also demonstrated that NODAL is a potent 
regulator of tumour growth, vascularization and invasion in breast cancer 
[102,109,110]. Of note, inhibition of NODAL signalling in the MDA-MB-231 
significantly reduces tumour growth in vivo and vascularization of angioreactors. 
Although Vascular Endothelial Growth Factor (VEGFA) and Platelet Derived 
Growth Factor (PDGFA) expression are positively associated with NODAL 
signalling, how NODAL regulates breast cancer vascularization and growth is not 
fully clear. For instance, the addition of exogenous recombinant human NODAL 
only partially rescues vascularization deficiencies following NODAL knockdown in 
breast cancer cells. Furthermore, VEGF is not able to rescue tumour growth of 
MDA-MB-231 breast cancer cells lacking NODAL in a chick CAM assay. Together, 
these findings suggested NODAL may regulate tumour vascularization through 
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VEGF-dependent and independent mechanisms by altering the recruitment of 
accessory cells including bone marrow derived cells. Moreover, aggressive and 
undifferentiated cancers which are difficult to treat by current means may be 
sensitive to NODAL-targeted therapies. 
1.6 The tumour microenvironment – a reservoir of biomarkers 
and therapeutic targets 
Current research efforts aimed at tackling cancer are not limited to targeting 
tumour cells alone but the tumour microenvironment (TME) as a whole [3,111]. 
The TME is integral to all areas of cancer progression and is comprised of all 
cellular, biochemical and biophysical components in which cancer develops [4]. It 
harbours a wealth of information pertaining to tumour biology and is a rich source 
of biomarkers and potential drug targets [3]. Moreover, modulating interactions 
between auxiliary cell types within the TME is a complementary approach to 
reduce tumour burden in the case of anti-angiogenic and immune therapies [4]. 
Therefore, improved characterization and modeling of the TME can yield better 
diagnostics and treatments.  
1.7 Non-transformed cells of the TME 
In many cancers, non-transformed cells form a substantial proportion of the overall 
tumour mass. These cells exhibit distinct yet overlapping behaviours and can be 
broadly classified as endothelial, stromal (fibroblasts) and immune.  
 Endothelial cells 
Endothelial cells form the main building block of all vessels in the body which are 
essential for the transportation and exchange of oxygen, nutrients and cellular (by-
)products needed for cell survival [112]. New blood vessel formation 
(neovascularization) occurs during embryonic development and wound repair but 
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also in diseases like cancer. In adult tissues, neovascularization primarily occurs 
through a process known as angiogenesis which entails endothelial cell sprouting 
and branching from pre-existing vasculature [113,114].  Importantly, tumours must 
also become vascularized in order to grow beyond 1-2mm (the diffusion limit of 
oxygen) [115]. This was first recognized by the late Judah Folkman who proposed 
targeting tumour vascularization as a means to starve growth [112,116]. Given that 
tumours utilize angiogenesis heavily, neutralizing the highly potent angiogenic 
factor VEGFA significantly impaired rhabdomyosarcoma, glioblastoma multiforme 
(GBM) or leiomyosarcoma tumour growth in vivo [117]. This study and work by 
other groups ultimately led to the development and clinical approval of the VEGFA 
monoclonal Antibody (mAb) Bevacizumab (Avastin™)  [118]. While promising 
results were achieved in vivo, Bevacizumab in combination with chemotherapy 
only modestly improved PFS and OS in renal cell carcinoma (RCC), clear cell 
carcinoma (CCC), metastatic breast cancer (mBC), glioblastoma multiforme 
(GBM), and lung cancer [119]. Unfortunately, most cancers develop resistance to 
anti-angiogenic therapies or exhibit limited responses, in part due to the 
emergence of VEGF-independent vascularization [112,120]. Indeed, tumour 
vasculature is often described as tortuous and comprised of leaky, immature 
vessels, indicating processes other than angiogenesis. Moreover, anti-angiogenic 
therapies may even reduce the efficacy of chemotherapy and inadvertently 
promote metastasis or selection of aggressive cancer cells [121]. 
Vasculogenesis or de novo blood vessel formation in the absence of pre-existing 
vasculature precedes angiogenesis during early embryonic development. 
Hemangioblasts are multipotent precursor cells within the yolk sac which give rise 
to haematopoietic and endothelial lineages and form primitive vessel like networks 
termed blood islands [122]. Although vasculogenesis was initially thought to be 
restricted to embryonic development, Asahara et al. identified a small population 
of Bone Marrow Derived Cells (BMDCs) referred to as Endothelial Progenitor Cells 
(EPCs) that could migrate to sites of ischemia and wounds to support postnatal 
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neovascularization [123]. Green fluorescent protein (GFP) or β-galactosidase 
(LacZ+) expressing EPCs from mouse bone marrow also augmented tumour 
angiogenesis by incorporating into a small but significant percentage vessels [124]. 
For reference, VEGF, Id1/3 and Tie-2 receptors have been shown to mediate the 
vasculogenic effects of EPCs [124–126]. For example, inhibiting VEGF receptor 
1/2 (VEGFR1/2) or deleting VEGFR2 in EPCs dramatically reduces tumour 
frequency, growth rate and size in vivo [127]. Alternatively, tumour cells can 
generate channel-like networks through a process referred to as “vasculogenic 
mimicry” [128]. In light of this, multi-pronged approaches may be necessary to 
overcome resistance associated with anti-angiogenic therapy. 
 Stromal cells 
Stromal cells, primarily Carcinoma Associated Fibroblasts (CAFs), often comprise 
the largest mass of non-transformed cells within the TME [129,130]. CAFs are 
mostly derived from fibroblasts within connective tissue which have become 
activated/transformed following exposure to signals from the TME [131].  Normally, 
during wound repair and tissue/ECM remodeling, fibroblasts become temporarily 
activated and express myofibroblast markers including ⍺-smooth muscle actin (⍺-
SMA) and fibroblast activation protein (FAP).  In cancer however, activated 
fibroblasts persist as CAFs to promote tumourigenic behaviours including growth, 
vascularization, metastasis and resistance to therapy. Indeed, tumours often 
resemble a chronic state of wound healing and hence are referred to as  “Wounds 
that do not heal” [132,133]. Since early observations of desmoplastic stroma 
(fibrous connective tissue) in cancer, a substantial amount of work has focused on 
uncovering the molecular mechanisms associated with CAF phenotypes. TGF-β, 
connective tissue growth factor (CTGF), stromal derived factor-1 (SDF-1 also 
known as CXCL12), collagens and pro-inflammatory cytokines are just some of 
the proteins expressed by CAFs [134]. Targeting these signalling pathways is one 
method to prevent stromal cell recruitment and cancer progression 
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Multipotent Stromal Cells (MSC) are highly plastic stromal cells also found within 
the TME [135,136]. MSC were first discovered within the bone marrow but also 
reside in many other vascularized niches including adipose tissue and often 
promote tumour progression in vivo [137]. In vitro, MSC form cartilage, bone, fat 
and muscle, and express adult stem cell-associated markers (CD133) and can 
form vessel-like networks [138].  Mounting evidence suggests MSCs are important 
for tumour neovascularization although their contributions may be restricted to 
perivascular roles and paracrine roles [139,140]. Moreover, MSCs can also 
differentiate into CAFs or myofibroblasts to remodel the extracellular environment 
by secreting ECM components and proteases linked to cancer aggressiveness 
[141]. Furthermore, up to 20-25% of CAFs have been found to originate from BM-
MSC [142,143]. A number of chemokine/cytokine signalling networks have been 
implicated in MSC recruitment in breast, prostate and gastric cancer mouse 
models which involve CXCL12/CXCR4, migration inhibitory factor (MIF)/CXCR4, 
CXCL16/CXCR6 [144–146]. Of note,  the contributions and effects of MSC in the 
TME appear to vary depending on their origin and cancer model [137]. In one 
study, adipose MSCs were shown to preferentially localize to sites of 
vascularization while bone marrow MSCs tended to remain at the periphery of 
tumours [147].  
 Immune cells 
Although not investigated in this this, immune cells or tumour infiltrating 
lymphocytes (TILs) are the last main subset of non-transformed cells within the 
TME. TILs comprise a diverse repertoire of cell types which can enhance or 
abrogate tumour progression [148]. For example, cytotoxic CD8+ T-cells mediate 
cancer cell death while Treg CD4+ T-cells suppress CD8+ T-cell cytotoxicity [149]. 
Gamma delta T-cells (γδTc) are another subset of TILs with both cytotoxic and 
regulatory roles depending on the type of cancer [150]. In a mouse model of PDGF-
driven GBM, CSF1R inhibition resulted in tumour regression via re-education of 
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tumour associated macrophages (TAMs) from a pro-tumourigenic M2 state to an 
anti-tumourigenic phenotype [151]. However, a follow-up study by the same group 
found >50% of GBM tumours acquired resistance to prolonged CSF1R inhibition 
[152]. Intriguingly, resistance was linked to PIK3CA pathway activation in response 
to macrophage-derived IGF1 which, when blocked in combination with CSF1R, 
could reduce tumour recurrence. In a mouse model of pancreatic ductal 
adenocarcinoma (PDAC), a sub-population BM macrophages we required to 
establish a pre-metastatic niche in the liver, and subsequently PDAC metastasis 
[153]. A more comprehensive overview of TIL subset within the TME is provided 
by Gajewksi et al. [148]. In summary, many cell types within the TME are regulated 
by numerous extracellular factors that may be useful targets for cancer therapy. 
1.8 The extracellular proteome 
The complement of proteins and vesicular cargo that are secreted, shed or 
released by cells into the extracellular space is collectively known as the 
secretome [154]. Proteins secreted within the TME or tumour secretome harbour 
a diverse array of functions and can be broadly categorized into 4 groups: 1) 
signalling factors 2) extracellular matrix (ECM) proteins 3) proteases (enzymes) 
and 4) vesicular cargo. 
 Signalling factors 
Growth factors, cytokines, chemokines and developmental morphogens all belong 
to a group of signalling factors which mediate autocrine, paracrine, and endocrine 
signalling events between cells in TME. Many of these factors regulate immune 
responses and wound healing but are often associated with worse patient 
prognosis and malignant progression [155]. For instance, CXCL12 and TGF-β 
potently stimulate fibroblast migration and invasion and their expression is often 
dysregulated in the tumour stroma [156]. Moreover, the pleiotropic cytokine 
interleukin-6 (IL6) is perhaps one of the most frequently elevated cytokines in 
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cancer [157]. IL6 is expressed by multiple cells within the TME and carries out a 
number of pro-inflammatory and tumour promoting functions. For example, in 
breast cancer, IL6 promotes monocyte and macrophage recruitment and high 
levels are correlated with worse overall survival [158]. Additionally, IL6 expression 
is associated with basal-like and stem-like CD44+/CD24- breast cancer cells [159]. 
Of note, the effects of IL6 are largely mediated through downstream activation of 
the JAK/STAT pathway which is consequently hyperactive in most cancers. IL6 
signalling involves binding to and activation of the IL6 receptor/gp130 complex to 
recruit and phosphorylate Janus kinases (JAKs). JAKs subsequently 
phosphorylate and activate downstream signal transducer and activator of 
transcription (STAT) proteins, particularly STAT3, which in turn regulate 
transcription of target genes such as VEGF and matrix metalloproteainses (MMPs) 
[157]. Thus, given the link between inflammation and tumour progression, a 
number of drugs have been developed to target the IL6/JAK/STAT pathway for not 
only treating chronic inflammatory diseases but also cancer [157]. 
In addition to inflammatory cytokines, a number of proteins have been shown to 
exhibit pro-angiogenic functions like VEGFA. In particular, PDGFA, Placental 
Growth Factor (PlGF), Angiopoietins (ANGPTs) and FGFs may be important 
during acquired resistance to VEGF targeted therapies like Bevacizumab™ [160]. 
More recently, the extracellular factor microseminoprotein (MSMP) was found to 
harbour neovascular properties in ovarian tumour xenografts resistant to anti-
VEGF therapy [161]. In this study, ovarian cancer conditioned media (CM) was 
found to induce endothelial tube formation and ERK activation in an MSMP/CCR2 
dependent manner. Notably, combined inhibition of MSMP and VEGF in vivo 
profoundly reduced tumour burden and vessel density in xenografts previously 
resistant to anti-VEGF therapy [161]. Thus, multiple modes of anti-angiogenic 
interference may be required to prevent or overcome resistance. 
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 Extracellular matrix proteins 
The 3D network of scaffolding proteins in which tissues exist is termed the 
extracellular matrix (ECM) [162]. The ECM is deposited by cells to support tissue 
integrity and structure and to regulate cellular phenotypes and behaviours. For 
example, stemness, EMT, apical-basal polarity, migration, invasion and 
angiogenesis are all regulated by components of the ECM [162,163]. The ECM is 
a dynamic structure that is continuously remodeled during wound repair and 
cancer progression [163]. Although many proteins form the ECM, only ~300 within 
the mammalian genome are annotated as core matrisomal proteins which exhibit 
distinct, and often repeating, domains and post translational modifications (PTMs) 
[164]. The remaining matrisome-associated or ‘ECM-affiliated’ proteins are more 
diverse and varied. Core matrisomal proteins are comprised of collagens, 
proteoglycans and glycoproteins and a number of these proteins are cross-linked 
via transglutaminase or contain inter-chain disulfide bonds which make their 
extraction and solubilisation difficult [165,166]. Collagens form homo- and hetero-
trimers that are characterized by repeating Gly-X-Y triplets with proline and 4-
hydroxyprolines frequently located in the X and Y positions, respectively [167]. 
Collagen VI, in particular, has been shown to regulate apoptosis, proliferation, 
angiogenesis and inflammation and is often highly abundant in tumours relative to 
benign tissues [167]. Moreover, the COL6A3 fragment, Endotrophin, is 
upregulated in mammary tumours during breast cancer progression in mice 
expressing the mammary tumour virus–polyoma middle T antigen (MMTV-PyMT) 
promoter [168].  Proteoglycans are heavily modified with glycosaminoglycans 
(GAGs) or polymeric repeating units of disaccharides with carboxyl and sulfate 
groups [166]. GAGs sequester water and divalent cations due to their negative 
charge and therefore confer lubricating and space filling properties. The largest 
and most complex subset of core matrisomal proteins are glycoproteins. They may 
include basement membrane components like laminins, CCN-family members 
such as CTGF and growth factor binding proteins like latent transforming growth 
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factor binding protein (LTBP). In the case of TGF-β, LTBPs facilitate folding in the 
ER, proteolytic processing in the trans-Golgi network, secretion, matrix association 
and activation [169]. Insulin-like growth factor binding proteins (IGFBPs) are also 
glycoproteins which regulate the activity and stability of IGFs which are potent 
growth factors that are often highly expressed in cancer [170]. Growth factor 
binding proteins such as LTBPs and IGFBPs often have multiple binding partners 
and functions which complicate our understanding of their roles in normal 
physiology and cancer. For instance, LTBPs may also signal independently of 
TGF-β to modulate the organization of fibrillin microfibrils [169]. There are 
numerous other glycoproteins within the ECM however a full catalogue of their 
functions is lacking.  
 Proteases 
Protease expression and activity is frequently dysregulated in cancer [171]. Next 
to kinases, proteases form the second largest group of enzymes in mammalian 
cells and provide exciting opportunities for targeting. This large family of proteins 
includes matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases 
(ADAMs), convertases, cathepsins, kallikreins and other endoproteases which are 
important for regulating tissue homeostasis, ECM remodelling and the bio-activity 
and availability of signalling ligands. Proprotein convertases (PC) belong to a 9 
membered family of mammalian Ca2+-dependent serine proteases related to 
bacterial subtilisin that proteolytically process hormones, growth factors, receptors, 
cell adhesion molecules and enzymes [172]. PC function both intra and 
extracellularly and typically cleave the pro-domains of inactive precursors to 
generate mature ligands. FURIN is a ubiquitously expressed PC which becomes 
upregulated in a number of cancers and is also involved in NODAL signalling  
[173]. For instance, in the TNBC cell line MDA-MB-231, Lapierre et al. observed a 
decrease in the maturation of pro-PDGFA and pro-IGF1R when the PCs furin, and 
to lesser extent, PACE4, were inhibited [174]. However, inhibition of FURIN and 
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PACE4 differentially decreased and increased MDA-MB-231 cell motility, 
migration and invasion, respectively. Accordingly, FURIN and PACE4 activity were 
positively and negatively associated with MMP9 activity, respectively. For 
reference, MMP9 is a matrix metalloproteinase that is frequently upregulated in 
cancers including breast cancer and is important for ECM remodelling and cancer 
cell intravasation and extravasation [175]. Tissue kallikreins and kallikrein-related 
peptidases form a 15 membered group (KLK1-15) of serine proteases with tryptic 
and/or chymotryptic-like activity which regulate substrate activation, inactivation or 
degradation [176]. KLK expression profiles vary between tissues and their 
physiological roles include maintaining proper kidney, brain and skin-barrier 
function. Prostate specific antigen (PSA; also known as KLK3) is perhaps the most 
widely known KLK. The main function of KLK3 is seminal liquefaction via cleavage 
of fibronectin (FN) and seminogelin-1 and 2. However, during prostate cancer 
progression, KLK4 overexpression and low Zn2+ levels lead to increased KLK3 
levels and in turn, cleavage of tumour-derived ECM proteins [176]. For example, 
cleavage of IGFBP3 by KLK3 promotes IGF1 dissociation and increased 
proliferation of prostatic stromal cells [177]. Other members of the kallikrein family 
have also been implicated in cancer progression and disease [178]. Cathepsins 
(CTS) are an 11 membered family of cysteine proteases with most members 
containing endopeptidases activity [179]. Like most proteases, cathepsin are 
synthesized as inactive zymogens with inhibitory pro-peptides that are cleaved by 
autocatalysis at low pH or other proteases. Cathepsins generally function within 
endosomal/lysosomal compartments but can be secreted into the extracellular 
space upon alterations in trafficking which occur in cancer and activated stromal 
cells. Of note, TAMs express CTS more robustly than any other cell type in the 
TME which is relevant given that Cathepsin S and L promote shedding of cell 
adhesion molecules (ALCAM, CD44 and neuropilin-1) and migration of MDA-MB-
231 breast cancer cells [180]. Moreover, similar to KLKs, CTS may be useful 
diagnostic markers for cancer. For example, high CSTB expression is associated 
with worse overall survival in many cancers including breast and ovarian 
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[179,181,182]. Lastly, a recent large scale proteomic screen employing terminal 
amine isotopic labeling of substrates (TAILS) identified over 1110 substrates of the 
cathepsin family in prostate cancer [183]. This report highlights the widespread 
substrates of CTS (and proteases in general) in the TME and how proteomic 
technologies can aid in their detection. 
 Vesicular cargo  
Intracellular proteins, counterintuitively, often comprise the largest fraction of 
species identified in secretome studies employing MS-based proteomics [184]. 
Indeed, highly abundant metabolic, transcriptional and translational proteins are 
liberated upon cell death and consequently, easily contaminate secretomes [184]. 
However, when cell death is carefully minimized, many intracellular proteins still 
remain suggesting the presence of non-classical secretion pathways for proteins 
lacking signal peptides [184]. Additionally, many intracellular proteins may be shed 
and located within extracellular vesicles (EVs) [185]. Several types of EVs are 
released by cells which vary in size, protein content and density. Exosomes, for 
example, are EVs ~30-120 nm in diameter which can transmit proteins and RNA 
(mRNA and miRNA) between cells. They are generated through endosomal 
trafficking and often express the surface markers CD9, CD63 and CD81 [186]. 
Little is known regarding role of EVs in intercellular protein transfer. Intriguingly, in 
2008,  Khalid Al-Nedawi et al. demonstrated the capacity of exosomes to transfer 
truncated EGFRvIII between expressing and non-expressing U373 glioma cells 
[187]. Remarkably, EGFRvIII containing exosomes were found to promote tumour 
growth in vivo and induce ERK1/2 and Akt activation in vitro which was correlated 
with VEGF and Bcl-x production. These findings have significant implications for 
cancer detection and treatment and also show that oncogenic transmission can be 
reversed upon blocking exosomal mediated protein transfer. In addition to 
exosomes, cells also release/shed vesicles and apoptotic blebs ranging from 50-
1000 nm in diameter comprised of various waste and cellular (by-)products. A 
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recent study by Harel et al. characterized plasma microparticles by LC-MS and 
identified a signature of protein biomarkers (PPTN1, SFXN3 and LPP) which could 
identify prostate cancer with a receiver operating characteristic area-under-the-
curve (ROC-AUC) of ~0.84 [188]. Taken together, the complement of EV 
associated proteins may reveal useful biomarkers and insights in biological 
processes exploited by cancers. 
1.9 Modelling the complexity of TME 
The TME is complex and dynamic and a number of approaches have been used 
to investigate its components individually or as a whole [189].  Properties intrinsic 
to the sample(s) or the model in question can limit the applicability of experimental 
findings and therefore complementary approaches may help generate a more 
comprehensive picture of the TME. Monolayer cultures of established cell lines are 
the most widely utilized model for examining cancer related questions [190,191]. 
This can be primarily attributed to ease of propagation and manipulation afforded 
by tissue culture plastic formats. Moreover, commonly used cancer lines have well 
defined genetic and molecular profiles which make experimental outcomes and 
findings relatable to previously published work [192,193]. Unfortunately, 
monolayer cultures and cancer lines do not accurately recapitulate the TME due 
to several reasons [194]. For one, cancer lines at their point of isolation, reflect a 
state of disease progression which over time in culture, may shift as a result of 
clonal selection and genomic instability. For instance, an analysis of the Cancer 
Cell Line Encyclopedia (CCLE) found a higher median mutation frequency in 
ovarian cell lines compared with tumours samples (4.3/Mb versus 1.6/Mb) [20]. 
Another shortcoming of monolayer cultures is the absence of accessory cell types 
frequently found in the TME. To examine these variables, Vincent et al. compared 
RNA sequencing data from breast cancer cell lines and breast tumours to measure 
differences in immune and stromal scores based on the ‘Estimation of STromal 
and Immune cells in MAlignant Tumours using Expression data’ (ESTIMATE) 
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algorithm [195,196]. Strikingly, 134 of the top 163 proteins differentially expressed 
between breast cancer cells and tumours were positively correlated with stromal 
score and likely attributed to the lack of stromal cells in monolayer cultures. This 
work and earlier studies also found proliferative, metabolic and transcriptional 
pathways upregulated in cell lines compared to tumours [191,196]. Conversely, 
pathways involved cell adhesion and communication were downregulated in cell 
lines. Regardless of their shortcomings, cell lines have been essential for 
understanding cell biology. For example, cell lines in isolation afford the ability 
determine the origin of extracellular factors involved in bi-directional cellular 
communication within the TME. Moreover, the NCI panel of 60 cell line resource 
has been exhaustively studied and is an import cornerstone for drug screening 
[192].  
However, several modifications to existing culture systems can be employed to 
better mimic the TME and limit the deficiencies highlighted above. First, primary 
patient derived samples which have undergone less selective pressure may 
resemble in vivo phenotypes more closely [193]. Moreover, tissue/tumour pieces 
can be cultured ex vivo for short periods of time to monitor invasion in response to 
inhibitors or drugs [197]. Co-cultures enable reciprocal signalling events between 
cancer cells and other cell types although tracing cell-type derived products require 
specific labelling techniques [198]. To represent the 3D structure of tissues in vivo, 
cell lines can be cultured in bioreactors or in ultra-low attachment conditions to 
promote spheroid formation [189,199]. These spheroids can develop regions of 
hypoxia with anoxia and necrotic cores that more accurately recapitulate tumour 
physiology.  
The ECM is another critical component of tumour biology often absent in 
monolayer cultures. Reconstituted basement membrane extracts (BME) such as 
Matrigel™ and GelTrex™ can be utilized to substitute the ECM in vitro and in vivo 
[200]. For example, Matrigel™ which is derived from the Engelbreth-Holm-Swarm 
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mouse sarcoma, is widely used to support feeder-free hESC cultures. Although 
predominantly comprised of laminin and entactin, mass spectrometry-based 
proteomic characterization of Matrigel identified over 1800 proteins including 
growth factors, regulatory proteins, intracellular contents and membrane bound 
proteins [200]. Furthermore, matrices preconditioned  by hESC can maintain 
pluripotency over multiple passages and thus highlights the importance of the ECM 
for modeling complex biological systems like stem cells and cancer [201].  
Finally, patient derived xenografts (PDXs) afford the most complex models of 
tumour biology which can be serially propagated in vivo [202,203]. While PDXs 
may be an attractive model of cancer pathology, a recent analysis of over 1100 
PDXs found divergence and loss of copy number alterations following serial 
propagation in mice [204].  Thus, there are a number of models to consider when 
studying the TME, each with their own benefits and drawbacks. 
1.10 Mass spectrometry-based proteomics 
As discussed above, the tumour secretome plays an integral role in dictating the 
activities and types of accessory cells within the TME [3]. The complexity of the 
TME, however, poses significant challenges for characterization. Commonly used 
‘omic’ approaches such as microarrays, RNA sequencing and whole exome 
sequencing can infer pathways involved in cancer progression [205]. Of caution, 
transcripts are not the functional machinery of cellular behaviours and their levels 
do not always correlate with protein expression [206]. Proteomics involves the 
study of proteomes or the protein complement of a biological sample, and is an 
alternative means of investigating cellular activities. Western blotting and Enzyme 
Linked Immunosorbent Assays (ELISAs) are perhaps the simplest proteomic tools 
available. Both are robust techniques with several limitations. ELISAs are widely 
used in clinical settings due to high sensitivity and accurate quantitation [207]. 
ELISAs are capable of processing large numbers of samples but are restricted to 
one or several targets and require access to high-quality antibodies [208]. Multiplex 
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cytokine arrays and Reverse Phase Protein Arrays (RPPA) are an alternative 
approach with limited throughput but the capacity to measure a larger number of 
factors (dozens to hundreds of targets) [208].  Like ELISAs and Western blotting, 
protein arrays also require validated antibodies and targets must be selected a 
priori.   
Although ELISAs and protein arrays are compatible with complex biological 
samples such as serum, they remain limited in their capacity for comprehensive 
tumour secretome characterization which is comprised of thousands of proteins. 
Bottom-up mass spectrometry-based approaches, however, identify peptide 
sequence information which can be matched to thousands of proteins in an 
unbiased, medium-to-high throughput manner [209]. Moreover, with some 
modifications, MS-based approaches are amenable to a wide array of biological 
formats including cell lines, fluids (i.e. blood, urine, saliva, effusions, ascites), and 
tissues. In effect, MS-based proteomics holds enormous potential for identifying 
drug targets, biomarkers and understanding cancer biology [207].  
 Sample preparation and fractionation strategies 
Sample preparation is critical task that should be carefully planned and optimized 
and is vital to the success of any proteomics study. The nature of experimental 
question(s) dictate the means in which samples are collected, processed and 
analyzed. A standard bottom-up proteomics workflow involves sample collection, 
protein extraction and solubilisation, reduction and alkylation, digestion, clean-up, 
chromatographic separation by HPLC, acquisition of MS and MS/MS spectra, and 
database searching. 
Depending on the source of material to be analyzed, samples may require 
enrichment or pre-processing. Harsh lysis buffers utilizing chaotropes, detergents 
and reducing agents combined with mechanical dissociation are often an effective 
means of protein extraction and amenable to most materials. For instance, urea 
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and disulfide reduction can improve the extraction and detection of ECM proteins 
that are otherwise insoluble. Unlike tissues/cell pellets, the protein concentrations 
of fluids are more dilute and may require concentration or enrichment. Molecular 
weight cut-off (MWCO) filter units combined with centrifucation are a simple yet 
effective apparatus for concentrating extracellular proteins. One caveat when 
working with biological fluids or cell culture media is the presence of high 
abundance proteins (HAP) such as Albumin. FBS or serum supplements can often 
be omitted for short periods of time in vitro. However, this is not possible with 
patient fluids like plasma. Depletion strategies are one method to overcome the 
presence of HAP which often exceed the dynamic range of MS instruments [210]. 
Alternatively, proteins with specific post-translational modifications can be affinity 
purified. For example, secreted proteins may be enriched using glyco-capture and 
phospho-peptide enrichment with TiO2 beads for measuring kinase signalling 
[211,212]. Moreover, extracellular vesicles can be isolated using affinity 
purification or ultracentrifugation [213]. With regard to the ECM proteins, 
ammonium sulfate precipitation has been used to crudely precipitate less soluble 
moderate-to-high molecular weight proteins (generally present in high abundance) 
from more soluble, low molecular weight proteins which often contain low 
abundance growth factors [200]. Lastly, fractionation strategies can improve the 
detection of low abundance proteins by analyzing more material across multiple 
LC-MS runs. A large number of strategies exist for sample fractionation with SDS-
PAGE traditionally being the most widely used. Recent innovations and newer 
techniques have significantly simplified fractionation workflows or achieved greater 
results. These include Stop-and-go-extraction Tip (StageTip) fractionation, offline 
HPLC basic reversed phase separation, and selective elution from beads via a 
novel SP3 approach [214–217]. Impressively, a recent study combined multiple 
enzyme digestions with high-pH fractionation and state-of-the-art mass-
spectrometry instrumentation to achieve unprecedented HeLa proteome coverage 
to a depth of 14K proteins [209]. Continuous advances in sample preparation 
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modalities and MS instrumentation are narrowing the gap between genomic 
sequencing and proteomic technologies.  
 Quantification strategies 
Quantification is a key aspect of modern day MS-based proteomics [218]. Robust, 
accurate and flexible quantification strategies are needed to enable comparisons 
between as little as two samples to potentially hundreds.  Mass spectrometry 
techniques can utilize a number methods for relative and absolute protein (peptide) 
quantification and like sample preparation, the method employed will vary 
depending on the experimental questions being asked. 
Unlike most quantification techniques, label free quantification (LFQ) does not 
require special considerations and can be implemented into most proteomic 
workflows. Although LFQ strategies have been available for decades, only recently 
have software and instrumentation improvements increased the accuracy and 
robustness [219]. Spectral counting and intensity based absolute quantification 
(iBAQ) have been largely utilized as  surrogates or proxies for protein abundance 
[206,220]. Interference due to co-eluting peptides with highly similar m/z values is 
a primary concern for all extracted ion chromatogram (XIC)-based quantification 
strategies such as LFQ. Of note, high resolution mass analyzers combined with 
narrow m/z search tolerances can alleviate most interference issues. Furthermore, 
feature detection algorithms utilizing retention time (RT) windows and isotopic 
distribution patterns improve quantification across adjacent runs and fractions 
where peak splitting and technical variation are encountered [219]. Stable Isotopic 
Labelling in Cell Culture (SILAC) is a metabolic labelling technique that also 
employs XIC-based quantification like LFQ [221].  SILAC uniquely enables protein 
samples from different cell lines or treatments to be mixed which eliminates 
technical variability associated with sample handling and LC-MS. SILAC, however, 
requires isotopically labelled cells in order to compare relative changes in protein 
expression/PTMs between two or more conditions. In a typical SILAC workflow, 
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cell lines are grown in media containing either light or heavy isotopes of Arginine 
and Lysine. Thus, newly synthesized proteins incorporate light or heavy amino 
acids and after several population doublings entire proteomes become isotopically 
labelled. Peak intensities between pairs of light and heavy peptides (m/z values) 
from pooled SILAC samples are used to compare relative protein (peptide) levels. 
SILAC provides more accurate quantification and can achieve more than twice the 
throughput than that of LFQ. However, sample complexity is effectively doubled 
with SILAC which therefore limits the number of unique peptides that can be 
sequenced in a given LC-MS run due to redundant MS/MS scans for light and 
heavy pairs. Of note, several variations of SILAC have increased its utility beyond 
comparing two cell types or conditions. Super SILAC, for example, employs a 
heavy standard comprised of multiple heavy labelled cell lines. When spiked into 
light (unlabeled) samples, the super SILAC standard acts as an internal reference 
which protein levels can be normalized to and compared across many samples. 
For reference, Pozniak et al. utilized super SILAC to compare proteomes from 
healthy breast ductal epithelia, lymph node negative, lymph node positive and 
metastatic breast tumours [222]. This study found key that DNA repair proteins 
involved in non-homologous end joining, mismatch repair, and the single-strand 
DNA break repair complex were downregulated in tumours while several enzymes 
involved in oxidative phosphorylation and glycolysis were significantly increased 
and decreased, respectively. Interestingly, in tumour versus normal tissues, these 
authors noted an inverse relationship between The Cancer Genome Atlas (TCGA) 
mRNA expression and protein levels for DNA repair, ribosomal and glycolytic 
enzymes.  Cell Type specific labeling using Amino acid Precursors (CTAP) is 
another elegant metabolic labelling technique that enables proteins to be traced to 
cell of origin in co-culture conditions [198]. In this technique, transgenic cell lines 
express enzymes (lysine racemase or diaminopimelate decarboxylase) which 
utilize different L-lysine precursors. Given that lysine precursors are only utilized 
by one cell type, transgenic line can be studied in the same culture dish. Using this 
strategy, Tape et al. investigated the reciprocal interactions between PDAC and 
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pancreatic stromal cells [223]. CyToF is another MS-based approach which 
employs antibodies labelled with metals to multiple surface protein expression on 
single cells to a greater extent than afforded by flow cytometry [224]. Using this 
technology, Bendall et al. were able to measure 34 parameters including 31 
proteins on single cells to generate a complex map of hematopoietic lineages. 
To overcome limitations associated with LFQ, chemical labelling strategies 
including isotope coded affinity tags (ICAT) and tandem mass tags (TMT) were 
developed [225]. These chemical labelling technique are implemented following 
sample digestion and do not induced mass differences between MS1 precursors 
like SILAC. Rather, quantification is performed on “tags” from different channels 
which are produced during MS/MS fragmentation. Up to 10 or more samples can 
be multiplexed with this technique allowing for high throughput proteome analysis 
[226].  Of note, noise associated with the low m/z regions where tags are quantified 
can interfere with quantification [227]. MS3 scans can significantly improve 
specificity and the cost of sensitivity and speed [228]. However, an elegant solution 
to these issues was the development of Notched MS3 scans (trademarked as 
synchronous precursor selection) by Coon’s group [227]. This feature is only 
available on state-of-the-art Orbitrap Fusion instruments.   
Selective reaction monitoring (SRM) and more recently, parallel reaction 
monitoring (PRM), are the last quantification strategies which harbour the greatest 
potential for diagnostic and clinical utility [229].  These targeted methods require 
peptide retention time (RT) information and are typically limited to small number of 
transitions. Synthetic stable isotope labeled (SIL) peptides can be utilized for 
absolute quantification. They afford highly accurate and sensitive MS2 
quantification that is less susceptible to interference from all sources and can be 
rapidly performed using shorter gradients. 
48 
 
 
 
1.11 Rationale and thesis objectives 
A variety of approaches and model systems are required to answer complex 
biological questions involving the TME. MS-based proteomics is a powerful 
technology that can improve our understanding the TME. In this thesis, I focused 
on better understanding the complexities of the TME by utilizing mass 
spectrometry to study several aspects of cancer biology important for: 1) the 
classification of ovarian cancer subtypes, 2) the identification of biomarkers 
for ovarian cancer detection, and 3) understanding the global effects of 
NODAL in the breast cancer microenvironment. 
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Chapter 2  
2 Comparison of sample preparation techniques for 
large scale proteomics 
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2.1 Abstract 
Numerous workflows exist for large scale bottom-up proteomics, many of which 
achieve exceptional proteome depth. Herein, we evaluated the performance of 
several commonly used sample preparation techniques for proteomic 
characterization of HeLa lysates (unfractionated in-solution digests, SDS-PAGE 
coupled with in-gel digestion, gel-eluted liquid fraction entrapment electrophoresis 
(GELFrEE) technology, SCX StageTips and High-/Low-pH reversed phase 
fractionation (HpH)). HpH fractionation was found to be superior in terms of 
proteome depth (>8400 proteins detected) and fractionation efficiency compared 
to other techniques. SCX StageTip fractionation required minimal sample handling 
and was also a substantial improvement over SDS-PAGE separation and 
GELFrEE technology. Sequence coverage of the HeLa proteome increased to 
38% when combining all workflows however total proteins detected improved only 
slightly to 8710. In summary, HpH fractionation and SCX StageTips are robust 
techniques and highly suited for complex proteome analysis. 
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2.2 Introduction 
Sample preparation strategies employed in bottom-up proteomics can be broadly 
categorized into workflows which omit or implement fractionation at the protein 
and/or peptide level prior to LC-MS [1]. Prior limitations in MS instrumentation and 
HPLC technology rendered unfractionated approaches insufficient when 
characterizing complex proteomes and thus necessitated the need for extensive 
fractionation [2]. Advances in instrumentation speed and sensitivity coupled with 
UPLC systems utilizing longer columns and smaller particles sizes has 
substantially improved proteome depth of unfractionated samples. This is 
exemplified by Nagaraj and colleagues and Pirmoradian et al., who detected over 
3900 yeast and 4800 HeLa proteins, respectively, by employing long gradients and 
50 cm reversed phase columns coupled to a high resolution Q Exactive mass 
spectrometer [3,4]. In fact, it is now possible to detect ~4000 yeast and ~4400 
HeLa proteins in approximately 1h with current state-of-the-art Orbitrap-based 
mass spectrometers (Orbitrap Fusion and Q Exactive HF) [5,6]. In contrast, 
fractionation approaches based on molecular weight (MW), charge, pI, or 
hydrophobicity require substantially more acquisition time and sample handling [7]. 
Nonetheless, these workflows contribute to our understanding of biological 
systems by characterizing PTMs, enriching for low abundance species and 
quantifying expression for thousands of proteins [8–11].  
 
SDS-PAGE protein separation coupled with in-gel digestion has been widely used 
in mass spectrometry-based proteomic studies [12,13]. Its robustness, low cost, 
high resolution and ability to handle detergent containing samples make it 
amenable to many workflows. In fact, two recently published drafts of the human 
proteome utilized SDS-PAGE to obtain unprecedented protein expression profiles 
for multiple tissues (peptide evidence from 84-92% of protein coding genes in the 
human proteome) [14,15]. However, SDS-PAGE fractionation is time consuming, 
manually intensive and subject to variable peptide extraction efficiencies [12]. 
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Newer fractionation strategies, like Gel Eluted Liquid Fractionation Entrapment 
Electrophoresis (GELFrEE) technology, can overcome most limitations associated 
with SDS-PAGE [16]. Exceptional proteome coverage has been reported with 
peptide based fractionation using MudPIT [17], IEF [18,19], and High-/Low-pH 
reversed phase chromatography (HpH) [6,20]. Alternatively, small scale peptide 
fractionation (C18, SCX, SAX) can be readily performed in StageTips without 
requiring dedicated fractionation equipment [21–23]. 
Many large scale proteomic studies employ methodologies such as those listed 
but few have compared their performance relative to one another [24–26]. In light 
of this, we compared HeLa proteomes obtained from unfractionated in-solution, 
SDS-PAGE, GELFrEE, SCX StageTip and HpH sample preparations across 
several parameters. When controlling for sample loading and LC-MS time, most 
workflows performed well, however, HpH fractionation provided the greatest 
proteome coverage. 
2.3 Results 
 Proteome coverage of different workflows on a Q 
Exactive mass spectrometer 
HeLa proteomes obtained from unfractionated in-solution, SDS-PAGE, GELFrEE, 
SCX StageTip and High-/Low-pH pH reversed phase (HpH) sample preparations 
were systematically compared (Figure 2.1). Where possible, experimental 
parameters were kept constant between workflows. To minimize sample handling 
and processing, all techniques, with the exception of SDS-PAGE, utilized 
chloroform methanol precipitation followed by in-solution digestion. In total, 10 
fractions were analyzed by LC-MS (~1µg per fraction) for each technique from 3 
biological replicates (3 different passages). Unfractionated in-solution samples 
were injected once per replicate. In our hands, long LC-MS gradients generate 
more protein identifications compared to shorter gradients when analyzing cellular 
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lysates (data not shown). Therefore, all fractions were run on a 4h gradient plus 
washing and re-equilibration.   
 
Replicates were searched both individually and grouped using the match between 
runs feature in MaxQuant. Where applicable, protein identifications containing ≥1 
unique peptide(s) in 2 out of 3 biological replicates were used for analysis [27]. In 
general, each method tested received more instrument time compared to previous 
reports and when necessary, utilized chloroform/methanol precipitation to remove 
SDS coupled with on-pellet, in solution digestion. 
 
Within each replicate from different workflows, ~7.1% of the HeLa proteins 
identified were “matched-between-runs” and >95% of the proteins were present in 
all biological replicates suggesting high reproducibility for each technique (data not 
shown). Moreover, only a small fraction of proteins were identified by one unique 
peptide (Figure 2.2A). In total, 5189, 6959, 5919, 7655, 8470 proteins were 
detected with in-solution, SDS-PAGE, GELFrEE, SCX and HpH workflows, 
respectively (Table 2.1).  
 
In terms of proteomic depth, nearly 5200 proteins were detected with 
unfractionated in-solution HeLa digests, which is on par with previous reports 
[4,27]. Recently, Beck et al. detected ~5200 HeLa proteins from triplicate, 90 
minute runs on a Bruker Impact II™ Q-TOF [28]. For gel-based techniques, 
proteome coverage with SDS-PAGE was also comparable to reports by other 
groups [29,30]. While Botelho et al. previously demonstrated similar performance 
between GELFrEE and SDS-PAGE using an LTQ ion trap, we detected ~1,000 
more proteins with SDS-PAGE fractionation compared to GELFrEE separation 
[26].  
 
69 
 
 
 
Regarding peptide fractionation approaches, we identified a respectable number 
of proteins using SCX StageTips but our numbers were less than that obtained by 
Kulak et al. using a similar technique (7655 versus 9667) [22]. Differences in 
sample preparation (lysis buffer and digestion) as well as column size may be 
contributing factors. Protein identifications with HpH was similar to Kelstrup et al. 
(8470 versus 8400 protein IDs) and the highest out of all workflows tested [6]. Even 
greater proteome depth has been achieved with HpH fractionation by Beck et al. 
who reported >11,000 proteins from a more complex mouse cerebral tissue [28].  
Several proteomic studies have documented increased proteome depth by 
combining data from multiple workflows and/or instrumentation [31–33]. 
Combining all our datasets yielded >8700 unique proteins. This represents a small 
increase of ~3% over HpH fractionation, which had nearly 700 exclusive proteins 
alone (Figure 2.2B).  
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Figure 2.1 Schematic of workflows tested. 
Hela lysates (100µg) were separated by SDS-PAGE and GELFrEE or subjected 
chloroform/methanol precipitation and on-pellet, in-solution digestion prior to High 
pH reversed phase and SCX StageTip fractionation. GELFrEE fractions were also 
chloroform/methanol precipitated to remove SDS. Three independent biological 
replicates were analyzed by LC-MS on the Q Exactive. 
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Table 2.1 Total HeLa proteins detected on a Q Exactive for each technique 
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Figure 2.2 High confidence identifications and large overlap between 
proteomes from different techniques.  
(A) Majority of proteins (~95%) were identified with high confidence (2 or more 
unique peptides; blue) for each technique. Only a small number (~5%) were 
identified by a single peptide (red). (B) Total proteins exclusive (11%) and common 
(50%) to 5 different preparative techniques analyzed on a Q Exactive. Gene 
symbols were used for analysis and proteins exclusive to one biological replicate 
were omitted. 
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 Comparison of fractionation efficiency 
The capacity of pre-fractionation to resolve unique proteins or peptides into 
discrete packets, reduces sample complexity and improves peptide detection and 
identification by MS [34]. To assess the fractionation efficiency for each technique, 
we examined how many unique peptides, and proteins where applicable, were 
exclusive to 1, 2 or ≥3 fractions. For this analysis, biological replicates were 
searched individually without the "match-between-runs" feature in MaxQuant. 
 
In principle, SDS-PAGE displays good protein separation and resolution over a 
wide range of MWs, generally within a few kDa. Surprisingly, we found with SDS-
PAGE that only 27.7% and 59.5% of proteins identified were exclusive to 1 or 2 
fractions, respectively (Figure 3A). However, at the peptide level, 58.2% and 
82.8% were exclusive to 1 or 2 fractions, respectively (Figure 2.3C). Of note, the 
GELFrEE protocol was less efficient at separating proteins than SDS-PAGE 
(Figure 3B, D). Silver stained GELFrEE fractions ran on 1D SDS-PAGE revealed 
moderate overlap between adjacent lanes (Figure 4A). Moreover, Box-and-
Whisker plots of median fraction MW further illustrate limited separation with 
GELFrEE compared to SDS-PAGE (Figure 2.4C). Peptide fractionation efficiency 
with SCX StageTips was similar to Kulak et al. with 53.8% and 77.4% exclusive to 
1 or 2 SCX fractions, respectively (Figure 2E) [22]. However, the HpH method gave 
the best fractionation performance with 80.1% and 94.5% of all peptides exclusive 
to 1 or 2 fractions, respectively (Figure 2.3F).  
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Figure 2.3 Fractionation efficiency varies between protein and peptide 
separation techniques. 
Pie chart displaying percentage of unique proteins and peptides (mean +/- SD) 
exclusive to one (black), two (light grey) and three or more fractions (grey) for SDS-
PAGE (A,C), GELFrEE (B,D), SCX (E) and HpH (F). SDS-PAGE and HpH 
exhibited the greatest fractionation efficiency for protein and peptide based 
separation techniques, respectively. 
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Figure 2.4 Overview of GELFrEE separation 
(A) Silver stained 1D SDS-PAGE of fractions collected on an 8% Tris-acetate 
GELFrEE cartridge starting with 100ug of HeLa lysate. Fraction 14 was run on the 
same gel. (B) Gradient was slightly modified to allow leading dye front to be eluted 
in the first fraction. Fraction 1 was discarded and fractions 2 and 3, 11 and 12, and 
13 and 14 were combined to produce a total of 10 fractions. (C) Box-and-Whisker 
plot of median protein MW detected in each fraction for SDS-PAGE (black) and 
GELFrEE (blue). Boxes represent 75% and 25% percentiles and Whiskers indicate 
90% and 10% percentiles. 
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 Distribution of proteins and peptides  
Fractionation techniques which exhibit orthogonal separation should be more 
efficient at maximizing MS/MS time across the entire gradient space [34]. For each 
method, the distribution of peptides and proteins across all fractions varied. We 
did not observe any trends between gel- and peptide-based fractionation 
approaches, however, changes in unique peptides and proteins per fraction 
consistently mirrored each other within each technique. For example, total 
peptides and proteins increased slightly with MW for SDS-PAGE separation before 
declining in later fractions (Figure 2.5A). SCX displayed a sharp increase in 
peptides/proteins detected in early fractions before both plateaued (Figure 2.5C). 
Changes between fractions with GELFrEE and HpH fractionation were relatively 
smaller (Figure 5B and D). Peptide density versus retention time plots also 
illustrate a similar trend (Figure 2.6). For example, SDS-PAGE exhibited a higher 
peptide density with increasing fraction number (MW) while HpH remained even 
throughout, most likely due to its concatenation scheme. 
 
We next examined peptides:protein ratios for each technique and found gel-based 
methods had approximately 1 less peptide identified per protein compared to 
peptide fractionation even though gel-based approaches generated roughly 300K 
more MS2 scans (Table 2.2). As expected, in-solution digests had the lowest 
peptides:protein ratio (10.1:1) but identified the greatest proteins/hour (1298/hour). 
While total unique peptides was indicative of proteins identified for each technique, 
this was not the case with PSMs. For example, GELFrEE had the greatest number 
of PSMs but the fewest unique peptides and proteins. 
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Figure 2.5 Peptide and protein distribution profiles deviate for each 
technique. 
(A-D) Distributions of unique peptides (right y-axis, grey) and proteins (left y-axis, 
black) identified per fraction for SDS-PAGE, GELFrEE, SCXand HpH, 
respectively. 
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Figure 2.6 HpH fractionation is highly orthogonal compared to other 
methods. 
Peptide density distribution was assessed using the hexbin package in R, each 
hexagon represents 500 peptides with red indicating the highest density. HpH 
fractionation yields a more even distribution of peptides throughout the entire 
gradient and across all fractions compared with gel- and SCX-based fractionation 
which exhibit more extreme (low and high) peptide densities. 
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Table 2.2 Total MS/MS scans, peptides and proteins detected with each 
technique 
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 Evaluating peptide characteristics 
Examining the median sequence coverage achieved for each method revealed a 
peak in peptide density between 10% and 15% before tailing off (Figure 2.7A). For 
gel-based workflows, median sequence coverage with GELFrEE (~27%) was 
higher than SDS-PAGE (22.6%) (Figure 2.7B). SCX and HpH peptide fractionation 
improved median sequence coverage to ~27% and 24.4%, respectively, over the 
unfractionated in-solution digest (22.8%) (Figure 2.7B). Combining sequence 
information from all methods improved median sequence coverage of all HeLa 
proteins identified to 38.0%. This can be attributed to a 48.6% increase in total 
unique peptides (165K) over HpH, which had the second highest number of unique 
peptides (111K) (Table 2.3). For comparison, Kelstrup et al. achieved a median 
sequence coverage of >40% with HeLa digests fractionated by HpH (14 fractions) 
using the latest generation Q Exactive HF [6].  
 
Next, we calculated GRAVY scores for unique peptides detected by each workflow 
to determine whether any bias towards hydrophobic or hydrophilic species existed 
(Figure 2.9A) [35]. All methods displayed a propensity to enrich for hydrophilic 
peptides as indicated by negative GRAVY scores. Dunn’s multiple comparison, 
post hoc analysis revealed a significantly higher (P<0.001) median GRAVY score 
with unfractionated in-solution digests compared to all other techniques (Figure 
2.9B). These findings are in line with previous groups which found cellular digests 
to be primarily hydrophilic and also suggests a proportion of hydrophobic peptides 
are lost during sample handling [36,37]. 
 
Lastly, analysis of missed cleavages revealed that a large number were present in 
most sample preparations although many (~70%) were restricted to 1 site (Table 
2.3). As expected, SDS-PAGE was the highest (44.5%) which may be explained 
by poor absorption and diffusion of trypsin into the gel pieces. Missed cleavages 
with GELFrEE was relatively high (34.8%) compared to unfractionated in-solution 
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samples (25.6%) even though digestion was performed essentially the same for 
both techniques. SCX fractionation exhibited the least missed cleavages (15.9%) 
followed by HpH (22.1%).   
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Figure 2.7 Different fractionation techniques provide complementary 
sequence coverage 
(A) Kernel density estimation comparing percent sequence coverage for each 
technique. A slight maxima is observed near 40% (black line) when combining 
sequence information from all methods. (B) Box-and-Whisker plots displaying 
median percent sequence coverage for individual techniques (blue). Box and 
whiskers indicate 75% and 25% percentiles, and 95% and 5% percentiles, 
respectively. One-way ANOVA was performed using the Kruskal-Wallis test to 
assess differences in mean sequence coverage distribution between methods. 
Combined data set is shown in red. All methods were significantly different from 
each other (p<0.05), with the exception of GELFrEE and SCX. 
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Figure 2.8 All workflows preferentially enrich for hydrophilic peptides. 
(A) Kernel density estimation was performed using GRAVY scores from each 
method. GRAVY scores <0 indicate the presence and relative abundance of 
hydrophilic species. (B) Box-and-Whisker plot displaying mean GRAVY scores. 
Boxes represent 75% and 25% percentiles and whiskers indicate 95% and 5% 
percentiles. One-way ANOVA was performed using the Kruskal-Wallis test to 
assess differences in mean GRAVY score distribution between methods. 
Combined dataset is shown in red. In-solution was significantly from different from 
all other methods (p-value <0.0001). 
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Table 2.3 Total missed cleavages present in all preparative techniques 
 
  
85 
 
 
 
2.4 Discussion 
In this study, we compared the performance of several commonly used sample 
preparative techniques for bottom-up proteomics. As expected, fractionation 
yielded more protein identifications, and in most cases, greater sequence 
coverage, than unfractionated in-solution digests. Peptide-based fractionation 
outperformed gel-based workflows in terms of protein IDs and fractionation 
efficiency but not necessarily sequence coverage.  
 
Interestingly, in our hands, we did not achieve similar proteome depth with 
GELFrEE compared to SDS-PAGE. GELFrEE appears to suffer from poor 
resolution which may be inherent to the low 8% tris-acetate cartridges and short 
resolving gel (1cm) required for eluting high MW proteins within a reasonable time 
frame. In addition, the GELFrEE collection chamber was not rinsed between 
cycles. Hence, carry over between fractions from residual sample in the GELFrEE 
collection chamber could have led to an under representation of 
separation.  However, both GELFrEE and SDS-PAGE exhibited poor protein 
separation in comparison to other studies which found 64-67% of proteins 
identified were exclusive to a single fraction [26,29]. At the peptide level, our 
numbers more closely resemble these values. Therefore, we believe that 
proteoforms (isoforms, PTMs and cleaved/fragmented proteins) migrating at 
different MWs are recorded as single entries during database searching, thereby 
underestimating the true fractionation efficiency of both SDS-PAGE and GELFrEE. 
For example, Titin, a 3.6 MDa protein was detected in low, intermediate and high 
MW SDS-PAGE and GELFrEE fractions. Nonetheless, GELFrEE remains an 
invaluable tool for top-down proteomics [38].  
 
Differences between digestion efficiency with in-gel and in-solution preparations is 
another factor which likely affected proteome coverage and warrants further 
investigation. For reference, we investigated peptides with missed cleavages from 
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HpH preparations which contained internal lysine and/or arginine residues. 
Notably, we found the frequency of internal K residues to be ~2 fold higher than R 
even though their abundance in the human proteome (Uniprot) is approximately 
even (~5.8% for K and ~5.6% for R) (data not shown). This difference can be 
explained by trypsin's higher affinity for arginine compared to lysine [39]. Hence, 
future sample preparations may benefit from utilizing Trypsin/LysC to minimize the 
number of missed cleavages occurring at lysine [40]. 
 
Reproducibility, feasibility/cost and throughput are important parameters to 
consider when choosing a sample preparation to employ in bottom-up proteomics. 
Although it is difficult to objectively quantify these parameters for each technique, 
SCX StageTip fractionation was by far the most efficient and straightforward 
method due to the capacity to process samples in parallel and short elution times. 
HpH fraction collection was automated but is limited to processing one sample at 
a time. In addition, HpH requires a dedicated fractionation system as well as 
additional time for concatenation, drying and column cleaning between replicates. 
GELFrEE can multiplex up to 8 samples but needs ~3 hours to run plus 
chloroform/methanol precipitation of each fraction. It also requires a dedicated unit 
and custom cartridges. SDS-PAGE, as expected, was the most labour intensive 
technique and required an additional day for destaining. However, SDS-PAGE as 
well as SCX StageTips, were the most cost-effective and accessible methods. 
 
Although combining multiple techniques improved protein identifications and 
sequence coverage, the additional acquisition time needed is not feasible for the 
majority of medium to large scale proteomic studies (≥1 proteome/day of 
instrument time). It is doubtful that faster mass spectrometers with increased 
sensitivity and dynamic range will bypass the need for some form of sample 
fractionation to achieve maximum proteome coverage.  Utilizing multiple enzyme 
digestion strategies or iterative exclusion in tandem with techniques like HpH 
fractionation may be more appropriate for achieving optimal sequence coverage 
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[10,41–43]. Additional improvements to protein extraction/handling, column 
technology and instrumentation could also yield increased proteome depth. In 
summary, the findings reported here illustrate the benefits and limitations of 
different techniques for analyzing a complex cellular proteome and should help aid 
in the design of future bottom-up proteomics studies.  
2.5 Materials and Methods 
 Cell culture and protein extraction 
HeLa cells (obtained from the ATCC) were maintained in DMEM F12 media 
supplemented with 10% FBS (Life Technologies, Grand Island, NY). Confluent 
15cm plates of HeLa cells were rinsed with PBS, trypsinized and then centrifuged 
at 400 xg for 5 minutes to pellet cells. Cell pellets were re-suspended in PBS, 
pelleted again and stored at -80°C. To prepare lysates for LC-MS, frozen cell 
pellets were incubated in 8M Urea, 50mM ammonium bicarbonate (ABC), 10mM 
DTT, 2% SDS and sonicated with a probe sonicator (20 X 0.5 second pulses; Level 
1) (Fisher Scientific, Waltham, MA) to shear DNA. Lysates were quantified using a 
Pierce™ 660nm Protein Assay (ThermoFisher Scientific) and stored at -80˚C until 
future use. 
 Chloroform/methanol protein precipitation 
HeLa lysates were reduced in 10mM DTT for 30 minutes and alkylated in 100mM 
Iodoacetamide (IAA) for 30 minutes at room temperature in the dark. Next, lysates 
were precipitated in chloroform/methanol in 1.5mL microfuge tubes according to 
Wessel and Flügge [44]. Briefly, 100μg aliquots of HeLa lysates were topped up to 
150µL with 50mM ABC. To each sample, 600μL of cold methanol was added 
followed by 150μL of chloroform and thorough vortexing. A volume of 450μL of 
water was added before additional vortexing and centrifugation at 14,000 xg for 5 
min. The upper aqueous/methanol phase was carefully removed to avoid 
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disturbing the precipitated protein interphase. A second 450μL volume of cold 
methanol was added to each sample followed by vigorous vortexing and 
centrifugation at 14, 000 xg for 5 min. Remaining chloroform/methanol was 
discarded and the precipitated protein pellet air dried in a fume hood. 
 Unfractionated on-pellet in-solution digestion 
On-pellet protein digestion was performed using a modified protocol described by 
Duan et al. [45]. Briefly, 150µL of 50mM ABC (pH 8) trypsin solution was added to 
precipitated protein pellets (1:50 ratio) and incubated overnight at 37°C in a water 
bath shaker. An additional aliquot of trypsin was added the next day (1:100 ratio) 
for ~4 hours before acidifying (pH 3-4) with 10% formic acid (FA). Digests were 
centrifuged at 14,000 xg to pellet insoluble material before LC-MS or peptide 
fractionation. 
 SDS-PAGE followed by in-gel digestion 
HeLa lysates were fractionated by SDS-PAGE as previously described [46]. 
Briefly, 100µg of lysate was separated on a 12% acrylamide tris-glycine gel 
followed by fixing, staining with Coomassie blue and destaining overnight on a 
horizontal shaker. Each lane was divided into 10 equal gel fractions which were 
manually processed into ~1x1 mm3 cubes using a razor blade. Gel pieces were 
reduced in 10mM DTT for 30 minutes and alkylated in 100mM IAA for 30 minutes 
at room temperature in the dark.  After dehydration with ACN, gel pieces were 
swelled in 100μL of 50mM ABC (pH 8) trypsin solution (1:25 ratio distributed evenly 
across 10 fractions) and incubated overnight in a water bath shaker at 37°C. 
Peptides were extracted from gel pieces in the presence of a water bath sonicator 
by adding a small volume of 10% FA followed by dehydration in 300μL ACN for 10 
minutes, two times. Samples were dried in a SpeedVac (Thermo Scientific, 
Waltham, MA) and re-suspended in 0.1% FA prior to LC-MS. 
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 GELFrEE fractionation followed by in-solution digestion 
HeLa lysates (100μg/chamber) were fractionated on an 8% tris-acetate cartridge 
using the GELFrEE system according to the manufacturer (Expedeon, San Diego, 
CA). The voltage gradient used to operate the GELFrEE station is outlined in 
Supplementary Figure 1B. Sample collection was not started until blue loading dye 
was visible in the collection chamber after which 150-200µL of liquid was removed 
and replaced following each time interval. Running buffer was changed every hour 
or half hour when using 50 or 100V, respectively. Fractions 2 and 3, 11 and 12, 
and 13 and 14 were concatenated to generate a total of 10 fractions that were 
processed using chloroform/methanol and in-solution digestion as described 
above. 
 SCX peptide fractionation 
Tryptic peptides recovered from chloroform/methanol precipitated, in-solution 
digests of HeLa lysate (100µg) were fractionated using SCX StageTips similarly to 
Kulak et al.[22]. Approximately 100µg of peptides, acidified with 1% TFA, were 
distributed evenly between four 12-plug SCX StageTips. In total, 10 SCX fractions 
were collected by eluting in 75, 100, 125, 150, 175, 200, 225, 250 and 300mM 
ammonium acetate/20% ACN solutions followed by a final elution with 5%mM 
ammonium hydroxide/80% ACN. Fractions eluted with identical buffers from 
quadruplicate StageTips were combined, dried in a SpeedVac, resuspended in 
ddH2O and dried again to evaporate residual ammonium acetate. All samples were 
resuspended in 0.1% FA prior to LC-MS analysis. 
 High pH reversed phase peptide fractionation 
Proteins (100µg) obtained from chloroform/methanol precipitation were digested 
in-solution with trypsin as described above. Next, tryptic peptides were fractionated 
on a Waters XBridge BEH130 C18 5µm 4.6mm x 250mm column connected to an 
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Agilent 1100 HPLC system at a flow rate of 1 mL/min at 20°C. Buffer A (100% 
water) and buffer B (10% water/90% ACN) were maintained at pH 10.0 by the 
addition of ammonium hydroxide immediately prior to fractionation. The gradient 
consisted of 5% to 35% B over 55 minutes, 70% B over 8 min, hold at 70% B for 
2 minutes, return to 5% B over 5 min and then hold for 15 minutes. A total of 50 
fractions were collected during the first 75 minutes of the gradient (1.5 mL per 
fraction) using an automated fraction collector. The volume of each fraction was 
reduced using a SpeedVac and every 10th fraction was concatenated. The final 10 
fractions were dried completely using a SpeedVac and resuspended 0.1% FA prior 
to LC-MS. 
 LC-MS 
All fractions/digests were analyzed using an M-class nanoAquity UHPLC system 
(Waters) connected to a Q Exactive mass spectrometer (Thermo Scientific). Buffer 
A consisted of Water/0.1% FA and Buffer B consisted of ACN/0.1%FA. Peptides 
(~1µg measured by BCA) were initially loaded onto an ACQUITY UPLC M-Class 
Symmetry C18 Trap Column, 5 µm, 180 µm x 20 mm and trapped for 4 minutes at 
a flow rate of 10 µl/min at 99% A/1% B. Peptides were separated on an ACQUITY 
UPLC M-Class Peptide BEH C18 Column, 130Å, 1.7µm, 75µm X 250mm 
operating at a flow rate of 300 nL/min at 35°C using a non-linear gradient 
consisting of 1-7% B over 7 minutes, 7-19% B over 173 minutes and 19-30% B 
over 60 minutes before increasing to 95% B and washing. Settings for data 
acquisition on the Q Exactive are outlined in Table 2.4. 
 Data Analysis 
All raw MS files were searched in MaxQuant version 1.5.2.8 using the Human 
Uniprot database (reviewed only; updated May 2014 with 40,550 entries) [47,48]. 
Missed cleavages were set to 3 and I=L. Cysteine carbamidomethylation was set 
as a fixed modification. Oxidation (M), N-terminal acetylation (protein), and 
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deamidation (NQ) were set as a variable modifications (max. number of 
modifications per peptide = 5) and all other setting were left as default. Precursor 
mass deviation was left at 20 ppm and 4.5 ppm for first and main search, 
respectively. Fragment mass deviation was left at 20 ppm. Protein and peptide 
FDR was set to 0.01 (1%) and the decoy database was set to revert. Match-
between-runs was enabled where specified in the main text in order to transfers 
missed proteins identifications between replicate LC-MS/MS runs due to 
limitations in instrument speed during data dependent acquisition of complex 
samples. Bioinformatics analysis was performed using Perseus version 1.5.5.3. 
Briefly, protein lists obtained from MaxQuant search results were loaded into 
Perseus and entries (proteins) indicated as identified by site, reverse or potential 
contaminant were removed [49]. When using the match-between-runs feature, 
datasets were filtered for proteins containing a minimum of one unique peptide in 
at least 2 out of 3 biological replicates. Kernel density estimation was performed 
using R statistical software version 3.2.3. Graphpad Prism version 6.01 was used 
to conduct nonparametric Kruskal-Wallis test coupled with Dunn’s multiple 
comparison, along with the Mann-Whitney test to assess significance. 
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Table 2.4 Overview of parameters used for data acquisition on a Q Exactive. 
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Chapter 3  
3 Proteomic-based discovery of putative biomarkers 
for improved classification of endometrioid and high 
grade serous ovarian cancer subtypes 
  
98 
 
 
 
3.1 Abstract 
Epithelial ovarian cancer (EOC) is a heterogeneous disease consisting of 5 main 
subtypes. Overall survival for EOC remains low and treatment modalities do not 
differ significantly between subtypes. However, patients may benefit from alternate 
therapies targeting pathways associated with EOC subtypes, such as Poly (ADP-
ribose) polymerase (PARP) inhibitors for high grade serous ovarian cancer 
(HGSC). Thus accurate subtype classification will become increasingly important 
for patient management and outcomes. HGSC and endometrioid ovarian cancer 
(EC) are associated with poor and good patient prognosis, respectively. However, 
in a subset of cases, the differential diagnosis of HGSC from EC (primarily high-
grade) based on pathological assessment is challenging. Although histotype 
specific markers for HGSC exist in the clinic, positive markers for EC are lacking. 
Therefore, we undertook a label free quantitative proteomics approach to 
characterize differences between EC and HGSC tumours that may reveal markers 
specific to EC. Our findings highlight differences between HGSC and EC biology 
that relate to integrin, estrogen and interferon signalling pathways. Although a 
subset of EC and HGSC tumours exhibited similar protein expression profiles, we 
identified a number of proteins consistently enriched in EC. Accordingly, several 
candidates, including progesterone receptor (PR), were validated by 
immunohistochemistry on a cohort of over 300 (EC and HGSC) tumour sections. 
KIAA1324 was identified as a novel marker for EC with diagnostic performance 
similar to PR, the current best marker of EC, and may aid in pathological 
assessment of difficult to discriminate tumours.  
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3.2 Introduction 
Ovarian cancer affects 1.27% of females and remains a difficult disease to treat 
with a 5-year overall survival of only 46.5% [1]. Approximately 90% of all ovarian 
cancer cases are classified as invasive epithelial ovarian cancer (EOC) which can 
be divided into 5 main subtypes: high grade serous (HGSC), low grade serous 
(LGSC), clear cell (CCC), endometrioid (EC) and mucinous. Although EOC is 
comprised of heterogeneous entities, cytoreductive surgery combined with 
platinum/taxol-based chemotherapy remains the standard first line treatment 
regardless of subtype [2]. For example, CCC, mucinous, and LGSC respond poorly 
to chemotherapy but are treated identically to HGSC and EC [3–5]. In light of 
advances in genetic and molecular profiling, only recently have targeted therapies 
for managing EOC begun to emerge [6]. For example, clinically approved poly 
(ADP-ribose) polymerase (PARP) inhibitors are now a promising second line 
treatment option for BRCA1/2 defective, chemoresistant or recurrent HGSC [7]. 
Immunotherapy might be an alternative treatment option for EC which is 
associated with defects in DNA mismatch repair genes (Lynch syndrome) [8,9]. 
Moreover, the anti-angiogenic therapy bevacizumab (Avastin™) significantly 
increases median progression free survival (PFS) and may preferentially improve 
overall survival (OS) in EOC with mesenchymal and proliferative molecular 
subtypes [10]. Therefore, accurate characterization and discrimination of EOC 
subtypes is becoming increasingly pertinent for making informed treatment 
decisions and developing targeted therapies.  
Pathological assessment of EOC can be supported by immunohistochemistry 
(IHC) in a reproducible manner. For example, TP53 combined with WT1 or 
p16/CDKN2A staining can be used to discern HGSC and LGSC [11,12]. 
Alternatively, hepatocyte nuclear factor-1 beta (HNF-1β) is a highly specific marker 
of CCC [13]. In a proportion of EOC cases, discrimination between HGSC and EC 
tumours remains challenging, in particular high-grade (2 and 3) EC [9,11,14,15]. 
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Although WT1 can help confirm HGSC cases misclassified as EC, positive 
markers for EC exhibit limited specificity. For instance, progesterone receptor (PR) 
is expressed by ~81% of EC but present in 56% of HGSC [16]. Thus, identification 
and validation of EC specific markers are needed to improve clinicopathologic 
assessment and treatment selection for difficult diagnosis. 
High-resolution mass spectrometry-based proteomics is a powerful and unbiased 
technology which is being increasingly applied to characterize complex biological 
systems which are inherent in cancer. A recent study by Hughes et al. exemplified 
the translational capabilities of mass spectrometry by performing high-throughput 
quantitative proteomic characterization of formalin fixed paraffin embedded 
(FFPE) tumour samples from HGSC, CCC and EC. One of the findings reported 
in this study was the identification of cystathionine γ-lyase (CTH), a highly specific 
and novel marker for CCC [17]. In another large scale proteomic study, ovarian 
cancer cell lines were stratified based on clustering with mesenchymal, clear cell 
and epithelial expression profiles to identify their possible site of origin [18]. In an 
attempt to elucidate histotype specific markers of EC, we undertook a mass 
spectrometry-based proteomics approach using fresh frozen tumour samples from 
HGSC and EC patients. In addition to previously reported markers, we observed 
several proteins by proteomics that may offer improved diagnostic performance 
over PR alone for detecting EC. Lastly, IHC was performed on a cohort of up to 
311 (HGSC and EC) ovarian tumour sections to determine the specificity and 
sensitivity for a subset of proteins (PLCB1, PAM, KIAA1324, PR, CTNNB1, 
MUC5B, PIGR, SCGB2A1 and PIGR) for detecting EC.   
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3.3 Results 
 Global proteomic analysis of serous and endometrioid 
ovarian cancer 
To identify markers enriched in or exclusive to endometrioid (EC) versus high-
grade serous ovarian cancer (HGSC) subtypes, we performed label free 
quantitative proteomics on 20 unfractionated EC and HGSC tumour samples (10 
samples from each subtype) and 4 normal ovarian tissues (Figure 3.1). Patient 
characteristics for each subtype are listed in Table 3.1. On average, ~4500 
proteins were identified in each sample of which ~97% contained LFQ intensity 
values (Figure 3.2A). As anticipated, most proteins detected were of cytoplasmic 
origin (cell part) or belonging to macromolecular protein complexes and organelles 
according to PantherDB (Figure 3.2B) [19]. Approximately 78% of all proteins 
identified in the dataset were present in at least one sample from each group 
(Normal, HGSC or EC) and 13.5% (870 proteins) were exclusively shared between 
HGSC and EC groups (Figure 3.2C). Entries with LFQ values in ≤2 samples/group 
(Normal, EC or HGSC) were subsequently removed to minimize the number of 
proteins detected in a limited number of samples. Missing LFQ values were 
imputed in Perseus and Principal Component Analysis (PCA) was performed on 
the remaining proteins (~5800) [20]. EC samples clustered relatively well as 
illustrated by PCA however HGSC clustering was more dispersed (Figure 3.2D). 
In addition, only 3 of 4 normal samples were distinct from malignant samples. 
Interestingly, several tumour samples clustered more tightly with the opposite 
subtype suggesting similarities in protein expression profiles and/or intra-subtype 
heterogeneity. Indeed, ovarian cancers are known to be highly complex and 
heterogeneous. One HGSC sample contained substantially less protein IDs 
(~3100) which likely impacted its clustering with other HGSC samples. 
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Figure 3.1 Proteomics-based workflow for detecting EC enriched markers 
Proteins were initially extracted, precipitated and digested from normal ovarian 
tissue (Normal), high-grade serous ovarian cancer (HGSC) and endometrioid 
ovarian cancer (EC) tumours. Unfractionated digests (peptides) were analyzed by 
liquid chromatography-mass spectrometry (LC-MS) on an Orbitrap Elite followed 
by database searching and label free quantification (LFQ) in MaxQuant with 
match-between-runs enabled and a minimum ratio count of 1 to improve proteome 
coverage and quantification. Protein LFQ intensities were used to identify 
differentially expressed proteins and perform gene ontology (GO) and pathway 
analysis. A subset of protein candidates specific to or highly expressed by EC 
tumours were validated by immunohistochemistry (IHC) on tumour microarrays 
consisting of EC and HGSC tumour sections to assess their performance.  
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Table 3.1 Patient characteristics 
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Figure 3.2 Proteome coverage and clustering ovarian (tumour) samples. 
(A) Stacked bar plot showing total proteins identified (light and dark grey) and 
quantified (light grey) in normal ovarian tissue samples (Normal), endometrioid 
ovarian cancer (EC) and high-grade serous ovarian cancer (HGSC) tumour 
samples. (B) Distribution of GO cellular components (GOCCs) for all proteins 
identified. (C) Venn diagram showing overlap between Normal, HGSC and EC 
datasets.  (D) Principal Component Analysis (PCA) using protein entries containing 
≥3 LFQ intensities in at least one group (Normal, HGSC or EC). Missing LFQ 
values were imputed in Perseus using a down shift of 1.8 and width of 0.3.  
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We next determined which proteins were differentially expressed (two sample t-
test, p<0.05) between ovarian tumour samples (EC or HGSC) and normal ovarian 
tissue (Normal). Substantially more proteins were significantly elevated in EC and 
HGSC tumours compared to normal tissue (Figure 3.3A and B). Interestingly, log2 
fold-changes in protein expression between EC versus Normal and HGSC versus 
Normal correlated relatively well (Pearson correlation coefficient of ~0.8) 
suggesting a fair degree of similarity between these two subtypes (Figure 3.3C). 
Indeed, regardless of subtype (EC or HGSC), multiple proteins were highly 
elevated in ovarian tumours, such as phosphoserine aminotransferase (PSAT1) 
and L-amino-acid oxidase (IL4I1), that may warrant further investigation.  
To better interrogate differences between EC and HGSC, we omitted the normal 
ovarian samples from further analyses. Proteins shared between HGSC and EC 
samples were relatively unchanged however clustering within each subtype 
appeared to improve slightly (Figure 3.4A and B).  Moreover, numerous proteins 
were found to be differentially expressed between the two subtypes (two-sample 
t-test, p<0.05) (Figure 3.4C, ESM3.1). Accordingly, cellular tumour antigen p53 
(TP53) and PR expression were significantly lower (-2.06 log2 fold-change, -log10 
p-value = 2.03) and higher (4.20 log2 fold-change, log10 p-value = 4.46) in EC 
tumours relative to HGSC tumours, respectively. We did not detect Wilms tumour 
protein (WT1), a known positive marker of HGSC, in our proteomics data however 
CDKN2A/p16 was significantly higher in HGSC [11]. Additional proteins previously 
found to be differentially expressed between EC versus HGSC included MSLN (-
2.67 log2 fold-change, -log10 p-value = 1.50), IGF2 (-1.62 log2 fold-change, -log10 
p-value = 1.51), MMP7 (1.45 log2 fold-change, -log10 p-value = 2.23) and CTNNB1 
(0.86 log2 fold-change, -log10 p-value = 2.15) [21].  
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Figure 3.3 Utilizing normal ovarian tissues to assess commonalities between 
EC and HGSC proteomes. 
(A and B) Volcano plot of log2 fold-changes in LFQ protein intensities between EC 
tumours and normal ovarian tissue or HGSC tumours and normal ovarian tissue. 
Proteins significantly elevated (p-value<0.05) in tumour samples or normal ovarian 
tissue are highlighted in red and blue, respectively. (C) Scatter of plot of log2 fold-
changes versus log2 fold-changes from A and B. Proteins differentially expressed 
in both datasets (EC versus Normal and HGSC versus Normal) are highlighted in 
red and blue. A subset of significant proteins highly expressed in ovarian tumours 
regardless of subtype (EC and HGSC) or normal ovarian tissue are labelled in 
black.  
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Figure 3.4 Interrogating differences between HGSC and EC proteomes. 
(A) Venn diagram reveals high overlap between proteins expressed in HGSC and 
EC subtypes. (B) Principal Component Analysis (PCA) illustrating moderate 
clustering of tumour samples within each subtype. (C) Volcano plot of log2 fold-
changes in LFQ intensities (EC versus HGSC) reveal a large number of 
differentially expressed proteins. Proteins significantly elevated in EC or HGSC are 
coloured in red and blue, respectively. Several of the top differentially expressed 
proteins are labelled in black. Only protein entries containing LFQ intensities in at 
least 3 out of 10 samples for either subtype (HGSC or EC) were retained for 
downstream comparisons. 
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 Pathway annotation reveals differences between HGSC 
and EC biology  
To document pathways and processes which may differ between EC and HGSC, 
we utilized two approaches. First, proteins significantly elevated in EC or HGSC 
proteomes were analyzed using ‘EnrichR’ to identify over-represented pathways 
(Reactome, BioCarta, NCI-Nature, KEGG) or GO biological processes (GOBPs) 
[22]. Second, using the entire proteomic expression dataset, we performed gene 
set enrichment analysis (GSEA) which is sensitive to cumulative changes in the 
expression of groups of multiple proteins.   
In terms of over-representation, a wide variety of signalling pathways, 
metabolic/enzymatic processes, immune associated responses and 
transcriptional/translational activities were significantly associated with each 
subtype (Figure 3.5, ESM3.2 and 3.3). For example, “Neutrophil mediated 
immunity”, “Lysosome” and “Alpha6 beta4 integrin ligand interactions” were 
significant in EC (Figure 3.5A). Alternatively, “Interferon signaling”, “Mismatch 
repair” and “Integrin family cell surface interactions” were over-represented in 
HSGC (Figure 3.5B). Accordingly, significant differences in integrin signalling were 
supported by higher ITGA6, ITGB4 and ITGA1 expression in EC and elevated 
ITGA3 and ITGA5 levels in HGSC.  
GSEA was performed using Hallmark and canonical pathways (v6.1) from the 
Molecular Signatures Database (MSigDB) and identified a moderate number of 
gene sets with nominal p-values≤0.05 albeit a subset were within the 
recommended FDR cut-off of 0.25 (Table 3.2) [23,24]. Substantially more gene 
sets were enriched in EC compared to HGSC. Indeed, melanoma, bladder cancer, 
and DNA replication (KEGG) were among the limited gene sets potentially 
enriched (negative normalized enrichment score (NES)) in HGSC. Conversely, 
numerous gene sets were highly enriched (positive NES) in EC with estrogen 
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response early (Hallmark; NES ~1.6) among the most significant (p-value<0.001 
and FDR q-value <0.25).   
To further illustrate differences between EC and HSGC biology, we compared 
normalized (z-scored) expression values of core proteins enriched in estrogen 
response early (Hallmark) and interferon alpha beta signalling (Reactome) gene 
sets (Figure 3.6A). In general, EC samples expressed high levels of proteins 
associated with estrogen signalling while proteins associated with interferon 
signalling were elevated in HGSC samples. Interestingly, HGSC-1 and EC-9 
appeared to exhibit protein expression profiles characteristic of the opposing 
subtype.  
As a complement, we performed 1D annotation enrichment in Perseus on the 
combined list of ~5600 proteins which revealed modest but significant alterations 
in GOBPs (BH FDR<0.02) (Figure 3.6B and ESM3.4) [20]. Proteins associated 
with defense response to fungus (1.24 log2 fold-change), O-glycan processing 
(0.99 log2 fold-change), and fatty acid metabolic processes (0.44 log2 fold-change) 
were enriched in EC. High mucin expression (MUC1, MUC5AC, MUC5B, MUC6 
and MUC16) was primarily associated with elevated O-glycan processing in EC. 
Conversely, processes enriched in HGSC included response to type 1 interferon 
(0.90 log2 fold-change), DNA strand elongation (0.61 log2 fold-change), positive 
regulation of adaptive immune response (0.51 log2 fold-change) and mitochondrial 
translation (0.36 log2 fold-change). High expression of HLA-A histocompatibility 
antigens, and interferon induced and regulatory proteins were primarily 
responsible for increased interferon signalling in HGSC. 
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Figure 3.5 Pathway annotation of proteins differentially expressed between 
EC and HGSC tumours  
Proteins significantly elevated in EC or HGSC tumour samples were analyzed in 
EnrichR using Reactome (red), BioCarta (blue), KEGG (black) and NCI-Nature 
(purple) pathways and GO biological processes (GOBPs; green). (A and B) The 
top 3 most significant (Benjamini-Hochberg (BH) adjusted p-value<0.05) pathways 
and GOBPs in (A) EC or (B) HGSC tumours are labelled. Horizontal dotted line 
indicates an adjusted p-value cut-off of 0.05 and no significant BioCarta pathways 
were observed in HGSC tumours. 
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Table 3.2 Gene sets enriched in EC and HGSC tumours 
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Figure 3.6 Selected pathways and processes characteristic of EC and HGSC 
biology. 
(A) Heat map showing normalized (z-score) expression of core proteins enriched 
in estrogen response early (top panel) or interferon alpha/beta signalling (bottom 
panel). (B) Selected GOBPs enriched in HGSC and EC subtypes following 1D 
annotation enrichment in Perseus. Bars and black dots represent total proteins and 
log2 fold-enrichment for each GOBP listed, respectively. 
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 Selecting EC enriched proteins for IHC validation 
An ideal diagnostic marker is one that achieves high sensitivity (detects all or most 
true positives) and high specificity (reports no or few false positives). To filter 
candidates of EC for validation by IHC, we first tabulated proteins with peptide 
evidence in ≥80% of tumour samples from one subtype and ≤20% of samples from 
the other subtype (Table 3.3). This approach identified 15 and 7 proteins that were 
largely exclusive to EC and HGSC tumours, respectively. Of note, PR was among 
the list of proteins enriched in EC with a log2 fold-change (EC versus HGSC) of 
4.20. While this strategy may detect proteins with high specificity, it may not 
capture all proteins with high differential expression in EC. Therefore, we analyzed 
our proteomics data using the R package ‘geNetClassifier’ (GNC) to rank proteins 
with the greatest classification power in an unbiased fashion [25]. In total, 106 
proteins passed the posterior probability cut-off of 0.95 and were used in training 
the support vector machine (Figure 3.7A and ESM3.4). The lowest error rate 
achieved by GNC was 0.1 (10%) and corresponded to a set of 69 proteins (Figure 
3.7B). Interestingly, the top 2 ranked proteins (MUC5B and PIGR) were not 
identified based on our initial filtering criteria. We subsequently performed 
unsupervised hierarchical clustering utilizing Pearson correlation coefficients 
calculated from LFQ expression data restricted to the top 106 ranked proteins. 
While this analysis segregated HGSC and EC samples relatively well, hierarchical 
clustering revealed a third central cluster comprised of 3 EC and 2 HGSC samples 
(Figure 3.7C). This finding was in agreement with our earlier PCA which indicated 
some tumour samples cluster more closely with opposite subtype, such as HGSC-
1 and EC-9.  
 Validation of EC enriched proteins by IHC  
Based on our proteomic analysis, we opted to select several candidates with large 
log2 fold-changes (MUC5B and PIGR) and/or high specificity (PLCB1, PAM, 
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KIAA1324 and SCGB2A1) to validate using IHC on a cohort of up to 311 tumour 
sections (174-176 EC and 134-136 HGSC). For comparison, we included known 
markers of EC (PR and CTNNB1 [beta-catenin]) in our IHC panel. Receiver 
Operating Characteristic (ROC) Area Under the Curves (AUCs) ranged from 0.82-
0.99 for these candidates when calculated from LFQ expression values (Figure 
3.4D). PPM1H exhibited the highest ROC-AUC but was not validated in our initial 
cohort. 
IHC staining for each of the candidates were scored using a 4-tier system; absent 
= 0, 1-50% focal = 1, 50-95% diffuse = 2, ≥95% block pattern = 3 (Figure 3.5). PR 
was scored as absent (0) or present (1) and CTNNB1 as membranous (0) or 
nuclear (1). IHC images from tumour sections demonstrating positive staining in 
EC (score ≥2) and negative staining in HGSC (score = 0) for each marker are 
shown (Figure 3.8). Importantly, staining scores ≥1 were observed in a significantly 
greater proportion of EC tumour sections than HGSC (Figure 3.9A). Of note, 
KIAA1324 was the only marker which exhibited performance similar to that of PR 
with a sensitivity of 88.5% and specificity of ~53% (Figure 3.9B). Increasing the 
cut-off score to ≥2 reduced sensitivity to 65% but increased specificity to 84% for 
KIAA1324 (data not shown). Although PAM yielded a very high ROC-AUC, it was 
the second least sensitive marker next to CTNNB1 (Figure 3.4D and Figure 3.9B). 
SCGB2A1 (mammaglobin-B), conversely, was the least specific marker which was 
unexpected given the expression, like KIAA1324, was relatively exclusive to EC 
versus HGSC samples in our proteomics analyses (Table 3.3 and Figure  3.9B). 
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Table 3.3 High confidence proteins frequently detected in HGSC and EC 
tumours. 
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Figure 3.7 Protein selection for downstream validation of EC markers. 
(A) Proteomes with LFQ intensities from each tumour sample were analyzed using 
the Bioconductor package ‘geNetClassifier’ (GNC) in R.  (A and B) Total number 
of proteins assigned a posterior probability ≥0.95 by GNC. A minimum set of 69 
genes was found to discriminate between HGSC and EC at an error rate of 10% 
after being trained. Unsupervised hierarchical clustering of tumour samples 
according to Pearson correlation coefficients using the 106 proteins with posterior 
probability ≥0.95. (D) Receiver-operating-characteristic (ROC) area under the 
curve (AUC) of several EC targets selected for validation by IHC. 
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Figure 3.8 Immunohistochemical staining for markers of EC. 
Images taken from EC and HGSC tumour sections showing positive (score ≥ 2) 
and absent (score = 0) staining for each marker (PLCB1, PAM, KIAA1324, PR, 
CTNNB1, SCGB2A1, MUC5B and PIGR). 
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Figure 3.9 Proportion of tumours staining positive for EC markers. 
(A) Mosaic plots showing the proportion of EC and HSGC sections with positive 
(blue region) or negative (red region) staining for PLCB1, PAM, KIAA1324, PR, 
CTNNB1, SCGB2A1, MUC5B and PIGR. Nuclear and membranous staining for 
CTNNB1 was assigned a score of 1 and 0, respectively. The proportion of tumour 
sections staining positive (score ≥1) was significantly higher for all markers in EC 
compared to HGSC (Fisher’s exact test, p<0.001). (B) Corresponding sensitivity 
and specificity values of each target for detecting EC using a cut-off score ≥1. PR 
and KIAA1324 were the best performing markers with relatively good sensitivity 
but intermediate specificity. 
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3.4 Discussion 
Accurate subtype classification is becoming increasingly important for the 
management of patients with EOC. However, differential diagnosis between EC 
and HGSC tumours remains troublesome in a small proportion of cases [2,15]. In 
light of this, we performed label free proteomic analysis on fresh frozen tumours to 
identify markers specific to the EC histotype. We did not employ fractionation or 
multiplexed-based quantification strategies but achieved relatively good proteomic 
coverage (~4500 protein identifications/sample) and detected a significant number 
of proteins that may aid in the discrimination of EC from HGSC.  
While not the main focus of this study, pathway analysis revealed several 
interesting differences between EC and HGSC biology. For instance, members of 
integrin signalling pathways which have been implicated in a wide range of 
diseases including cancer were differentially expressed between EC and HGSC 
[26]. More specifically, integrin α6/β4 were elevated in EC and commonly 
expressed by epithelial cancers [26]. Integrin α5 (ITGA5) expression, in contrast, 
was higher in HGSC and has been previously associated with worse patient 
prognosis compared to tumours with low expression [27]. Proteins linked to 
interferon and estrogen signalling were also elevated in HGSC and EC, 
respectively, and may provide opportunities for therapeutic intervention. 
Interestingly, mismatch repair was significantly over-represented in HGSC 
compared to EC. Our group and others have previously found mismatch repair to 
be defective in a subset EC which supports this finding [9,28,29]. Given the limited 
treatment options for EOC, fractionation techniques which yield greater proteome 
coverage and in-depth pathway analysis are warranted [30]. 
Importantly, our proteomics analyses identified several proteins highly enriched in 
EC. All markers validated by IHC were expressed in significantly higher proportion 
of EC tumours however KIAA1324 was the only marker which exhibited sensitivity 
and specificity comparable to PR. According to the Human Protein Atlas 
126 
 
 
 
(www.proteinatlas.org), KIAA1324 is a prognostic (favourable) indicator for 
endometrial, lung and ovarian cancer [31]. Little is known regarding the role of 
KIAA1324 in ovarian cancer although it was initially identified as a novel-estrogen 
induced gene (EIG121) in endometrial cancer [32]. More recently, KIAA1324 was 
reported in HGSC with high ERα and KIAA1324 gene expression correlated with 
worse OS [33].  In this study, the authors note KIAA1324, compared to ERα alone, 
may better stratify HGSC patients for which hormonal therapy is beneficial. For 
reference, up to 88% of HGSC tumours express ERα but the number of patients 
estimated to respond to hormonal to therapy ranges from 13-26%. We did not 
correlate ERα with KIAA1324 in this study however if KIAA1324 can stratify 
hormone sensitive EC or HGSC, retrospective analysis of tumour samples from 
patients treated with estrogen antagonists are warranted. 
Similar to KIAA1324, the human protein atlas lists PR, PAM, SCGB2A1, and PIGR 
but not PLCB1 or MUC5B as prognostic indicators of endometrial cancer [31]. Of 
note, TCGA studies have revealed a number of similarities between EC and the 
copy-number low (endometrioid) endometrial cancer subtype [34,35]. For 
instance, PR is upregulated in both EC and copy-number low endometrial cancer. 
Given the prognostic value of these markers in endometrial cancer and their high 
expression in EC, one or more of these factors may exhibit prognostic potential if 
detected in EC or HGSC. However, this needs to be confirmed by comparing PFS 
and OS data. Beyond the markers we validated by IHC, it would be useful to 
investigate additional targets with potentially greater specificity for EC including 
PPMH1 and PPAP2C.  
Several limitations of our proteomic analysis that may mask or exaggerate 
differences between EC and HGSC is the unknown contribution of stromal proteins 
and potential differences in protein localization or activity. Stromal cell 
contributions remains an issue for most ‘omic’ studies but have been approximated 
with the ‘Estimation of STromal and Immune cells in MAlignant Tumours using 
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Expression data’ (ESTIMATE) score [36]. However, like CTNNB1, putative 
diagnostic proteins may not exhibit high differential expression but rather differ in 
their compartmentalization and activity and are therefore likely to be overlooked 
during candidate selection. Techniques such as laser capture microdissection, 
PTM enrichment and/or subcellular fractionation may reveal additional subtype 
specific proteins missed by our approach. 
In summary, the lack of identifying a strong candidate for discriminating EC from 
HGSC (>90% sensitivity and specificity) resonates with the challenges reported by 
previous histopathological studies [2,11]. This was evident following PCA and 
hierarchical clustering whereby several EC and HGSC proteomes clustered 
together and appeared to share similar expression profiles. A similar finding was 
also documented in the quantitative proteomic study of FFPE ovarian cancer 
tumour sections by Hughes et al. where HGSC and EC samples clustered more 
closely at the proteome and transcriptome level compared to CCC samples [17].  
In light of prior and current findings, it may be difficult to establish a single marker 
which discriminates EC from HGSC. Alternatively, multiple markers may be 
required to aid in accurate diagnosis. For example, ward’s algorithm was utilized 
to determine which combination of TP53 and CDKN2A staining features could best 
discriminate HGSC from LGSC [12]. Moving forward, multivariate analysis of our 
IHC data may reveal subtype specific expression patterns for improved diagnosis 
of EC in challenging cases. 
3.5 Materials and methods 
 Protein extraction from fresh frozen tumours  
Fresh frozen tumour biopsy cores where provided by Dr. Köbel at the University of 
Calgary and confirmed to be HGSC or EC based on pathological assessment. To 
prepare samples for LC-MS, tumours cores were partially thawed on ice and a 
section corresponding to ~100mg was removed with a razor blade. Tumour 
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sections were immediately wrapped in tin foil and submerged in liquid nitrogen for 
~10 minutes. Cryopreserved tumour pieces wrapped in tin foil were hit with a mallet 
3-5 times to pulverize the tissue into a fine powder. One mL of 8M Urea, 50mM 
ammonium bicarbonate (ABC), 10mM dithiothreitol (DTT), 2% SDS lysis buffer 
was added directly to the dissociated tumour sample on tin foil and carefully 
transferred into a 1.5mL microfuge tube. Tumour samples were sonicated with a 
probe sonicator (~20 X 0.5s pulses; Level 1) (Fisher Scientific, Waltham, MA) on 
ice to break up residual tissue chunks and reduce viscosity. Lysates were 
quantified using a Pierce™ 660nm Protein Assay (Thermo Scientific™) and stored 
at -80˚C until future use.  
 Chloroform/Methanol protein precipitation 
A 100µg aliquot of tumour lysate was reduced in 10mM DTT for 30 minutes and 
alkylated in 100mM iodoacetamide (IAA) for 30 minutes at room temperature in 
the dark. Proteins were precipitated in chloroform/methanol in 1.5mL microfuge 
tubes according to Wessel and Flügge [37]. Briefly, samples in lysis buffer were 
topped up to 150µL with 50mM ABC then mixed with ice cold methanol (600μL) 
followed by adding ice cold chloroform (150μL) and vortexed thoroughly.  An 
additional volume (450μL) of 4°C water was added followed by vortexing and 
centrifugation at 14, 000 xg for 5 min. The upper aqueous/methanol phase was 
carefully removed to avoid disturbing the precipitated protein interphase. A second 
450μL volume of cold methanol was added to each sample followed by vigorous 
vortexing and centrifugation at 14, 000 xg for 5 min. The remaining 
chloroform/methanol supernatant was discarded and the precipitated protein pellet 
was left to air dry in a fume hood. 
 On-pellet in-solution digestion 
On-pellet in-solution protein digestion was performed similarly to Duan et al. [38]. 
Briefly, precipitated tumour proteins were reconstituted in 100µL of 50mM ABC 
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(pH 8) and sonicated for 1-3 x 0.5s pulses to the break up the pellet. LysC (Wako 
Chemicals, USA) and mass spec grade trypsin/LysC mix (Promega, Madison, WI, 
USA) were added to protein samples at a 1:100 and 1:50 ratios, respectively. 
Protein digestion was carried out 37°C on a ThermoMixer C (Eppendorf) held at 
300 rpm overnight (~18h). The next day an additional volume of trypsin/LysC mix 
(1:100 ratio) was added to each sample and mixed at 1400 rpm. After 4h, digests 
were acidified to pH 3-4 with 10% FA and centrifuged at 14,000 xg to pellet 
insoluble material prior to LC-MS. 
 LC-MS 
Digests were analyzed using an M-class nanoAquity UHPLC system (Waters) 
connected to an Orbitrap Elite mass spectrometer (Thermo Scientific). Buffer A 
consisted of Water/0.1% FA and Buffer B consisted of ACN/0.1%FA. Peptides 
(~1µg measured by BCA) were initially loaded onto an ACQUITY UPLC M-Class 
Symmetry C18 Trap Column, (5 µm, 180 µm x 20 mm) and trapped for 6 minutes 
at a flow rate of 5 µl/min at 99% A/1% B. Peptides were separated on an ACQUITY 
UPLC M-Class Peptide BEH C18 Column (130Å, 1.7µm, 75µm X 250mm) 
operating at a flow rate of 300 nL/min at 35°C using a non-linear gradient 
consisting of 1-7% B over 1 minute, 7-23% B over 173 minutes and 23-35% B over 
60 minutes before increasing to 95% B and washing. Settings for data acquisition 
on the Orbitrap Elite are outlined in Table 3.4. 
 Data analysis 
MS files were searched in MaxQuant (1.5.8.3) using the Human Uniprot database 
(reviewed only; updated May 2017 with 42, 183 entries) [39,40]. Missed cleavages 
were set to 3 and cysteine carbamidomethylation was set as a fixed modification. 
Oxidation (M), N-terminal acetylation (protein), and deamidation (NQ) were set as 
a variable modifications (max. number of modifications per peptide = 5) and all 
other settings were left default. Protein and peptide FDR was set to 0.01 (1%) and 
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the decoy database was set to revert. The match-between-runs feature was 
utilized to maximize proteome coverage and quantitation by LFQ [41]. Datasets 
were loaded into Perseus (version 1.5.5.3) and proteins containing peptides only 
identified by site (modified peptides exceeding 1% FDR) or matched to reverse 
(decoy) database hits were removed [20]. Protein identifications with quantitative 
values in ≥2 samples in a least one tumour subtype (HGSC or EC) were retained 
for downstream analysis unless specified elsewhere. Missing values were imputed 
using a width of 0.3 and down shift of 1.8. Gene ontology cellular component 
(GOCC) analysis was performed using PantherDB. Pathway annotation was 
performed in using EnrichR [19,22]. Gene set enrichment analysis was carried out 
using GenePattern or GSEA 3.0 with all settings left as default [24]. Support Vector 
Machine (SVM) analysis and Pearson correlation heatmaps were produced using 
the Bioconductor packages ‘geNetClassifier’ and ‘complexHeatmap’, respectively 
[25,42]. ROC-AUC was performed in GraphPad Prism (Version 6.01). 
 Immunohistochemistry 
Immunohistochemistry (IHC) staining was performed by Calgary Laboratory 
Services in the Department of Pathology and Laboratory Medicine at the University 
of Calgary using a DAKO Omnis platform on two 0.6mm representative cores (4 
micron sections) from previously constructed tissue microarrays (174-176 EC and 
134-136 HGSC tumour sections). Antibody information is provided in ESM3.5.  All 
markers were scored using a 4-tier system by pathologists Dr. Martin Köbel and/or 
Dr. Peter Rambau. Absent staining was assigned a score of 0. Tumour cells 
staining as focal (1-50%), diffuse (>50-95%), or block pattern (≥95%) were 
assigned scores 1, 2, or 3, respectively. For CTNNB1, nuclear and membranous 
staining were assigned a score of 1 or 0, respectively. Fisher’s exact test was used 
to determine statistically significant differences (p<0.05) between the proportion of 
EC and HGSC tumour sections staining positive and negative for each marker. 
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Table 3.4 Orbitrap Elite instrument parameters for data acquisition 
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Chapter 4  
4 Proteomic profiling of ovarian cancer extracellular 
vesicles for biomarker discovery 
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4.1 Abstract 
Epithelial ovarian cancer is often detected at later stages and is thus associated 
with poor survival rates. Combined with transvaginal ultrasound, CA-125 is the 
most widely used biomarker for diagnosing and monitoring ovarian cancer 
progression and recurrence. However, other common gynecological conditions 
increase CA-125 levels and not all ovarian cancer patients exhibit elevated CA-
125 levels, necessitating the discovery of additional markers or refined detection 
methods. Extracellular vesicles (EVs) such as exosomes and microparticles 
contain cell-of-origin specific cargo and may be reservoirs for cancer-associated 
biomarkers. Moreover, EVs can be fractionated from high abundance proteins 
including albumin, enabling the de novo detection of low abundance proteins in 
plasma using mass spectrometry-based proteomics. Herein we describe the 
systemic analysis of EVs derived from established and primary ovarian cancer cell 
lines, from patient ascites and from plasma. We found that samples taken directly 
from patients are more appropriate for biomarker discovery, as cell lines whether 
normal or malignant, cluster similarly in terms of EV cargo. In addition, we 
discovered that crude EV collection via ultracentrifugation isolates more cancer-
associated cargo than does CD9-immunopreciptation. Using liquid 
chromatography-mass spectrometry, we uncovered proteins present in EVs 
derived from patient ascites that were absent or extremely low in EVs derived from 
the plasma of healthy donors. Several of these proteins included GPRC5A, 
SLC34A2, ACTBL2, and MUC16 (CA-125). We used this information to create an 
EV-specific parallel reaction monitoring method for plasma EVs that was able to 
differentiate between patients with ovarian cancer compared to non-malignant 
controls. Collectively, these results suggest that when paired with EV-isolation, 
several analytes, including CA-125, may be used in combination to detect ovarian 
cancer in plasma samples. 
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4.2 Introduction 
Cancer biomarker discovery and validation has profound clinical implications for 
screening, diagnosis, personalized medicine and monitoring response to therapy 
[1]. Importantly, cancer biomarkers may improve patient survival by detecting 
preclinical or early stage disease. Currently, most protein based FDA approved 
cancer biomarkers are restricted to differential diagnosis and monitoring disease 
progression and recurrence but not screening or detection [2,3].  
In developed countries, epithelial ovarian cancer (EOC) is the second most 
common gynecological malignancy but most lethal with a 5-year overall survival of 
about 46.2% [4,5]. Early detection is hampered by the lack of symptoms and 
therefore, patients are frequently diagnosed during later stages for which 
prognosis is poor [6].  Women experiencing abdominal and/or pelvic discomfort 
may undergo a transvaginal ultrasound (TVUS) to check for pelvic masses 
however this procedure cannot accurately discriminate between benign or 
malignant masses [7]. Therefore, if ovarian cancer is suspected, invasive surgical 
staging and debulking is required [8].  
A biomarker includes any measurable entity (molecule and/or physiological 
process) which indicates a biological state or phenotype [9–11]. In addition to 
TVUS, CA-125 is the most widely used biomarker to assist in diagnosing and 
monitoring ovarian cancer progression and response to therapy [12]. CA-125 is an 
extracellular epitope consisting of repeating domains generated through cleavage 
of the transmembrane glycoprotein MUC16 [12]. Approximately 83% patients with 
advanced epithelial ovarian exhibit elevated CA-125 levels (>35 U/mL) in the 
blood. However, other common gynecological conditions increase CA-125 levels 
and not all ovarian cancer patients have elevated CA-125 levels making it 
problematic for screening and diagnosis [12,13]. To address this, several 
algorithms have been developed to improve its diagnostic performance. For 
example, the Risk of Malignancy Index (RMI) incorporates menopausal status, CA-
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125 levels and ultrasound characteristics [14]. Alternatively, the Risk of Ovarian 
Cancer Algorithm (ROCA) monitors CA-125 levels over time, rather than using a 
set cut-off, to assess the risk of developing ovarian cancer [15]. In addition to these 
diagnostic assays, three large randomized control trials were recently completed 
which sought to determine whether screening asymptomatic women for ovarian 
cancer could improve patient survival [16]. Unfortunately, results from the US 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) found no 
survival advantage for screening by CA-125 and TVUS compared to standard care 
[17]. While the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 
found a mortality reduction of 15% and 11% in the multimodal (CA-125+TVUS) 
and TVUS screening groups compared to standard care, respectively, this 
difference was not statistically significant based on primary analyses [18]. 
Given the limited sensitivity and specificity of CA-125, there is an unmet need for 
discovering and/or validating alternative biomarkers for the early detection and 
diagnosis of ovarian cancer. However, due to the low incidence of EOC, it has 
been suggested that any biomarker used to screen postmenopausal women will 
require a sensitivity of 99.6% and specificity of >75% in order to achieve a positive 
predictive value of 10% or higher (1 correct diagnosis for every 10 positive test 
results) [19,20]. Plasma is a non-invasive resource which contains numerous 
tissue derived biomarkers beyond CA-125 that can potentially aid in diagnosis and 
monitoring progression. For example, the risk of ovarian malignancy algorithm 
(ROMA) monitors human epididymis protein 4 (HE4) and CA-125 [21]. The FDA 
approved OVA1 in vitro diagnostic multivariate index assay measures 5 
biomarkers (CA-125-II, transferrin [TF], transthyretin (prealbumin), apolipoprotein 
A1 [APOA1], and beta-2 microglobulin [B2M]) and was recently shown to predict 
the malignancy of pelvic masses better than a physician's pre-operative 
assessment or CA-125 alone  [22]. Moreover, Yip et al. screened 259 serum 
biomarkers from nearly 500 patients with ovarian cancer or benign disease and 
found a panel of 9 biomarkers with greater specificity than OVA1 (88.9 versus 
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63.4%) at a sensitivity threshold of 90% [23]. Høgdall et al. screened serum from 
150 cancer patients and found B2M, TF, and inter-alpha-trypsin inhibitor heavy 
chain H4 (ITIH4) robustly predicted overall survival and progression free survival 
[24]. Unfortunately, despite the best efforts of academia and industry, no 
biomarkers for ovarian cancer detection have been approved. The difficulties 
associated with this task are reflected by the fact that on average, only 1.5 protein 
based biomarker tests (plasma or blood) were introduced into the clinic each year 
between 1993 and 2008 for any disease or condition [25]. 
While plasma is comprised of over 10,000 proteins and is the primary biofluid 
utilized for biomarker discovery, plasma proteins span a dynamic range greater 
than 10 orders in magnitude and therefore low abundance species are often 
underrepresented which could potentially provide valuable biomarkers [26–29]. 
Conventional, immunoaffinity-based assays (ELISAs and antibody arrays) afford 
extreme sensitivity (pg/mL) and specificity but require high-quality antibody pairs 
and are limited to predefined analytes [26]. Alternatively, mass spectrometry (MS)-
based proteomics can detect and quantify thousands of proteins across several 
orders of magnitude in an unbiased manner. Unfortunately, high abundance 
proteins (HAPs) which comprise ~99% of the total plasma protein content (i.e. 
albumin, immunoglobulins, and transferrin) hinder MS-based plasma profiling [25–
27]. HAP depletion techniques can improve proteome coverage however they are 
often laborious, incomplete and expensive [30]. For example, Keshishian et al. 
combined protein depletion (14 most abundant and ~50 moderately abundant 
plasma proteins) with extensive high-pH reversed phase fractionation to detect 
~5300 plasma proteins from 4 patient samples [31,32]. In practice, most plasma 
profiling strategies are limited in comparison to cellular lysates in which ~10,000 
proteins are being reported [33–36] .  
Extracellular vesicles (EVs) include exosomes and membrane bound 
microparticles that are released or shed from cells which contain cellular (by-
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)products and range between 40-1000 nm in diameter [37]. Unlike soluble plasma 
proteins, MS-based profiling of EVs purified from biological fluids (plasma and 
urine) are less susceptible to severe dynamic range issues associated with HAPs. 
While EVs may contain valuable biomarkers for clinical use, only a handful of 
studies have characterized their proteomes in prostate, ovarian, and colorectal 
cancer cell lines or biofluids [38–41].  
To circumvent the limitations of traditional plasma-based biomarker discovery and 
foster the development of targeted proteomics assays for ovarian cancer detection 
and diagnosis, we characterized EV proteomes obtained from cell lines, plasma 
and ascites. Our proteomics approach identified a large number of previously 
annotated and unknown biomarkers associated with malignant EV samples. While 
many proteins were highly enriched in ascites, the majority remained difficult to 
detect or undetectable in plasma EVs.  As a proof-of-principle, we performed 
targeted proteomics using parallel reaction monitoring (PRM) to measure ~471 
peptides (240 proteins) in a cohort of non-malignant and malignant plasma EVs. 
In this cohort, ROC-AUC analysis revealed several peptides with similar or better 
performance than CA-125 which warrant further validation.   
4.3 Results 
 MS-based workflow for interrogating ovarian cancer EV 
proteomes 
Cell lines remain an integral tool for studying disease however they may not fully 
reflect in vivo biology [42]. Patient samples (tissues and biofluids) can provide 
uncompromised insight into human physiology but are complex in nature and 
limited in quantity. In light of these factors, we undertook a multi-pronged MS-
based approach to characterize EV proteomes from cancer cell lines, healthy 
donor plasma, and ascites for biomarker discovery (Figure 4.1). Bulk EVs were 
primarily obtained by differential ultracentrifugation (UC) however CD9-affinity 
142 
 
 
 
purification (CD9AP) was also performed on healthy donor plasma and ascites to 
preferentially capture exosomes (endosome derived EVs <150nm in size which 
express the transmembrane protein CD9) [43]. LC-MS analyses were performed 
on Q Exactive mass spectrometer and data were searched in MaxQuant with the 
match-between-runs enabled across all sample types (cell lines, plasma and 
ascites) to improve coverage and label free quantification (LFQ) [44].  
Two established (OV-90, OVCAR3) and two primary (EOC6 and EOC18) ovarian 
cancer cell lines and one non-malignant human immortalized ovarian surface 
epithelium cell line (hIOSE) were initially chosen for comparison. EOC6 and 
EOC18 were derived from patient ascites and characterized to be high-grade 
serous and low-grade serous, respectively. In cellular EV preparations, ~6230 
proteins were identified in each sample on average with 76% of the total proteins 
detected shared amongst 4 out of 5 cell lines (Table 4.1, Figure 4.2A). We next 
profiled EV proteomes from healthy donor plasma and ascites (3 individuals each) 
which yielded substantially fewer proteins but was comparable in size to a previous 
study characterizing prostate cancer plasma microparticles by LC-MS [41]. 
Between 61-75% proteins detected within plasma or ascites were present in 2 out 
of 3 samples (Figure 4.2B and C). Within each purification technique (UC or 
CD9AP), 60-66% of the proteins identified were shared between plasma and 
ascites. Unexpectedly, a large number of proteins were exclusive to CD9AP 
preparations that were not found with UC (Figure 4.2D). This may be due to 
enrichment of proteins specifically associated with CD9-labelled vesicles and/or 
non-specific absorption of plasma proteins to beads during purification [43]. 
Regarding differences between plasma and ascites, we noticed two interesting 
results. Firstly, ascites contained more exclusive proteins than plasma in the UC 
group (1546 versus 503) (Figure 4.2B). Secondly, UC yielded substantially more 
exclusive proteins than CD9AP in ascites samples (2075 versus 424) (Figure 
4.2D). We reasoned that aberrant secretion/shedding of EVs by either cancer cells 
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and cell types within the intraperitoneal cavity, as well as accumulation or reduced 
clearance, significantly expanded the repertoire of EV enriched proteins detected 
in ascites compared to plasma [37]. Furthermore, UC crudely isolates small to 
large membrane bound cargo irrespective of surface marker expression and 
therefore yields greater more heterogeneous EVs compared to selective 
purification techniques [37,43]. In total, ~7700 proteins were identified in at least 
one sample with ~2400 proteins common to all groups (Figure 4.2E). Few proteins 
were unique to plasma or ascites with cellular EVs containing the majority of 
exclusive proteins. 
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Figure 4.1 Workflow for extracellular vesicle sample preparation. 
Extracellular vesicles (EVs) were purified from cell lines, healthy donor plasma and 
ascites by differential ultracentrifugation (UC) or CD9-affinity purification (CD9AP). 
Following purification, EV proteins were extracted, precipitated in 
chloroform/methanol and digested with trypsin/LysC overnight. Peptides were 
fractionated using SCX StageTips and analyzed by LC-MS on a Q Exactive mass 
spectrometer. *CD9AP was performed on healthy donor plasma and ascites only. 
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Table 4.1 Total proteins identified and quantified 
 
*Healthy donor plasma and ascites samples were obtained from 3 different individuals within each 
purification technique (UC, Ultracentrifugation; CD9AP, CD9-affinity purification).   
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Figure 4.2 Effect of sample type and purification technique on EV proteome 
coverage. 
(A) Occurrence of proteins identified in 1 or more cell lines and overlap between 
non-malignant hIOSE cells and 4 ovarian cancer cell lines. (B and C) Variability in 
proteins detected within individual plasma and ascites samples from UC and 
CD9AP preparations. (D) Number of proteins common and exclusive to each 
sample preparation technique for plasma and ascites. (E) 5-way Venn diagram 
showing exclusive and common proteins for each group of samples. 
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 Annotation of EV proteomes reveals similarities and 
differences between sample types and preparations 
EVs may form via budding of ectosomes from the plasma membrane or through 
exocytosis of multivesicular bodies (MVB) containing intraluminal vesicles (ILVs) 
[45]. While differential UC can yield a heterogeneous population EVs, 
immunoaffinity purification approaches like CD9AP may preferentially capture 
small ILVs ~50-100nm in diameter (exosomes) that may be important for cellular 
communication [43]. To analyze the composition of EV preparations, we first 
performed GO cellular component (GOCC) analysis on proteomes from each 
group using the statistical over-representation test in PantherDB [46]. Importantly, 
all proteomes were significantly enriched for GOCC terms associated with EVs 
including SNARE complex, vesicle coat, integral to membrane and endosome 
(Figure 4.3). Several intracellular terms were also enriched in EV proteomes so we 
next compared LFQ intensities for a subset of subcellular markers to more 
precisely investigate their purity (Figure 4.4). Unsupervised hierarchical clustering 
revealed high LFQ intensities for many EV/exosomal markers suggesting good 
enrichment [47]. CD9, HSPA8 and GAPDH are among the most frequently 
detected exosomal markers and in our hands, exhibited the least variability and 
highest LFQ intensities across all samples (Figure 4.4 and Figure 4.5) [47]. 
However, many additional EV markers including CD63, CD81, CFL1, ANAX2 
displayed variable and decreased levels in CD9AP samples (Figure 4.4 and Figure 
4.5). Plasma and ascites samples contained abundant levels of the serum proteins 
ALB, TF and APOA1 and thereby suggesting incomplete removal following UC or 
nonspecific binding during CD9AP. Nonetheless, most golgi (TGOLN2), 
autophagosomal (ATG12), mitochondrial (ACO2, VDAC1) and nuclear (NUP98, 
LMNA) markers were extremely low in all samples. Low to high LFQ values were 
observed for several cytoskeletal and endoplasmic reticulum proteins which may 
associate with EVs naturally. 
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Figure 4.3 GO cellular component analysis of EV proteomes 
(A-E) Fold enrichment (black dots) and total proteins (bars) associated with 
specified GOCC terms. Integral to membrane, vesicle coat, endosome, organelle 
and Golgi apparatus GOCC terms were in enriched sample preparations (cell lines, 
plasma and ascites) indicating the presence of vesicular proteins from cell lines, 
plasma and ascites by either UC or CD9AP.  The presence of intracellular proteins 
within EVs may account for GOCC terms associated with cytoplasmic proteins. 
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Figure 4.4 High but variable detection of markers associated with EVs in UC 
and CD9AP preparations. 
Heat map of LFQ intensities from common EV and subcellular markers across all 
samples reveals high levels of EV/exosomal proteins (purple text) with minimal 
(intra) cellular contamination. Samples prepared by UC clustered more closely and 
plasma proteins were highly abundant in patient samples but not cell lines. 
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Figure 4.5 Effect of sample type and preparation technique on EV/exosome 
markers. 
(A-F) LFQ intensities for frequently detected EV/exosomal markers in each sample 
reveals differences between purification techniques. (A and E) CD9 and HSPA8 
were the most reliable markers across all conditions. CD9AP was associated with 
decreased marker intensities. 
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 Integrated proteomic analyses reveals putative 
biomarkers associated with malignant EVs 
To more stringently filter our proteomics dataset, we removed entries exclusive to 
a single sample within each group and imputed missing LFQ intensities as 
described in the materials and methods. Cell lines correlated moderately well with 
Pearson coefficients ranging from 0.65 to 0.81. Similarly, Pearson correlation 
coefficients within ascites or plasma samples were relatively good (0.72-0.84) but 
low between these sample types (0.43-0.61). Interestingly, Principal Component 
Analysis (PCA) revealed little to no clustering amongst cancer lines and no clear 
distinction from the non-malignant hIOSE cells (Figure 4.6A). Independent plasma 
or ascites samples, in contrast, clustered together regardless of the purification 
strategy employed (Figure 4.6B and C). As a complement, following analysis of 
the main dataset, we acquired LC-MS data using EVs derived from immortalized 
fallopian tube epithelial cells (FTEC) which have been documented as the cell of 
origin for most HGSC. However, a secondary PCA comparing the additional 
cellular EV proteomes had a negligible effect on clustering (Figure 4.7).  
To identify proteins enriched in EVs from ovarian cancer cells, we subtracted LFQ 
intensity values of the non-malignant hIOSE sample from the proteomes of each 
cancer line. A one sample t-test revealed 385 proteins significantly (p<0.05) 
elevated in ovarian cancer EVs with EPCAM, MUC16 and SLC34A2 comprising 
the most differentially elevated proteins (Figure 4.6D and ESM4.1). Of note, log2 
fold-changes (cancer line-hIOSE cells) for most targets varied in 1 out of 4 cancer 
lines suggesting a high degree heterogeneity between malignant proteomes 
(Figure 4.8). MUC16 expression, for example, was substantially lower in OV-90 
EVs compared to OVCAR3, EOC6 and EOC18 EVs (Figure 4.8A). Like MUC16, 
EPCAM overexpression is common in EOC tumours and associated with 
decreased overall survival [48]. Interestingly, less work has been published on the 
Sodium-Dependent Phosphate Transport Protein 2B (SLC34A2) which is elevated 
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in ovarian and lung cancer and the target of antibody drug conjugate in clinical 
trials [49,50]. E-cadherin (CDH1) was also abundant in ovarian cancer EVs which 
is consistent with previous reports documenting elevated expression in EOC 
[51,52]. 
To confirm biomarkers with bona fide expression in malignant human samples, we 
next examined differences between plasma and ascites EV proteomes from UC 
and CD9AP preparations. In agreement with our earlier findings, a disproportionate 
number of proteins (1162) were significantly elevated (two-sample t-test, p<0.05) 
in ascites EVs compared to plasma in the UC group (Figure 4.6E and ESM4.2). 
Similar to our cancer cell line comparison, MUC16 and SLC34A2 were among the 
most differentially expressed proteins in ascites EVs from the UC group. 
Macrophage migration inhibitory factor (MIF), cellular retinoic acid-binding protein 
2 (CRABP2) and claudin-3 (CLDN3) were abundant in ascites EVs and are known 
to be frequently elevated in EOC [13,35]. Retinoic acid-induced protein 3 
(GPRC5A) was highly elevated in ascites EVs and may be relevant for predicting 
cellular responses to all-trans-retinoic acid (ATRA) in which some ovarian cancer 
cell lines, but not others, are sensitive to its the growth inhibitory effects [35,53,54].  
Regarding CD9AP samples, the number differentially expressed proteins (two-
sample t-test, p<0.05) between plasma and ascites was substantially smaller and 
more evenly distributed than UC preparations. Specifically, 259 proteins were 
significantly elevated in ascites EVs (Figure 4.6F and ESM4.3). Surprisingly, 
MUC16 and EPCAM levels were not different between plasma and ascites 
although a number of proteins previously implicated in EOC progression were 
highly enriched such as CRP, FBLN1 and MXRA5 [13,55]. For example, increased 
levels of C-reactive protein (CRP) are associated with worse overall survival and 
fibulin-1 (FBLN1) was initially identified as an estrogen responsive extracellular 
matrix protein in EOC [56,57]. Furthermore, Bukanovich et al. found Aldican or the 
matrix-remodeling-associated protein 5 (MXRA5) expression 10-350 fold higher in 
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ovarian cancer vasculature compared to normal ovarian tissues [58]. Intriguingly, 
we did not detect HE4 in any EV proteomes which suggested it may not associate 
with EVs. Indeed, Zhao et al. detected EPCAM and CA-125 but not HE4 on CD9+ 
exosomes purified from ovarian cancer plasma using a microfluidic ExoSearch 
chip [59]. In light of these comparisons, we believe CD9-negative vesicles harbour 
potentially valuable biomarkers that may be lost during selective enrichment 
strategies like immunoaffinity purification.  
While EVs may be important for EOC detection and diagnosis, they can also 
provide insight into disease biology. Therefore, we selected protein entries from 
each comparison with Log2 fold-changes >0 and searched them in EnrichR against 
the NCI-Nature pathway database (Figure 4.6G-I). PDGFRβ signalling was among 
the top significantly enriched pathway in the cancer lines and ascites (UC group). 
Proteins involved in CXCR4, ErbB1 (EGFR), VEGFR1/2, E-cadherin (CDH1) and 
hepatocyte growth factor (c-Met) signalling pathways were also significantly 
enriched (over-represented) in these conditions. The CD9AP ascites proteome, in 
contrast, was enriched in proteins primarily associated with integrin and syndecan 
signalling. Taken together, these observations indicate a number of proliferative 
and angiogenic processes likely to be utilized by HGSC. 
As a complement, we examined whether EV proteomes from each comparison 
(cancer lines versus hIOSE, ascites versus plasma (UC group), and ascites versus 
plasma (CD9AP group)) were potentially correlated. Scatter plots of log2 fold-
changes versus log2 fold-changes revealed little to no similarities between any of 
our three comparisons (Figure 4.9). Only a small fraction of proteins including 
MUC16, EPCAM, CRP, MIF were highly correlated between two out of three 
malignant sample types. UC and CD9AP groups were the only comparison which 
appeared marginally correlated. Lastly, we reduced the dataset to ~1300 entries 
comprised of proteins with LFQ values shared between ≥2 cell lines, plasma and 
ascites samples (UC and CD9AP groups). PCA illustrated tight clustering within 
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each sample type (Figure 4.10A). Ascites samples from the UC group clustered 
in-between the cell lines and plasma samples. CD9AP samples were loosely 
clustered although each sample type (plasma or ascites) could be distinguished 
from one another. In addition, we performed unsupervised hierarchical clustering 
after z-scoring (Figure 4.10B). Similar to PCA, ascites samples (UC group) 
clustered more closely to the cell lines. Taken together, our integrated proteomics 
approach revealed a number of similarities and differences between ovarian 
samples and purification strategies which may significantly impact downstream 
biomarker validation.  
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Figure 4.6 Label free proteomics identifies highly abundant proteins 
associated with ovarian cancer EVs. 
(A-C) Principle Component Analysis (PCA) of EV proteomes reveals heterogeneity 
between ovarian (cancer) cell lines but high similarity within plasma and ascites 
samples from each preparation strategy (UC and CD9AP). (D-F) Volcano plots of 
log2 fold-changes LFQ intensities between ovarian cancer and hIOSE cells, UC 
ascites and UC plasma samples, and CD9AP ascites and CD9AP plasma 
samples. Highly abundant EV proteins associated with ovarian cancer samples 
and ascites are highlighted. (G-I) Corresponding NCI-Nature Pathways 
significantly enriched in EVs from cancer cells or ascites using protein lists with 
log2 fold-changes >0 from volcano plots in (D-F). Pathways were ranked based on 
the combined score (log10 p-value multiplied by the z-score of the deviation from 
the expected rank) calculated by EnrichR. Notably, pathways involved in 
proliferation, angiogenesis and cell adhesion were highly enriched. 
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Figure 4.7 Principle component analysis of cellular EVs including a fallopian 
tube epithelial cell line. 
PCA reveals low similarity between EV proteomes derived from high grade serous 
ovarian cancer cell lines. The primary EOC lines cluster more closely to the 
immortalized fallopian tube epithelial line FT194 while established cancer lines OV-
90 and OVCAR3 formed their own group. Biological duplicates for EOC6 and 
EOC18 are shown. 
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Figure 4.8 Variable levels of EOC markers detected in cellular EVs. 
LFQ intensities for differentially expressed proteins were varied in 1 out 4 cell lines 
revealing heterogeneity within ovarian cancer lines. 
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Figure 4.9 Proteins elevated in malignant EVs are weakly correlated between 
different sample types and preparation techniques. 
(A-C) Scatter plots of log2 fold-changes versus log2 fold-changes from each 
comparison in Figure 4D-F indicate most differences in EV protein levels between 
malignant and non-malignant samples are not correlated. Only a small number of 
proteins elevated in malignant EVs were highly correlated between each 
comparison and are highlighted in red. (C) Log2 fold-changes in EV proteins 
appear most correlated in the Ascites-Plasma (UC) versus Ascites-Plasma 
(CD9AP) comparison.  
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Figure 4.10 Clustering of EV proteomes. 
(A) PCA showing the effect sample type and preparation method on clustering. 
CD9AP samples clustered more tightly compared to UC samples. Ascites (UC 
group) exhibited protein expression profiles characteristic of both cell lines and 
plasma samples (UC group). (B) Unsupervised hierarchical clustering of ~1300 
proteins with quantitative values present ≥2 samples in each comparison from 
Figure 4D-F. Similar to PCA, sample type and preparation technique were 
clustered with ascites (UC group) between cell lines and plasma samples. 
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 Monitoring ovarian cancer biomarkers in patient plasma 
Based on the aforementioned comparisons, we sought to determine which proteins 
enriched in ascites, were the strongest predictors of disease status. For this, 
proteomes from the three plasma and ascites samples belonging to UC group were 
used to train the support vector machine (SVM) ‘geNetClassifier’ (GNC) in R [60]. 
As a consequence of the small training set size and limited sample heterogeneity, 
over 1300 proteins exceeded the posterior probability cut-off of 0.95 set by GNC 
(ESM4.4). However, GPRC5A, SLC34A2, ACTBL2, and MUC16 were amongst 
the top proteins identified by GNC for classifying ascites samples from healthy 
donor plasma (Table 4.2). Additional proteins frequently elevated in ovarian 
malignancies with high classification power included MIF, CLDN3, and CRABP2.  
 
Given the global differences between EV proteomes from healthy donor plasma 
and ascites, we next investigated if any proteins significantly elevated in ascites 
EVs could be identified in an independent cohort of patient plasma samples. For 
this, EVs were purified by UC from 9 non-malignant and 8 malignant plasma 
samples (~0.5mL of plasma/sample). Of the 1435 proteins significantly enriched 
in either UC or CD9AP ascites EVs, we detected 354 in one or more unfractionated 
plasma EV samples (Figure 4.11A). Using this list, plus several housekeeping EV 
markers, a spectral library was built in Skyline to develop a targeted LC-MS 
method using Parallel Reaction Monitoring (PRM) [61,62]. A refined list of 271 
proteins corresponding to 470 peptides were subsequently targeted using a PRM 
method in the same cohort of plasma EVs for more accurate label free 
quantification (Figure 5.11A). Peak areas were normalized to heavy 
glufibrinopeptide (hGFP) which was equally spiked into each sample. While 
median CV values demonstrated good reproducibility between technical replicates 
and low inter-sample variability, we observed heterogeneity between peptides for 
common EV housekeeping markers such as CD9, CD81, and HSPA8 (Figure 
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4.11B; data not shown). Therefore, peak areas were additionally normalized to the 
CD9 peptide EVQEFYK (extracellular region, AAs 120-126) which was used a 
surrogate marker of EV recovery and purity. We calculated Receiver Operating 
Characteristic Area Under the Curves (ROC-AUC) for the most differentially 
expressed targets to determine peptides with the greatest performance (Figure 
4.11C and D). Of note, only one peptide derived from the extracellular domain of 
MUC16 (ELGPYTLDR) met our selection criteria with an AUC value of 0.75 (95% 
CI of 0.5-1.0) (Figure 4.5E). Although this peptide was 2.92 median fold higher in 
malignant EVs, this difference was not quite significant (Mann Whitney test, 
p=0.0894) (Figure 4.11E). In contrast, several peptides belonging to complement 
factor H related protein 4 (CFHR4), MUC1, and Serum amyloid P-component 
(APCS) were significantly elevated in malignant EVs (Mann Whitney test, p<0.05) 
(Figure 4.11E and F). CFHR4 and APCS were exclusively enriched in the CD9AP 
dataset while MUC1 was specific to UC comparison. Pregnancy zone protein 
(PZP) was significantly higher in malignant plasma EVs and enriched in both UC 
and CD9AP groups (log2 fold-changes of 6.63 and 5.74, respectively). MXRA5 and 
GPRC5A were also significant but not SLC34A2 and CLDN3 which had lower 
AUCs of 0.75 and 0.722, respectively. In general, most candidates were slightly 
elevated in malignant plasma but not significant. In our hands, proteins enriched 
in ascites EVs were challenging to detect in unfractionated samples and we were 
unable to monitor all peptides due to the large number of targets. While most 
peptides were well correlated, further work is needed to refine this list and confirm 
the best predictors of disease status. 
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Table 4.2 Top ranking proteins of ascites EVs identified by ‘geNetClassifier’ 
  
165 
 
 
 
 
166 
 
 
 
Figure 4.11 Monitoring ascites enriched biomarkers in plasma EVs 
EVs were purified by ultracentrifugation from 9 non-malignant and 8 malignant 
patient plasma samples (~0.5mL/sample). (A) Unfractionated plasma EV 
preparations were initially analyzed by LC-MS and searched in Peaks®. Protein 
identifications common to plasma EVs and those significantly enriched in ascites 
EVs (UC and CD9AP datasets) were retained and used to build a spectral library 
in Skyline and a scheduled PRM method. A minimum of 3 transitions were required 
to measure peak areas with most containing 4 or 5.  Peak areas were subsequently 
normalized to hGFP to correct for technical variability between LC-MS runs. (B) 
Box and whisker plots showing median CV values (horizontal line) between 
technical duplicates within the acceptable cut-off of 20%. Boxes indicate 75% and 
25% quartiles and whiskers represent 90% and 10% ranges and mean CVs are 
indicated by the ‘+’ sign. Peak areas were further normalized to the CD9 peptide 
EVQEFYK to account for differences in EV recovery and purity following 
ultracentrifugation. Peak boundaries for hGFP and CD9 were manually selected 
to ensure accuracy prior to normalization and non-transformed peaks were used 
to measure peak areas. (C) Bar plot of ROC-AUC values from peptides with the 
largest differences between non-malignant and malignant plasma EVs. (D) ROC 
curves for the top 4 peptides with the largest AUCs and MUC16 (CA-125) are 
shown. (E) ROC-AUC values, (median) fold-changes and p-values for the top 4 
peptides and MUC16. (F) Dot plots comparing peak areas between non-malignant 
and malignant samples for the top 4 peptides and MUC16. Horizontal lines indicate 
median peak areas. The top 4 peptides were significantly elevated (p<0.05) in 
malignant samples however MUC16 was not (p=0.0894). 
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4.4 Discussion 
In this study, we characterized EV proteomes derived from three different sources 
(cell lines, plasma and ascites) using two different techniques (UC and CD9AP) to 
identify proteins which may be used as biomarkers for detecting ovarian cancer. 
Importantly, our findings complement and expand upon previous work by several 
other groups that also utilized mass spectrometry to characterize ascites or EVs 
derived from ascites or ovarian cancer cell lines [39,40,55,59,63–67].  
Our comparison of EV proteomes from ovarian (cancer) cells suggests the 
presence intercellular heterogeneity although OVCAR3, OV-90 and EOC6 are 
likely HGSC, albeit OVCAR3 was not specified in the original publication [68]. Of 
caution, this heterogeneity may reflect differences in tissue of origin [35,68].  For 
example, three distinct proteomic expression profiles (epithelial, clear cell and 
mesenchymal) were identified during a recent large scale proteomic analysis of 
ovarian cancer lines, HGSC tumours, and FTEC and hIOSE cell lines [35]. From 
our PCA, it is difficult to ascertain whether any cellular EV proteomes can be 
stratified according to this criteria. For example, OVCAR3 and FTEC were 
categorized as epithelial in origin by Coscia et al. but in our hands they were 
dissimilar. Although intra-subtype profiling may have downstream implications for 
treatment decisions, we opted to focus our efforts on interrogating plasma and 
ascites EVs which likely harbour high confidence biomarkers. 
In total, ~6000 proteins were identified in at least one or more EV preparation from 
ascites samples obtained by UC or CD9AP purification (4878 proteins in two or 
more samples).  To our knowledge, this is the most in depth ascites EV proteome 
reported to date. Several factors which enabled us to achieve this level of coverage 
include the ‘match-between-runs’ feature in MaxQuant, the recently developed 
minimal encapsulated SCX StageTip fractionation technology and the use of high 
resolution Orbitrap-based instrumentation [44,69,70]. Indeed, over 10 years have 
passed since the first global proteomic analysis of ovarian cancer ascites was 
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reported by Gortzak-Uzan et al. whom identified 229 high confidence proteins in 
the soluble fraction of ascites from a single patient [64]. Although these authors 
employed multi-dimensional protein identification technology (MuDPIT) and gel-
enhanced fractionation, the presence of HAPs and complexity were noted as 
potential reasons for their limited detection of low abundance factors such as 
VEGF and TGF-β [64,71].  To reduce interference associated with HAPs, Kuk et 
al. preferentially isolated low molecular proteins (≤30kDa or ≤100kDa) by size-
exclusion chromatography (SEC) or filtration and established a set 52 biomarker 
candidates not previously reported in ascites [55]. We cross-referenced this 
dataset with our results for comparison and found 48 out of 52 proteins in ascites 
EVs; 28 of which were significantly enriched (data not shown). In a follow-up study, 
this group utilized combinatorial peptide libraries (CPL) on beads containing 
~2.4X107 unique peptides to deplete HAPs in ascites and enrich for low abundant 
species [72]. This strategy revealed a number of new ascites biomarkers and 
enabled the quantification of 30 low abundant proteins by multiple reaction 
monitoring (MRM). While these studies elucidated numerous biomarkers, it 
remained to be determined which were specific to malignant versus non-malignant 
ascites or plasma samples. To better delineate proteins exclusive to or upregulated 
in EOC, Shender et al. compared ascites from patients with ovarian cancer to 
those with alcohol induced cirrhosis [66]. These authors combined CPL depletion 
with gel-based fractionation similar to Drabovich et al. and identified 424 proteins 
associated with malignant ascites. We also cross-referenced this dataset with our 
list of proteins significantly enriched in ascites EVs and observed ~43% overlap 
(data not shown). The difference in overlap may be attributed to the fact that our 
proteome analysis was predominately restricted to proteins associated with EVs 
(and residual HAPs) and may be lacking extracellular signalling factors and ECM 
components. For example, KLK6 was identified by Shender et al. but not present 
in our dataset [66]. These authors also documented a large number of factors 
involved in RNA splicing which appeared to be missing from our dataset. To date, 
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we are not aware of any study which has compared EV depleted ascites to 
determine which factors are shared or exclusive to each fraction. 
In addition to profiling EVs from cell lines, plasma and ascites, we performed PRM 
analysis on a cohort of patient plasma EVs as a proof-of-concept to verify potential 
biomarkers for detecting EOC. Although we performed two rounds of 
ultracentrifugation to dilute HAPs from EVs, we experienced a significant degree 
of contamination. This combined with the absence of fractionation was a 
substantial obstacle in the detection of low abundance cancer derived factors. 
Nonetheless, we identified a subset of peptides associated with malignant (ovarian 
cancer) EVs from HGSC patients compared to individuals with non-malignant 
conditions. While MUC16 was higher in malignant samples, it was not significant 
and among the best performing peptides. Interestingly, CFHR4, one of the top 
performing candidates, was specifically enriched in the CD9AP, but not UC, 
comparison. Two isoforms of CFHR4 have been identified and both have been 
shown to bind and recruit C-reactive protein (CRP) to necrotic cells and tumour 
tissue [73]. CRP is important for initiating complement activation and opsonisation 
of dead cells for phagocytosis and clearance. In effect, necrotic tissue produced 
during EOC progression is a likely culprit for elevated CFHR4 and CRP. CRP was 
also significantly elevated in malignant plasma EVs and previously reported in 
EOC, however, to our knowledge, CFHR4 has not been documented [57].  
Taken together, we identified several peptides with high confidence that are likely 
elevated during EOC progression. In tandem with CA-125, these markers may 
enhance the specificity and sensitivity of blood based assays for detecting EOC. 
Additional work is required to refine our list of targets and employ heavy synthetic 
peptides for absolute quantification in a larger cohort patients to monitor levels 
across multiple stages of EOC 
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4.5 Materials and Methods 
 Cell culture 
OV-90 (ATCC® CRL-11732) and NIH:OVCAR3 (ATCC® HTB-161) were obtained 
from the ATCC. hIOSE (OSE364) and immortalized FTEC (FT194) were kindly 
provided by Dr. Ronny Drapkin (Department of Obstetrics and Gynecology, 
University of Pennsylvania).  Primary cell lines EOC6 and EOC18 were isolated 
from the ascites of patients with high-grade and low-grade serous ovarian cancer, 
respectively. All cell lines, except OVCAR3, were maintained in M199+MCDB105 
supplemented with 5-15% FBS. NIH:OVCAR3 cells were cultured in RPMI-1640 
supplemented with 20% FBS and 5ug/mL insulin. Media was exchanged with 
serum free media for 20-30 hours to generate conditioned media (CM) for EV 
purification. All work involving the use of patient samples (cell lines, plasma and 
ascites) was approved by the Health Research Ethics Board of Alberta-Cancer 
Committee (Appendix D). 
 Ultracentrifugation (UC) 
CM, plasma and ascites samples were first centrifuged at 200-300 xg at 4°C to 
pellet cells. Supernatants were transferred to clean tubes, diluted 1:10 in PBS 
(except CM) and centrifuged at 3,000 xg for 20 minutes at 4°C to remove cell 
debris. To remove large membrane fragments, supernatants were spun at 10,000 
xg for an additional 20 minutes at 4°C. Lastly, supernatants were transferred into 
clean tubes and ultracentrifuged at 120,000 to 140,000 xg (SW-28 rotor) for 2 
hours at 4°C to pellet EVs on an OptimaTM L-100 XP ultracentrifuge (Beckman 
Coulter). The supernatant was removed and EVs were resuspended in 100-300µL 
of PBS and stored at -20°C until further use 
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 CD9-affinity purification (CD9AP) 
Hydrophilic streptavidin magnetic beads (120mg) were washed 3x with PBS on a 
magnetic rack then resuspended in 5mL of PBS (New England Biosystems, 
S1421S, 20mg/5ml). The bead slurry was mixed with 650µg of biotin conjugated 
anti-CD9 antibody (Abcam ab28094) at room temperature for 30 minutes and then 
washed 2x with PBS to remove unbound antibody. Beads were resuspended in 
6mL of PBS and 1mL (~20mg) was added to 10mL of plasma or ascites (diluted 
1:1 in PBS). Samples were placed on a rotary mixer overnight at 4°C and then 
carefully rinsed 3x with PBS next day. Exosomes were eluted from beads with 
three, 500 µl glycine-HCl (0.1M, pH 2.39) washes. A small volume (75µL) of Tris-
HCl (1.8M, pH 8.54) was used to neutralize each eluent. 
 EV protein extraction 
To prepare EVs for LC-MS/MS, ~20-25μg of protein quantified by micro BCA was 
lyophilized to dryness and reconstituted in 8M Urea, 50mM ammonium 
bicarbonate (ABC), 10mM dithiothreitol (DTT), 2% SDS lysis buffer. EV protein 
samples were sonicated with a probe sonicator (3 X 0.5s pulses; Level 1) (Fisher 
Scientific, Waltham, MA), reduced in 10mM DTT for 30 minutes and alkylated in 
100mM IAA for 30 minutes at room temperature in the dark. Proteins were 
precipitated in chloroform/methanol in 1.5mL microfuge tubes according to Wessel 
and Flügge [74]. Briefly, EV samples in lysis buffer were topped up to 150µL with 
50mM ABC then mixed with ice cold methanol (600μL) followed by adding ice cold 
chloroform (150μL) and vortexed thoroughly.  An additional volume (450μL) of 4°C 
water was added followed by vortexing and centrifugation at 14, 000 xg for 5 min. 
The upper aqueous/methanol phase was carefully removed to avoid disturbing the 
precipitated protein interphase. A second 450μL volume of cold methanol was 
added to each sample followed by vigorous vortexing and centrifugation at 14, 000 
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xg for 5 min. The remaining chloroform/methanol supernatant was discarded and 
the precipitated protein pellet was left to air dry in a fume hood. 
 EV protein digestion 
On-pellet in-solution protein digestion was performed similarly to Duan et al. [75]. 
Briefly, 100µL of 50mM ABC (pH 8) plus LysC/Trypsin (1:50 ratio) was added to 
precipitated EV proteins and vortexed vigorously.  EV samples were incubated at 
37°C overnight (~18h) in a water bath shaker (Polyscience) at 190 rpm or 
ThermoMixer C (eppendorf) at 300 rpm. An additional volume of trypsin (1:100 
ratio) was added the next day for ~4 hours before acidifying to pH 3-4 with 10% 
FA. EV digests were briefly centrifuged at 14,000 xg to pellet insoluble material 
prior to LC-MS/MS or SCX peptide fractionation. 
 SCX peptide fractionation 
Tryptic peptides recovered from EV digests were fractionated using SCX 
StageTips similarly to Kulak et al. [69]. Briefly, peptides were acidified with 1% TFA 
and loaded onto a pre-rinsed 12-plug SCX StageTips (Empore™ Supelco, 
Bellefonte, PA, USA). In total, 6 SCX fractions were collected by eluting in 75, 125, 
200, 250, 300 mM ammonium acetate/20% ACN followed by a final elution in 5% 
ammonium hydroxide/80% ACN. SCX fractions were dried in a SpeedVac (Thermo 
Fisher), re-suspended in ddH2O, and dried again to evaporate residual ammonium 
acetate. All samples were re-suspended in 0.1% FA prior to LC-MS analysis. 
 LC-MS 
SCX fractions were analyzed using an nanoAquity UHPLC M-class system 
(Waters) connected to a Q Exactive mass spectrometer (Thermo Scientific) using 
a nonlinear gradient. Buffer A consisted of Water/0.1% FA and Buffer B consisted 
of ACN/0.1%FA. Peptides (~1µg estimated by BCA) were initially loaded onto an 
ACQUITY UPLC M-Class Symmetry C18 Trap Column, 5 µm, 180 µm x 20 mm 
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and trapped for 4 minutes at a flow rate of 10 µl/min at 99% A/1% B. Peptides were 
separated on an ACQUITY UPLC M-Class Peptide BEH C18 Column (130Å, 
1.7µm, 75µm X 250mm) operating at a flow rate of 300 nL/min at 35°C using a 
non-linear gradient consisting of 1-7% B over 3.5 minutes, 7-19% B over 86.5 
minutes and 19-30% B over 30 minutes before increasing to 95% B and washing. 
Settings for data acquisition on the Q Exactive and Q Exactive Plus are outlined in 
Table 4.3. 
 Data Analysis 
MS raw files were searched in MaxQuant (1.5.2.8) using the Human Uniprot 
database (reviewed only; updated May 2014 with 40,550 entries). Missed 
cleavages were set to 3 and I=L. Cysteine carbamidomethylation was set as a 
fixed modification. Oxidation (M), N-terminal acetylation (protein), and deamidation 
(NQ) were set as a variable modifications (max. number of modifications per 
peptide = 5) and all other setting were left as default. Precursor mass deviation 
was left at 20 ppm and 4.5 ppm for first and main search, respectively. Fragment 
mass deviation was left at 20 ppm. Protein and peptide FDR was set to 0.01 (1%) 
and the decoy database was set to revert. The match-between-runs feature was 
utilized across all sample types to maximize proteome coverage and quantitation. 
Datasets were loaded into Perseus (1.5.5.3) and proteins identified by site, reverse 
and potential contaminants were removed [76].  Protein identifications with 
quantitative values in ≥2 samples in a least one group (cells, plasma or ascites) 
were retained for downstream analysis unless specified elsewhere. Missing values 
were imputed using a width of 0.3 and down shift of 1.8.  
 Parallel Reaction Monitoring (PRM) assay development 
Plasma EVs were obtained and processed as described above with slight 
modifications. Plasma samples were first diluted ~1:20 in PBS and EVs were 
pelleted at 120, 000 xg (SW-41 rotor) for 2 hours at 4°C on an OptimaTM L-100 
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XP ultracentrifuge (Beckman Coulter). To reduce serum contamination, plasma 
EVs were resuspended in 5mL of PBS and ultracentrifugated a second time at 
111,000 xg (MLA-80 rotor) for 2 hours at 4°C on an Optima™ MAX ultracentrifuge 
(Beckman Coulter). To facilitate digestion, protein pellets were sonicated 1-3 times 
following precipitation and LysC (Wako) was added (1:100) during overnight 
digestion. Digests were transferred to pre-rinsed (100µL of 25mM ABC/50% ACN) 
10 kDa MWCO microcon YM-10 centrifugal filter units (Millipore) and spun at 14, 
000xg for 20 min to recover peptides. Centrifugal filter units were washed with an 
additional 50µL of 25 mM ABC/50% ACN for 15 min at 14,000xg to collect residual 
peptides with high binding capacity. Filtered samples were dried in a SpeedVac, 
reconstituted in 0.1%FA and quantified by BCA. Unfractionated plasma EV digests 
(~1µg/sample) were analyzed on a Q Exactive Plus using a non-linear 2.5h 
gradient consisting of 1-7% B over 1 minute, 7-23% B over 134 minutes and 23-
35% B over 45 minutes before increasing to 95% B and washing. Plasma EV raw 
files were searched against the human Uniprot databased (20, 274 entries) using 
the de novo search engine Peaks™ (version 8) [61,77]. Parent and fragment mass 
error tolerances were set to 20 ppm and 0.05 Da, respectively. Max. missed 
cleavages were set to 3 and 1 non-specific cleavage was allowed. 
Carbamidomethylation was set as a fixed modification and deamidation, oxidation 
and acetylation (protein N-term) were included as variable modifications with a 
maximum of 3 PTMs per peptide allowed. pepXML peptide information and 
mzXML spectral data were exported from Peaks® prior to building a spectral library 
in Skyline. Peptides with missed cleavages or containing tryptophan were removed 
and up to 3 peptides/protein, 7-18 amino acids in length, were chosen for 
monitoring. In Skyline, peptides with low dotp scores or lacking peak areas were 
removed prior to exporting isolation lists for PRM. An 8 minute window was chosen 
to account for deviations in chromatography and minimize the chance of truncation 
while maximizing the number of MS/MS scans. Heavy glufibribrinopeptide (hGFP) 
was spiked into each plasma sample which were run in a randomized order in 
technical duplicate. PRM results were imported into Skyline and transitions (b and 
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y ions) with interference were removed. A minimum of 3 transitions were used to 
measure peak areas and targets with dotp scores <0.8 were assumed to be noise 
and assigned a peak area of 0.  
 Statistical analysis 
Differential protein expression between conditions were determined using a two-
tailed Student’s t-test (p<0.05) in Perseus (version 1.5.5.3) [76]. ROC-AUCs and 
Mann-Whitney statistical tests were calculated in in GraphPad Prism version 6.01 
(GraphPad Software, San Diego, CA).  
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Table 4.3 Q Exactive (Plus) instrument parameters for data acquisition 
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Chapter 5  
5 Embryonic protein NODAL mediates stromal cell 
chemotaxis to breast cancer cells and broadly 
regulates secretome composition  
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5.1 Abstract 
The tumour microenvironment (TME), consisting of several stromal cell types 
including fibroblasts, endothelial cells, multipotent stromal cells (MSC) and 
immune cells, is an important mediator of breast cancer progression. Breast 
cancers regulate the composition of the TME by secreting a myriad of factors. One 
such factor is NODAL, an embryonic morphogen belonging to the Transforming 
Growth Factor-beta (TGF- NODAL has been shown to act directly 
on breast cancer cells and macrophages to induce tumour-promoting phenotypes. 
NODAL has also been shown to indirectly affect endothelial cell behavior, by 
supporting the secretion of angiogenic proteins by breast cancer cells. However, 
the global effects of NODAL on cellular secretomes, have not yet been described. 
Moreover, the effects of NODAL on other components of the breast cancer 
microenvironment, including fibroblasts and MSC, have not been explored. Herein, 
we report that NODAL acts directly on fibroblasts to induce an activated phenotype 
but was unable to directly signal to MSC. Instead, NODAL caused broad 
alterations in breast cancer secretome components such as IL6, concomitant with 
changes in MSC chemotaxis. These results demonstrate the ability of NODAL to 
impact the breast cancer TME. 
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5.2 Introduction 
Non-transformed stromal cells within the tumour microenvironment (TME) undergo 
a dynamic reciprocity with cancer cells to drive tumour progression [1]. For 
example, breast cancers contain a significant proportion of auxiliary cells, including 
endothelial cells, pericytes, cancer-associated fibroblasts (CAFs), tumour-
associated macrophages (TAMs) and additional immune and progenitor cell types, 
which co-operate to promote processes such as metastasis [2–4]. Extracellular 
factors, such as cytokines and matrix proteins, mediate the pro-tumorigenic 
behaviours of stromal cells. For instance, CAF-derived CXCL12/stromal derived 
factor (SDF-1) can mobilize endothelial progenitor cells (EPCs) to increase 
vascularization of MCF-7 xenografts [5]. Furthermore, secretion of both CXCL12 
and Transforming Growth Factor-beta (TGF-β) by CAFs drives malignant 
progression by directly affecting Ras-transformed MCF-7 breast cancer xenografts 
[6]. 
Mesenchymal stromal cells (MSC) are another cell type frequently associated with 
neoplastic development [7,8]. MSC primarily arise from the bone marrow (BM) but 
also reside in most connective tissues. MSC can form bone, cartilage and fat in 
vitro and home to sites of ischemia, injury and inflammation in vivo [9]. MSC also 
exhibit pro-tumorigenic properties. For example, MSC increase tumour size and 
metastatic potential of MDA-MB-231 breast cancer xenografts via CCL5 secretion 
and CCR5 activation on breast cancer cells [10]. MSC also acquire CAF-like 
phenotypes when cultured in tumour conditioned media or mixed with cancer cells 
in mouse xenografts [11–13].  The mechanisms underlying MSC recruitment are 
not fully understood; however, up to 20% of CAFs in a mouse model of gastric 
cancer were derived from BM-MSC in a CXCL6/CXCR6 dependent manner [14].  
Moreover, stereotactic body radiation therapy was found to promote MSC 
recruitment in Lewis Lung Carcinoma (LLC) and B16F10 xenografts via SDF-
1/CXCR4 and Platelet-Derived Growth Factor B (PDGFB)/PDGF Receptor β 
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(PDGFR-β) signalling pathways [15]. MSC engraftment was associated with 
tumour recurrence and increased pericyte coverage of endothelial cells, hence 
supporting their roles in neovascularization and vasculogenesis [15].  Therefore, 
improved characterization of factors involved in MSC homing may provide 
additional avenues for therapeutic intervention. 
Several recent studies have uncovered tumour promoting roles for the TGF-β 
superfamily member and embryonic morphogen NODAL [16,17]. NODAL 
expression, while primarily restricted to embryonic development and human 
embryonic stem cells (hESCs), has been observed in melanoma, glioblastoma, 
breast, pancreatic and hepatocellular cancers [16,18–22]. In breast cancer, 
NODAL clinically correlates with stage and vascularization, and has been shown 
to promote blood vessel formation [17]. Accordingly, NODAL inhibition reduces 
breast cancer-induced neovascularization and mitigates tumour growth in Nude 
mice, in part through decreased PDGF and Vascular Endothelial Growth Factor 
(VEGF) expression [17,23]. Notably, however, in a chick chorioallantoic membrane 
model, the effects of NODAL knockdown on blood vessel formation could not be 
rescued by VEGF, suggesting that alternative pro-angiogenic secreted factors are 
affected when NODAL expression is altered [17]. 
In this study, we utilized mass spectrometry-based proteomics to analyze the 
NODAL-regulated secretomes of a claudin-low triple negative breast cancer cell 
line (MDA-MB-231) and a triple negative inflammatory breast cancer cell line 
(SUM149) [24,25]. Our analyses revealed cancer cell-type specific alterations in 
several undocumented NODAL-regulated factors including CXCL1, CXCL8, 
Interleukin 6 (IL6) and colony-stimulating factor-1 (CSF1); suggesting that NODAL 
may impact the ability of breast cancer cells to recruit a variety of stromal cell types. 
As a corollary, we found that NODAL-regulated alterations (knockdown and 
overexpression) negatively affected the ability of breast cancer conditioned 
medium to attract MSC. This effect was not due to NODAL itself, but to alterations 
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in other factors such as IL6. Conversely, we demonstrate that NODAL itself can 
signal to fibroblasts, increasing their invasion and inducing activation toward a 
CAF-like phenotype. Collectively, these data reveal a previously unknown role for 
NODAL in the regulation of breast cancer TME composition. 
5.3 Results 
 Proteomics reveals alterations in the NODAL-regulated 
breast cancer secretome  
Mass spectrometry is a powerful approach for proteomic characterization of  
cancer cell lines and tissues [26,27]. In this study, we employed high resolution 
mass spectrometry to identify NODAL-regulated factors in serum-free conditioned 
media (CM) from breast cancer cells that may act on stromal cells (Figure 5.1). 
Stable Isotopic Labelling of Amino Acids in Culture (SILAC) was combined with 
SDS-PAGE fractionation to determine relative changes in secreted proteins from 
MDA-MB-231 breast cancer cells stably expressing scrambled (shControl) or 
NODAL knockdown (shNODAL) shRNA (Figure 5.2a). In total, this approach 
identified over 3200 proteins, which were reduced to ~1300 entries after filtering 
for proteins annotated with Gene Ontology Cellular Component (GOCC) terms 
containing “extracellular” and quantified in ≥2 out of 3 biological replicates (Figure 
5.2b, ESM5.1). A one-sample, two-sided t-test revealed 122 proteins that were 
significantly different (p<0.05) between shControl and shNODAL CM (Figure 5.2b, 
ESM5.1). From this list, 1D annotation enrichment in Perseus revealed a 
significant decrease (Benjamini Hochberg (BH) FDR threshold<0.02) in proteins 
involved in GO Biological Processes (GOBPs) associated with cell migration, 
inflammation and cytokine signalling following NODAL knockdown (Figure 5.2c, 
ESM5.2) [28]. Alternatively, proteins matching to GOBP terms mRNA processes, 
protein localization and macromolecular complex disassembly were significantly 
increased (BH FDR threshold<0.02). This was attributed to higher levels of 
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ribosomal proteins (RPS and RPL members) shed by shNODAL MDA-MB-231 
cells. We plotted Heavy/Light ratios (shNODAL/shControl) and their corresponding 
–log10 p-values for the ~1300 filtered extracellular proteins found in MDA-MB-231 
CM (Figure 5.2d). All proteins annotated with the aforementioned GOBP terms 
were highlighted in blue (depleted) or red (enriched); there was a clear trend 
towards a reduction in secretion of inflammatory and chemotactic proteins 
following NODAL knockdown and an opposing increase in transcriptional and 
translational proteins. CXCL chemokines (CXCL1/3/8), IL6 and CSF1 were 
significantly lower in shNODAL CM (p<0.05). Interleukin 11 (IL11), on other the 
hand, was significantly higher (~1.85 fold, p<0.05). These factors have been 
associated with malignant phenotypes and may contribute to MSC chemotaxis 
given that they can promote chemotaxis of various immune cells and, in some 
cases, MSC [29–31]. Similar to previous findings, PDGFA was significantly lower 
in shNODAL CM (-2.31 fold) [17]. 
As a corollary, we performed label-free quantitative proteomics on Strong Cation 
Exchange (SCX)-fractionated CM digests obtained from Green Fluorescent 
Protein (GFP) and NODAL overexpressing SUM149 cells (Figure 5.3a). 
Approximately 1500 proteins were annotated as “extracellular” and quantified in 
≥2 out of 3 biological replicates, and 344 proteins were significantly different (two-
sided, two-sample t-test, p<0.05) between NODAL and GFP expressing SUM149 
cells (Figure 5.3b, ESM5.3). GOBPs that were significantly enriched/depleted (BH 
FDR threshold<0.02) included terms associated with inflammation, cell 
migration/locomotion, translation and transcription (Figure 5.3c, ESM5.4). 
Unexpectedly, GOBPs depleted in shNODAL MDA-MB-231 samples were also 
depleted in NODAL overexpressing SUM149 CM.  For example, proteins matching 
to the cytokine- mediated signalling pathway had a mean log2 fold-change of -2.28 
and -2.44 following NODAL knockdown and overexpression, respectively. 
Conversely, proteins matching to “mRNA metabolic process” were increased 
significantly by NODAL knock down in MDA-MB-231 and NODAL over-expression 
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in SUM149 with mean log2 fold-changes of 1.51 and 1.88, respectively. We also 
plotted log2 protein fold-changes for SUM149 secretomes (NODAL-GFP) versus –
log10 p-values and highlighted all proteins annotated with the aforementioned 
GOBPs (Figure 5.3d). Several inflammatory and migratory factors decreased 
following NODAL overexpression while translational and transcriptional proteins 
were elevated. For instance, CXCL1 and 3, IL6 and CSF1 levels decreased 
following NODAL knockdown in MDA-MB-231 cells and NODAL overexpression in 
SUM149 cells. Although PDGFA was not detected in SUM149 CM, the angiogenic 
factors Angiopoietin-1 (ANGPT1) and Angiogenin (ANG) were significantly 
elevated in CM from NODAL overexpressing SUM149 cells [32,33]. Highly similar 
proteomic results were also observed when comparing CM from NODAL 
overexpressing SUM149 cells to cells expressing an empty vector (EV) (Figure 
5.4, ESM5.5 and ESM5.6). In total, 56 proteins were significantly altered by 
NODAL in both MDA-MB-231 and SUM149 datasets; however, only a handful 
were associated with NODAL expression in a positive (CLU and CLSTN3) and 
negative (Leukemia Inhibitory Factor [LIF] and Neuropillin-2 [NRP2]) manner in 
both cell lines. To verify the proteomic findings, ELISAs were performed with CM 
from MDA-MB-231 cells for CXCL1, CXCL8, IL6 and CSF1 and CM from SUM149 
cells for CXCL1 and IL6 (Figure 5.5a). For reference, CXCL1 and IL6 levels were 
substantially higher in GFP expressing SUM149 cells compared to MDA-MB-231 
cell lines (Figure 5.5b and c). In effect, NODAL appears to influence a subset of 
cellular processes involved in inflammation, motility, transcription and translation, 
albeit differentially based on the breast cancer line.  
  
190 
 
 
 
 
Figure 5.1 MS-based proteomics workflow for interrogating the NODAL 
regulated secretome in breast cancer. 
Serum free conditioned media (CM) were isolated from MDA-MB-231 (shControl 
and shNODAL) or SUM149 (EV, GFP and NODAL overexpressing) breast cancer 
cell lines. Extracellular proteins from MDA-MB-231 cell lines were concentrated 
from CM, fractionated by SDS-PAGE and digested into peptides. For SUM149 cell 
lines, extracellular proteins were concentrated, digested into peptides, and 
fractionated with SCX StageTips. Fractions were analyzed by liquid 
chromatography-mass spectrometry to detect secreted proteins altered by 
NODAL. 
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Figure 5.2 NODAL knockdown alters the MDA-MB-231 secretome. 
(a) NODAL expression in lysates from MDA-MB-231 breast cancer cells stably 
expressing scrambled (shControl) or NODAL knockdown (shNODAL) shRNA 
cultured in serum free media (SFM), SFM+0.5%BSA (0.5%BSA), or complete 
media (10% FBS).  Extracellular proteins from serum free, isotopically (SILAC) 
labelled shControl and shNODAL conditioned media (CM) were concentrated 
using 3kDa MWCO filter units, fractionated and in-gel digested using SDS-PAGE, 
and analyzed on a Q Exactive mass spectrometer. Raw files were searched in 
MaxQuant and protein lists were filtered and annotated in Perseus. (b) Venn 
diagram highlighting total protein identifications, number of “extracellular” and 
quantified proteins, and significantly different proteins between shControl and 
shNODAL CM. A two-tailed, one sample t-test was used to identify differentially 
expressed proteins (p<0.05).  (c) Number of significant proteins (bars) matching to 
a subset of significantly enriched GO biological processes (GOBPs). Mean log2 
fold-changes in GOBPs are indicated by black dots.  Blue and red bars highlight 
GOBPs decreased and increased in MDA-MB-231 CM following NODAL 
knockdown, respectively. (d)  Volcano plot of quantified “extracellular” proteins. 
Negative and positive Log2 Heavy/Light ratios indicate proteins decreased and 
increased in MDA-MB-231 CM following NODAL knockdown, respectively (n=3). 
All proteins matching to corresponding GOBPs mentioned are highlighted in blue 
and red.  Several cytokines and chemokines altered by NODAL are labelled in 
black. Vertical and horizontal dotted lines indicate log2 fold-changes ≥2 and the –
log10 p-value cut-off corresponding to p<0.05, respectively. 
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Figure 5.3 NODAL overexpression alters the SUM149 secretome. 
(a) NODAL expression in lysates from GFP or NODAL over-expressing SUM149 
breast cancer cells. Extracellular proteins from serum free CM (GFP or NODAL) 
were concentrated using 3kDa MWCO filter units, digested with trypsin, 
fractionated using SCX StageTips and analyzed on an Orbitrap Elite mass 
spectrometer. Raw files were searched with MaxQuant and protein lists were 
filtered and annotated in Perseus. (b) Venn diagram highlighting total protein 
identifications, “extracellular” and quantified proteins, and significantly different 
proteins between GFP and NODAL CM. A two-tailed, two sample t-test was used 
to identify differentially expressed proteins (p<0.05).  (c) Number of significant 
proteins (bars) matching to subset of significantly enriched GOBPs. Mean log2 fold-
changes in GOBPs are indicated by black dots.  Blue and red bars highlight 
GOBPs decreased and increased in SUM149 CM following NODAL 
overexpression. (d)  Volcano plot of quantified “extracellular” proteins. Negative 
and positive log2 fold-changes indicate proteins decreased and increased in 
SUM149 CM following NODAL overexpression, respectively (n=3). All proteins 
matching to corresponding GOBPs mentioned are highlighted in blue and red.  
Several cytokines, chemokines and growth factors altered by NODAL are labelled 
in black. Vertical and horizontal dotted lines indicate log2 fold-changes ≥2 and the 
–log10 p-value cut-off corresponding to p<0.05, respectively. 
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Figure 5.4 NODAL overexpression alters the SUM149 secretome compared 
to an empty vector control.  
Extracellular proteins (CM) from empty vector (EV) or Nodal overexpressing 
SUM149 cell lines were concentrated using 3kDa MWCO filter units, digested with 
trypsin, fractionated using SCX StageTips and analyzed on an Orbitrap Elite mass 
spectrometer. Raw files were searched with MaxQuant and protein lists were 
filtered and annotated in Perseus. (a) Venn diagram highlighting total protein 
identifications, “extracellular” and quantified proteins, and significantly different 
proteins between GFP and NODAL CM. A two-tailed, two sample t-test was used 
to identify differentially expressed proteins (p<0.05).  (c) Number of significant 
proteins (bars) matching to significantly enriched GO biological processes 
(GOBPs). Mean log2 fold-changes in GOBPs are indicated by black dots.  Blue 
and red bars highlight GOBPs decreased and increased in SUM149 CM following 
NODAL overexpression. (d)  Volcano plot of quantified “extracellular” proteins. 
Negative and positive log2 fold-changes indicate proteins decreased and increased 
in SUM149 CM following NODAL overexpression, respectively (n=3). All proteins 
matching to corresponding GOBPs mentioned are highlighted in blue and red.  
Several cytokines, chemokines and growth factors altered by NODAL are labelled 
in black. Vertical and horizontal dotted lines indicate log2 fold-changes ≥2 and the 
–log10 p-value cut-off corresponding to p<0.05, respectively. 
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Figure 5.5 Cytokine and chemokine levels in breast cancer CM. 
Cytokine and chemokine levels in breast cancer CM. (a) SILAC quantification in 
MaxQuant and ELISAs report similar fold-changes in secreted factors between 
shControl  and shNODAL MDA-MB-231 cells. (b and c) ELISAs reveal 
substantially higher levels of CXCL1 and IL6 in CM derived from GFP expressing 
SUM149 cells compared to MDA-MB-231 cell lines. Black and grey dots indicate 
replicate values.  
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 The NODAL-regulated breast cancer secretome impacts 
MSC chemotaxis and NODAL induces fibroblast 
activation 
The breadth of changes in the NODAL-regulated breast cancer secretome indicate 
that this morphogen may affect components of the TME via both direct and indirect 
mechanisms. Given the involvement of MSC in tumour growth and 
neovascularization, we first examined how NODAL affects the capacity of breast 
cancer cells to promote MSC chemotaxis. We first compared the ability of CM from 
shControl and shNODAL knockdown MDA-MB-231 breast cancer cells to 
influence MSC chemotaxis (Fig. 5.6a-d). Several primary human bone marrow 
(BM)-derived MSC lines were utilized herein, some of which have been previously 
shown to form tubes in vitro and stimulate islet regeneration and revascularization 
in vivo [34,35]. Compared to shControl CM, in 3 out 4 MSC lines, chemotaxis was 
significantly decreased (~1.8 to 3.5 fold, p<0.0001, Dunnett’s multiple comparison 
test) towards shNODAL CM. We did not observe appreciable differences in 
proliferation or viability of MSC cultured in CM for 24h, suggesting that the effects 
observed were not due to alterations in cell numbers, but rather a result of altered 
chemotaxis (Figure 5.7a; data not shown). As a corollary, we investigated whether 
CM derived from empty vector (EV), GFP and NODAL overexpressing SUM149 
breast cancer cells could also affect MSC chemotaxis (Figure 5.6e). In accordance 
with our proteomics results, CM from NODAL overexpressing SUM149 cells 
induced less chemotaxis in MSC2 cells compared to the GFP expressing control. 
Again, we confirmed by flow cytometry that differences in chemotaxis were not due 
to altered proliferation or viability (Figure 5.7b; data not shown). 
 
The reduction in MSC chemotaxis observed when NODAL was knocked down 
could not be rescued by the addition of 100ng/mL of recombinant human NODAL 
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(rhNODAL) (Figure 5.6 a,b and d) suggesting that MSC are unable to sense this 
morphogen, perhaps due to an absence of receptor components. Hence, we 
performed Real time-PCR and Western blotting for NODAL, its receptor (ALK4) 
and co-receptor (CRIPTO) on two MSC lines (Figure 5.84a and b). MSC expressed 
moderate levels of NODAL and high levels of ALK4 at the transcript and protein 
level (Figure 5.8a and b). CRIPTO mRNA expression approached the reliable limit 
of detection by quantitative real-time PCR (35 cycles). Hence, while MSC appear 
to make NODAL and to express NODAL receptors, they may not express enough 
CRIPTO to sense NODAL. Indeed, stimulation with 10 and 100 ng/mL rhNODAL 
had no effect on canonical or non-canonical signalling through SMAD2 or ERK1/2 
phosphorylation, respectively (Figure 5.8c).   
 
Fibroblasts are critical components of the TME and studies indicate CAFs can 
originate from BM-derived populations including MSC [14,36]. We examined 
whether NODAL affects breast cancer-induced fibroblast phenotypes by 
performing chemotaxis assays using primary Human Foreskin Fibroblasts (HFFs) 
(Figure 5.9a and b). We did not detect differences in HFF chemotaxis towards CM 
from shControl and shNODAL MDA-MB-231 cells; however, CM from NODAL 
overexpressing SUM149 cells significantly increased HFF chemotaxis compared 
to the GFP expressing control (two-sample t-test, p<0.001). We therefore asked if 
NODAL could directly promote fibroblast activation. Indeed, rhNODAL (10 and 100 
ng/mL) increased HFF chemotaxis (Figure 5.9c), invasion (Figure 5.9d) (Dunnett’s 
multiple comparison test, p<0.05) and proliferation (Figure 5.9e). In contrast to 
MSC, which did not respond to NODAL, we found that rhNODAL (10 and 
100ng/mL) caused an increase in both SMAD2 and ERK1/2 activation in fibroblast 
cells (Figure 5.9f). In addition, Real time RT-PCR revealed that rhNODAL (10 and 
100ng/mL) induced expression of α-Smooth Muscle Actin (α-SMA), Desmin and 
Connective Tissue Growth Factor (CTGF) (Figure 5.9g). We performed gene 
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expression profiling on human dermal fibroblasts (HDFs) treated with 10ng/mL 
rhNODAL for 6h. Transcripts upregulated by at least 1.7 fold were analyzed in 
DAVID and gene clusters associated with the GO terms “wound healing”, “cell 
motion”, “extracellular matrix” and “growth factor” were significantly enriched 
(Figure 5.9h; ESM5.7) [37]. We overlapped proteins differentially expressed from 
the proteomics and microarray datasets, and found several factors to be 
consistently altered by NODAL, albeit some inversely correlated with NODAL 
levels (Figure 5.9i). IL6, LIF and NRP2 were shared amongst all three datasets; 
however, CXCL1/3 appeared be exclusive to breast cancer cells. Hence, while 
NODAL indirectly affects MSC chemotaxis by altering the breast cancer 
secretome, NODAL can directly induce fibroblast activation. Moreover, certain key 
factors, such as IL6 and LIF, are commonly affected by NODAL in all cell types 
investigated here.  
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Figure 5.6 CM from NODAL expressing breast cancer cells indirectly 
modulates MSC migration. 
Human bone-marrow derived MSC lines (MSC1-4) were plated onto fibronectin-
coated transwells in the presence CM (shControl or shNODAL +/-100ng/mL 
recombinant human NODAL; rhNODAL). (a-d) MSC chemotaxis was quantified 
after ~24h and was significantly lower (p<0.05) towards shNODAL CM compared 
to shControl CM. Moreover, rhNODAL could not rescue MSC chemotaxis. (e) 
Paradoxically, CM from NODAL overexpressing SUM149 cells was less 
chemotactic compared to empty vector (EV) and GFP controls. Data are presented 
as mean fold-changes relative to controls from a minimum of 3 biological replicates 
± standard deviation (SD). Black dots indicate replicate values and asterisks 
indicate significance differences (one way ANOVA, Dunnett’s multiple comparison 
test) in MSC chemotaxis compared to shControl or GFP conditions (** p<0.01, **** 
p<0.0001). 
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Figure 5.7 MDA-MB-231 and SUM149 CM have a negligible effect on MSC 
proliferation.  
MSC were labelled with cell trace violet (CTV) in suspension and plated onto tissue 
culture plates. After ~48h, MSC were rinsed in PBS and cultured for additional 24h 
in CM from MDA-MB-231 (shControl and shNODAL) or SUM149 (EV, GFP and 
NODAL) cells. MSC were then trypsinized, pelleted and resuspended in 5% 
FBS/PBS. (a and b) Histograms and tables showing median CTV intensity of MSC 
after 24h in CM from MDA-MB-231 and SUM149 conditions.  Histograms are 
representative images from 3 biological replicates.  
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Figure 5.8 NODAL signalling in MSC 
(a) Real time PCR cycle threshold (Ct) values for NODAL, ALK4 and Cripto in 
MSC. (b) Western blots showing expression of NODAL and ALK4 (receptor) in 
lysates from four MSC lines. Lysates from shControl and shNODAL MDA-MB-231 
breast cancer cells were used as positive controls. (c) Serum starved MSC treated 
with varying concentrations (ng/mL) of recombinant human NODAL (rhNODAL) for 
1h had no effect on downstream SMAD2 (p-SMAD2) or ERK1/2 (p-ERK1/2) 
activation. TGF- β (10ng/mL for 30mins) and cell culture media were used as 
positive controls for SMAD2 and ERK1/2 activation, respectively. Data are 
presented as mean Ct values ± SD from 3 biological replicates except for Cripto 
(n=2 for MSC2). High Ct values indicate low transcript expression with the 
horizontal dotted line corresponding to a Ct value of 35 or the reliable limit of 
detection. Western blots are representative images taken from 3 biological 
replicates. 
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Figure 5.9 NODAL directly promotes phenotypes associated with activated 
fibroblasts in HFFs. 
(a and b) HFF chemotaxis towards CM from MDA-MB-231 and NODAL SUM149 
breast cancer cells (n=6). (c to e) Exposure to rhNODAL (10 and 100ng/mL) for 
24h significantly increased HFF chemotaxis, invasion and proliferation (n=3). (f) 
Stimulation with rhNODAL (10 and 100 ng/mL) for 30mins dose dependently 
activates SMAD2 and ERK1/2 phosphorylation in HFFs. (g) HFFs upregulate 
transcripts (a-SMA, DESMIN and CTGF) associated with activated fibroblasts 
following treatment with rhNODAL (10 and 100ng/mL) for 72h (n=3, n=2 for α-SMA 
from 100ng/mL treatment). (h) Total genes (bars) upregulated by NODAL 
(10ng/mL) more than 1.7 fold in human dermal fibroblasts (HDFs) after 6h 
treatment and their corresponding enrichment (black dots) following GO analysis 
in DAVID. (i) Overlap in proteins differentially expressed (increased or decreased) 
in MDA-MB-231 (shControl versus shNODAL), SUM149 (NODAL versus GFP) 
and HDF (treated versus untreated) datasets. Data are presented as mean fold-
changes relative to controls or mean values ± SD. Black dots indicate replicate 
values and asterisks indicate significance differences (one way ANOVA, Dunnett’s 
multiple comparison test) in MSC chemotaxis compared to controls (* p<0.05, *** 
p<0.001). Conditions stimulated with 10ng/mL and 100ng/mL rhNODAL were 
significantly different when compared using a paired two-tailed, two sample t-test 
(p<0.05).  
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 IL6 promotes MSC migration 
Given that NODAL consistently altered CXCL1 and IL6 levels in breast cancer CM, 
concomitant with differential MSC chemotaxis, we sought to determine whether 
receptors for these ligands were expressed by MSC. While three MSC lines were 
highly positive for IL6R based on flow cytometry (Figure 5.10a, Figure 5.11a and 
b), surface CXCR1 and CXCR2 expression could not be detected on 4 MSC lines 
by real-time PCR or flow cytometry (Figure 5.11c; data not shown). Accordingly, 
treatment with 10 and 25ng/mL recombinant human IL6 (rhIL6) induced STAT3 
phosphorylation in MSC2 cells, which could be blocked by the addition of an IL6 
neutralizing monoclonal antibody (mAb, Figure 5.10b). Moreover, low doses of 
rhIL6 (1 and 10ng/mL) significantly increased MSC2 chemotaxis by ~1.6 fold 
(Dunnett’s multiple comparison test, p<0.05) although higher concentrations had 
no effect (Figure 5.10c). Neutralizing IL6 in shControl CM or supplementing 
shNODAL CM with rhIL6 (1ng/mL) resulted in a small, but significant, reduction 
and increase in MSC2 chemotaxis, respectively (Figure 5.10d and 6e). These 
findings suggest that IL6 may be involved in promoting MSC recruitment to breast 
cancers. Notably, IL6 levels in CM from shControl MDA-MB-231 cells were far 
lower than in CM from GFP expressing SUM149 cells (~40pg/mL versus 
~800pg/mL), suggesting different regulatory mechanisms between these cell lines, 
which could explain the differential effects of NODAL. 
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Figure 5.10 IL6 contributes to MDA-MB-231 mediated MSC chemotaxis.  
(a) Flow cytometry showing nearly homogenous expression of the IL6 receptor 
(IL6R) by MSC. (b) Stimulation with rhIL6 (10 and 25ng/mL) for 30 minutes induced 
phosphorylation of STAT3 in MSC2 which could be blocked by a 5 minute pre-
incubation with an IL6 neutralizing mAb (2.5µg/mL).  (c) MSC chemotaxis towards 
0, 1, 10, 25 or 100ng/mL recombinant human IL6 (rhIL6) after 24h (n=4-8). Low 
concentrations (1 and 10ng/mL) of rhIL6 significantly induced MSC chemotaxis. 
(d) Neutralizing endogenous IL6 in MDA-MB-231 CM with an IL6 mAb (2.5µg/mL) 
significantly attenuates MSC chemotaxis. (e) Exogenous rhIL6 (1ng/mL) 
significantly increased MSC chemotaxis towards shNODAL CM.  Flow histogram 
and Western blots are representative images from 3 biological replicates.  Data 
are presented as mean fold-changes relative to controls ± SD. Black dots indicate 
replicate values and asterisks indicate significance differences (one way ANOVA, 
Dunnett’s multiple comparison test for IL6 dose response and two tailed, two 
sample t-test for MDA-MB-231 treatments) in MSC chemotaxis compared to 
controls (* p<0.05, ** p<0.01).  
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Figure 5.11 MSC express IL6R but lack CXCR1/2 gene expression.  
(a and b) Flow cytometry showing high surface expression of IL6R (grey region) 
on two additional MSC lines compared to unstained MSC (white region). (c) Real-
time PCR results reveal no detectable transcript or reliable gene expression for 
CXCR1 or CXCR2 in four primary MSC lines. Individual data points correspond to 
real-time PCR readings from 2 biological replicates. A Ct value of 0 indicates no 
transcript was detected. The dotted line indicates a Ct value of 35 or the reliable 
limit of detection. Histograms are representative images from 3 biological 
replicates. 
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 Differential signalling pathways may dictate cell-type 
dependent effects of NODAL 
NODAL/ACTIVIN regulates cell fate specification and phenotype by activating 
signal transduction pathways that directly affect transcription and/or mediate 
epigenetic modifications [38]. The ability of NODAL to broadly affect gene 
expression is context-dependent. These differential responses may be due, in part, 
to which signal transduction pathways are induced by NODAL. Canonically, 
NODAL triggers phosphorylation of SMAD2/3 via binding to its receptors 
ActRIIB/ALK(4/7) and co-receptor CRIPTO [39]. Phospho-SMAD2/3-SMAD4 
heterodimers subsequently translocate into the nucleus to regulate the epigenetic 
status and transcription of target genes. NODAL can also signal non-canonically 
to activate ERK1/2, which is required for the induction of Epithelial-to-
Mesenchymal Transition (EMT) and invasion [40].  
Given the disparate effects of NODAL on cytokine secretion in MDA-MB-231 
versus SUM149 cells, we hypothesized that NODAL may activate different 
signalling mediators in a cell-type dependent manner like TGF-β.  Accordingly, the 
activation of two documented mediators of NODAL signalling (SMAD2/3 and 
ERK1/2) were measured by Western blotting in breast cancer cells wherein 
NODAL levels were modified and then cells were cultured under serum free 
conditions for 24 hours (Figure 5.12). NODAL knockdown in MDA-MB-231 resulted 
in an expected and previously described reduction in both SMAD2/3 and ERK1/2 
phosphorylation [40]. While overexpression of NODAL in SUM149 increased 
SMAD2 phosphorylation, a small reduction in ERK1/2 phosphorylation was 
observed. Moreover, constitutive SMAD2 and ERK1/2 activation was respectively 
higher and lower in SUM149 cells as compared to MDA-MB-231 cells. We also 
probed for p38 activation, which is regulated by TGF-β. NODAL expression was 
associated with decreased p38 activation and increased STAT3 signalling. 
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Hence, NODAL appears to modulate several signalling pathways both positively 
and inversely correlated with the secretion of factors such as IL6 and CXCL1 in a 
cell-type dependent manner (Figure 5.13). One notable difference that may explain 
some of the cell-type-specific effects of NODAL relates to the levels of SMAD2/3 
and ERK1/2 activation; MDA-MB-231 cells have higher levels of ERK activation 
and lower levels of SMAD2/3 activation as compared to SUM149 cells. Hence 
NODAL may preferentially signal through SMAD2/3 or ERK1/2 in SUM149 and 
MDA-MB-231 cells, respectively.  
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Figure 5.12 Effects of NODAL manipulation on signalling pathways in MDA-
MB-231 and SUM149 cells. 
Transgenic MDA-MB-231 and SUM149 cells were serum starved and then 
cultured in serum free media for an additional 24h. Western blotting revealed 
similarities and differences in activation of downstream pathways. NODAL 
expression (NODAL and shControl cell lines) was associated with increased 
phosphorylation of STAT3, SMAD2 and SMAD3 and decreased phosphorylation 
of p38. Basal levels of p-SMAD2 and p-ERK1/2 were substantially higher in 
SUM149 and MDA-MB-231 cell lines, respectively. p-ERK1/2 decreased slightly 
following NODAL overexpression in SUM149 cells, respectively.  Western blots 
are representative images taken from 3 biological replicates and asterisks denote 
high contrast image settings. 
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Figure 5.13 Proposed model for NODAL signalling in the breast cancer 
microenvironment. 
NODAL directly signals to breast cancer cells and CAFs. NODAL indirectly 
regulates inflammatory, chemotactic and angiogenic factors which act on 
endothelial cells and MSC and possibly immune cell types. Collectively, NODAL 
promotes tumorigenic phenotypes including tumour growth, neovascularization 
and cell migration. 
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5.4 Discussion 
We demonstrate for the first time that NODAL signals directly on fibroblasts to 
induce an activated phenotype and that it can modulate the chemotaxis of MSC 
cells indirectly, by altering the breast cancer secretome (Figure 5.13). NODAL has 
been shown to directly induce migration and/or invasion of breast, pancreatic and 
hepatocellular cancer cell lines in vitro [22,40,41]. Moreover, ectopic 
overexpression of NODAL in breast cancer cells indirectly promotes endothelial 
tube formation by increasing the expression of pro-angiogenic proteins such as 
PDGFA [17]. We build upon these studies by showing that NODAL broadly 
regulates the breast cancer secretome, which may affect TME composition. 
Our robust proteomics approach allowed us to uncover dozens of secreted 
proteins that are affected by NODAL expression in breast cancer cells.  For these 
studies, we took two approaches: We knocked down NODAL in MDA-MB-231 that 
are claudin-low and basally express NODAL, and we overexpressed NODAL in 
SUM149, which represent inflammatory breast cancer cells and express low levels 
of NODAL. Consistent with the effects of NODAL in vitro and in vivo, the levels of 
several pro-angiogenic factors (PDGFA, ANGPT1, and ANG) in breast cancer CM 
were positively correlated with its expression [17]. However, we also made the 
seemingly paradoxical discovery that the expression of NODAL in MDA-MB-231 
and SUM149 breast cancer cells oppositely regulates cytokines involved in 
chemotaxis. This may be coincident with the models chosen: MDA-MB-231 
express relatively low levels of pro-inflammatory cytokines as compared to 
SUM149 and thus the epigenetic regulation of the genes encoding these proteins 
may vary dramatically. Genes regulated by NODAL appear to be dictated, at least 
in part, by accessibility of genomic regions, and NODAL induces histone 
modifications to affect gene expression [42]. Hence the differential effects of 
NODAL in MDA-MB-231 versus SUM149 cells may be due to differences in 
chromatin accessibility in the areas surrounding chemotactic and inflammatory 
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cytokines. The differences observed may be also due to the ability of NODAL to 
activate ERK signaling in MDA-MB-231 cells but not in SUM149 cells.  Several 
studies have demonstrated the role of ERK signaling in the up-regulation of 
inflammatory cytokines such as IL6 [43,44]. Hence the effects of NODAL knock 
down in MDA-MB-231 cells may be due to reduced ERK signalling.  
Our discordant results are not uncommon for studies involving members of the 
TGF-β family, which function in a context dependent manner.   TGF-β1, for 
example, induces IL6 production in PC3 and DU145 prostate cancer cells via 
SMAD2/TGFBRII and p38 MAPK [45]. Moreover, in MDA-MB-231 and MDA-MB-
468 breast cancer cells, TGF-β1 stimulates IL8(CXCL8) and IL11 secretion via 
SMAD3/TGFBRI and p38 MAPK [46]. However, in Polyoma virus middle T antigen 
transformed mouse mammary carcinoma, loss of TGF-β signalling results in an 
up-regulation of CXCL1, CXCL5 and CCL20 [47]. Remarkably, these factors 
decreased substantially in SUM149 CM following NODAL overexpression, thus 
suggesting negative regulatory roles for both NODAL and TGF-β. We did not 
observe significant differences in the levels of TGF-β1/2 between breast cancer 
lines; hence the effects of NODAL were not likely mediated via alterations in TGF-
β1/2. Taken together, both NODAL and TGF-β may differentially regulate 
chemokine and cytokine expression in cancer, depending on context. This should 
be considered as treatment modalities designed to target these pathways evolve 
[48].  
While IL6R was detected on MSC, CXCR1 and CXCR2 were not. Heterogeneity 
in MSC receptor expression has been reported among multiple studies and may 
be a product of culture conditions and donor heterogeneity [9,49]. For reference, 
Ponte et al. observed CXCR4 and CXCR5 but not CXCR1 or CXCR2 on human 
BM-MSC [50]. Chamberlain et al. also reported high expression for CXCR4 and 
CXCR5 but low to intermediate expression of CXCR1 and CXCR2, respectively 
[51]. Conversely, Ringe et al. extensively profiled chemokine receptors on human 
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BM-MSC and detected CXCR1 and CXCR2 but noted loss of expression following 
10 passages [52]. While these pathways may play a role in MSC recruitment to 
tumours in breast cancer patients, we were unable to test this possibility.  
In our hands, MDA-MB-231 cells produced less IL6 and CXCL1 compared to work 
by Hartman et al. who investigated the role of cytokines in triple negative breast 
cancer cell growth [29]. Notwithstanding, neutralizing IL6 in MDA-MB-231 CM was 
sufficient to attenuate MSC chemotaxis [12,53,54]. We did not neutralize IL6 in 
SUM149 CM, however CM from either SUM149 and/or SUM159 breast cancer 
cells was previously shown to promote migration of aldehyde dehydrogenase-high 
MSC or macrophage-educated MSC in an IL6 dependent manner [31,54].  
Although CXCR1/2 was not detected on MSC, differences in CXCL1 and CXCL8 
levels following NODAL knockdown/overexpression remain important for cancer 
progression and trafficking of additional cell types and justifies additional 
interrogation. For instance, CXCL1 mediated recruitment of CD11b+Gr1+ myeloid 
cells enhanced breast cancer cell survival, chemoresistance and metastasis [30]. 
Moreover, obesity-associated CXCL1 expression in prostate tumours was linked 
to adipose derived stromal cell migration in vitro and tumour engraftment in vivo 
[55]. Given the importance of NODAL-regulated cytokines in the TME, future 
studies interrogating the extent to which NODAL may modulate TME composition 
are warranted.  
In summary, our findings demonstrate the capacity of NODAL to bi-directionally 
regulate a number pro-tumorigenic factors in the breast cancer secretome. 
Moreover, NODAL regulates stromal cell recruitment and activation through direct 
and indirect means. Characterizing the effects of NODAL on cytokines and 
chemokine expression in additional cell lines and cancers may further improve our 
understanding of its complex roles during development and cancer progression. 
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5.5 Materials and methods 
 Cell culture 
MDA-MB-231 cells stably expressing scrambled (shControl) or NODAL targeting 
(shNODAL) short hairpin RNAs as previously described and validated[17,23,40] 
were maintained in DMEM/F12 (Gibco) supplemented with 10% FBS (Gibco) and 
500ng/mL puromycin. To generate SUM149 cells stably expressing an empty 
vector (EV), green fluorescent protein (GFP) or NODAL, cells were transduced 
with lentiviral particles (GeneCopia) overnight then selected and maintained in 
HAM’s F10 (Gibco) supplemented with 10% FBS, 5µg/mL insulin (Santa Cruz 
Biotechnology, Dallas TX, USA), 1µg/mL hydrocortisone (Sigma-Aldrich, St. Louis, 
MO, USA) and 100 ng/mL puromycin. Human BM-MSC lines were maintained in 
Amniomax with C100 supplement (Life Technologies, Carlsbad, CA, USA) and 
previously confirmed to express characteristic stromal markers (>95% CD90+, 
CD105+, and CD73+) and exhibit multipotent differentiation.[35,56] HFFs were 
maintained in DMEM/F12 supplemented with 10% FBS.  For SILAC labelling, 
shControl and shNODAL MDA-MB-231 cells were cultured in DMEM F12 
supplemented with dialyzed FBS (Life Technologies) containing light (Advanced 
ChemTech, Louisville, KY, USA ) or heavy (Cambridge Isotope Laboratories, 
Tewksbury, MA, USA and Silantes GmbH, Germany) isotopes of arginine 
(0.398mM) and lysine (0.274mM) for at least 9 days to achieve >90% label 
incorporation. SILAC media was additionally supplemented with 400 mg/L of 
proline (Sigma-Aldrich) to limit arginine to proline conversion.[57] CM was 
prepared by plating equal cell numbers onto flasks in culture media (Corning, NY, 
USA). After 24h (MDA-MB-231 cells) or 48h (SUM149 cells), media was removed 
and cells were thoroughly rinsed 3 times in PBS (with Ca2+ and Mg2+) to remove 
serum components. Cells were incubated in serum free media (SFM) with 0.5% 
BSA for an additional 24h to generate CM (BSA was omitted for LC-MS samples). 
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Conditions used to stimulate cells with rhNODAL and rhIL6 are specified in main 
text.  
 Sample preparation for liquid chromatography-mass 
spectrometry (LC-MS) 
CM (without BSA) were concentrated using 3 kDa molecular weight cut-off 
(MWCO) Amicon ultracentrifugal units (Millipore) and lyophilized overnight. The 
following day, CM was reconstituted in lysis buffer (8M urea, 50mM ammonium 
bicarbonate, 10mM dithiothreitol and 2% SDS), sonicated (3 X 0.5s pulses) with a 
probe sonicator (Level 1; Fisher Scientific, Waltham, MA) and quantified using a 
Pierce™ 660 nm assay (Thermo Scientific™) with ionic detergent compatibility 
reagent. For SlLAC samples, light shControl and heavy shNODAL CM was pooled 
based on equal cell numbers and ~100µg of protein was fractionated using SDS-
PAGE on 12% acrylamide tris-glycine gels. In-gel digestion with trypsin (1:25 
enzyme:protein ratio) was performed on 16-17 slices (fractions) from each lane in 
biological triplicate as previously described [58]. For label free samples, ~50µg of 
protein from SUM149 CM was precipitated in chloroform/methanol, digested 
overnight with trypsin (1:50 ratio) on a water bath shaker and fractionated on SCX 
StageTips as previously described [58–60]. Peptides were dried in a SpeedVac, 
reconstituted in 0.1% formic acid (FA; Fisher Scientific) and a volume 
corresponding to 1/10th of the total material recovered or 1µg as determined by 
BCA (Pierce™) was injected for each in-gel and SCX fraction, respectively. 
 LC-MS 
In-gel and SCX fractions were analyzed using a Q Exactive or Orbitrap Elite mass 
spectrometer (Thermo Scientific™), respectively. Samples were injected using a 
nanoAcquity HPLC system (Waters) and initially trapped on a Symmetry C18 Trap 
Column (5 µm, 180 µm x 20 mm) for 4 or 5 minutes in 99% Solvent A (Water/0.1% 
FA)/1% Solvent B (acetonitrile/0.1% FA) at a flow rate of 10 µl/min. Peptides were 
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separated on an ACQUITY Peptide BEH C18 Column (130Å, 1.7µm, 75µm X 
250mm) at a flow rate of 300 nL/min maintained at 35°C. The LC-MS gradient for 
in-gel digests consisted of 1-7% B over 1 minute and 7-37.5% B over 79 minutes. 
SCX fractions were separated using gradient consisting of 7.5% B over 1 minute, 
25% B over 179 minutes, 32.5% B over 40 minutes and 60% B over 20 minutes. 
Column washing and re-equilibration was performed following each run and 
settings for data acquisition are outlined in ESM5.8. 
 Data analysis and statistics 
MS files were searched in MaxQuant (1.5.2.8) with the Human Uniprot database 
(reviewed only; updated May 2014 with 40,550 entries) [61]. Missed cleavages 
were set to 3 and I=L. Cysteine carbamidomethylation was set as a fixed 
modification. Oxidation (M), n-terminal acetylation (protein), and deamidation (NQ) 
were used as variable modifications (max. number of modifications per peptide = 
5) and min ratio count was set to 1. All other settings were left default. The match-
between-runs feature was utilized to maximize proteome coverage and 
quantitation between samples. Datasets were loaded into Perseus (version 
1.5.5.3) and proteins identified by site, reverse and potential contaminants were 
removed [28]. Protein identifications with quantitative values in ≥2 biological 
replicates were retained for downstream analysis unless specified elsewhere. 
Missing values were imputed using a width of 0.3 and down shift of 1.8 for label 
free datasets. Statistical analysis was performed in Perseus or GraphPad Prism 
version 6.01 (San Diego, CA). All experiments were carried in at least 3 biological 
replicates unless specified otherwise. Where specified, replicate treatment values 
were normalised to the control group and relative fold-changes were reported. 
Two-tailed, one sample and two-sample t-tests (p<0.05) were performed to 
determine statistical differences unless more than 2 conditions were being 
compared and a one way ANOVA using Dunnett’s multiple comparison test 
(p<0.05) was performed instead. 
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 Chemotaxis and invasion assays 
MSC were rinsed in warm PBS (with Ca2+ and Mg2+) and serum starved for ~2h 
in Amniomax prior to dissociation with trypsin for chemotaxis assays. In parallel, 
8µM transwells (Falcon) were coated with 10µg/cm2 of bovine fibronectin (Sigma-
Aldrich) in 100µL of PBS for 2h. After coating, excess solution was aspirated and 
40K MSC in 0.5mL of DMEM F12+0.5% BSA were plated in each transwell. HFFs 
were serum starved 24h prior to dissociation and plated at a density of 50K 
cells/transwell. For HFF chemotaxis and invasion assays, fibronectin and 
Matrigel™ were omitted and included, respectively. To the bottom chamber, 1mL 
of DMEM/F12+0.5%BSA or CM was added +/- rhNODAL (R&D systems), rhIL6 
(eBioscience), isotype or IL6 neutralizing monoclonal antibodies (R&D systems). 
After ~24h, transwells were rinsed in warm PBS and placed in cold methanol for 
20 minutes to fix migrating cells. After fixing, transwells were rinsed in PBS and 
the inside membrane was thoroughly wiped with a cotton swab to remove non-
migrated cells. Membranes were excised and mounted onto glass slides with 
ProLong™ Gold Antifade Mountant with DAPI (InvitrogenTM). Migrated cells were 
counted from at least 5-10 high power fields uniformly distributed across the entire 
membrane for each condition.    
 Western blotting 
Cells were thoroughly washed with PBS (with Ca2+ and Mg2+) and directly lysed 
on tissue culture plates in lysis buffer. Lysates recovered by pipetting were 
sonicated with a probe sonicator (20 X 0.5s pulses) to shear DNA and reduce 
viscosity. Equal protein amounts (15-25µg) were separated on hand cast 8-20% 
acrylamide Tris-glycine gels then transferred to Immobilon-P® PVDF membranes 
(Millipore™, Billerica, MA, USA). Membranes were stained with amido black and 
rinsed in ddH2O for 5 minutes followed by blocking for 1h on rocker in 5% non-fat 
dry milk in TBST (Tris-buffered saline, 0.1% Tween 20) and overnight incubation 
221 
 
 
 
in primary antibody at 4°C. Chemiluminescent detection was performed using film 
or a VersaDoc CCD camera with Clarity™ Western ECL Substrate and 
horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) the next day. 
Antibody information is available in ESM5.9 and ACTIN and TUBULIN were used 
as loading control. PVDF membranes were stippled in 0.2 M NaOH and reprobed 
when possible, otherwise Western blots were run in duplicate. 
 Real-time PCR 
RNA was isolated from cells and treated with DNAse using a Perfect Pure RNA 
cultured cell kit (5 PRIME). RNA was quantified by NanoDrop™ (Thermo 
Scientific™) and 2µg was reverse transcribed with a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Carlsbad, CA, USA). Real-time PCR was 
performed with TaqMan™ Universal PCR mastermix on a Bio-Rad CFX96/384 
thermocycler. HPRT1 or RPLPO were used as housekeeping to genes monitor 
variations between biological replicates. TaqMan™ primer probes were purchased 
from Applied Biosystems and are listed in ESM5.10. 
 Flow cytometry 
MSC dissociated in 10mM EDTA/PBS solution for 5-10 minutes were resuspended 
in 5% FBS/PBS, counted and pelleted at 450 xg. Excess buffer was aspirated and 
MSC were divided 50-100K cell aliquots in 100µL of 5% FBS/PBS. Isotype controls 
and primary antibodies were added to cell suspensions and incubated for ~45 
minutes in the dark on ice (ESM5.9). Cell suspensions were washed in excess 5% 
FBS/PBS and pelleted to remove unbound antibody. Flow cytometry data was 
acquired on an LSR II (Becton Dickinson, NJ, USA) using FACSDiva at the London 
Regional Flow Cytometry Facility and analyzed with FlowJo (Treestar, Ashland, 
OR, Version 10.0.8r1). Gating strategy for live singlets was based on forward and 
side-scatter and is illustrated in figure 5.14.  
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 ELISAs 
ELISA kits were purchased from eBioscience (IL6) or R&D systems (CXCL1, 
CXCL8 and CSF1) and performed according to the manufacturer’s specifications 
using CM derived from MDA-MB-231 and SUM149 cell lines. 
 Gene expression profiling 
Human dermal fibroblasts (ATCC) were cultured in DMEM supplemented with 10% 
FBS until ~40-60% confluence, washed twice with PBS and incubated overnight 
in DMEM+0.5%FBS. The following day, cells were treated +/- rhNODAL (10 
ng/mL) for 6h and RNA was harvested using TRIzol™ (Invitrogen). RNA was 
subjected to expression profiling at the London Regional Genomics Centre 
essentially as previously described [62,63]. RNA quality was assessed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) prior to 
preparing single stranded complimentary DNA (sscDNA) from 200ng of total RNA 
(Ambion WT Expression Kit for Affymetrix GeneChip Whole Transcript WT 
Expression Arrays; Applied Biosystems, Carlsbad, CA) according to the Affymetrix 
User Manual  (Affymetrix, Santa Clara, CA). In total, 5.5µg of sscDNA was 
synthesized, converted into cRNA, end labeled and hybridized (16h at 45°C) to 
Human Gene 1.0 ST arrays. Liquid handling steps were performed by a GeneChip 
Fluidics Station 450 and GeneChips were scanned (GeneChip Scanner 3000 7G; 
Affymetrix, Santa Clara, CA) using Command Console v1.1 to generate Probe 
level (.CEL file) data. Gene level data was generated using the RMA algorithm 
[64]. Partek Genomics Suite v6.5 (St. Louis, MO) was used to determine gene level 
ANOVA p-values and fold-changes. Fold-changes were obtained by averaging 
data from two experiments (GeneSpring). Fold-changes exceeding 1.7 in 
response to rhNODAL were required to identify a transcript as being altered 
(p<0.05).  Altered genes were annotated using DAVID (version 6.7) and lists 
enriched >3.5 fold and comprised of >10 genes were reported (ESM5.10). 
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Figure 5.14 Gating strategy for flow cytometry analysis. 
(a and b) Forward- and side-scatter gating method used to select live singlets for 
surface marker expression and CTV analyses. 
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6.1 General discussion and conclusions  
Our understanding of the complex and heterogeneous nature of cancer and the 
TME as a whole is constantly evolving. This has significant repercussions for 
patient outcomes which depend heavily on early detection, accurate diagnosis, 
and tailored treatments options. Rapid advances in the proteomics pipeline have 
propelled the study of complex biological systems to an unprecedented depth. 
When applied to models of cancer, proteomics can provide valuable information 
on all aspects of disease progression including subtype specific signatures, 
biomarkers for screening and detection, and signalling pathways involved in 
malignant behaviours. In this thesis, I employed global mass spectrometry-based 
approaches to identify biological features that may aid in the diagnosis and 
detection of ovarian cancer and characterize signalling factors regulated by 
NODAL in the breast cancer secretome. More specifically, in Chapter 2, I 
systematically compared newer fractionation strategies with established methods 
for achieving large proteomic coverage. In Chapter 3, I contrast differences 
between two ovarian cancer subtypes, namely HGSC and EC, for which differential 
diagnosis is lacking. In Chapter 4, I performed detailed proteomic analysis of 
ovarian cancer EVs from malignant bio-fluids to identify novel biomarkers for 
detecting ovarian cancer. In Chapter 5, I demonstrated a role for NODAL in 
regulating cytokines and chemokines that mediate stromal cell recruitment within 
the breast cancer microenvironment. 
6.2 Sample preparation strategies for comprehensive 
proteome coverage 
Within each proteomic workflow, a vast array of parameters can be optimized and 
tweaked to achieve comprehensive proteomic information of complex biological 
samples. Sample preparation strategies remain an active area of the proteomics 
pipeline and are continually being improved. Our work in Chapter 2 has further 
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established high-pH/low-pH reversed phase fractionation (HpH) as a superior 
sample preparation scheme over other methods for large-scale proteomics when 
no other limitations are present (i.e. time/cost/access to specialized equipment) 
[1]. Importantly, our findings are in agreement with recent studies by other groups 
which have implemented HpH fractionation into their workflows [2–5]. For example, 
Kulak et al., whom vastly simplified SCX StageTip fractionation used in our 
comparison, recently developed a Loss-less Nano-fractionator (Spider 
Fractionator under commercial development by PreOmics, GmbH) to help 
streamline and automate LC-based fractionation which is commonly employed 
with HpH [6]. Fortunately, when UHPLC or HPLC systems are not available, HpH 
fractionation can be performed with StageTips [7]. One of the earliest examples of 
this was by Han et al. whom in 2013 performed StageTip-based HpH fractionation 
of digests from BV-2 mouse microglial cells [8]. Although we did not compare 
HPLC- and StageTip-based HpH fractionation, HPLC-based fractionation provides 
slightly better fractionation efficiency and more protein identifications (unpublished 
observations and personal communication with Dr. Kuljanin) [6]. Compared to 
HPLC-based setups, StageTips do not typically employ concatenation schemes 
and fractions are eluted in steps which may reduce orthogonality [9,10]. 
Protein digestion with trypsin remains an integral component of sample preparation 
protocols in nearly all bottom-up proteomic studies [11]. Paradoxically, the majority 
of tryptic peptides (56%) generated by in silico digestion of the yeast proteome are 
≤6 amino acids (AA) long while 97% of all peptides observed by mass spectrometry 
are between 7-35 AA with an average length of 8.4 AA [12]. These differences 
highlight a long standing issue with bottom-up proteomics whereby short peptides 
(≤6 AA) comprise the majority of species within each digest but are often excluded 
during acquisition or searching to avoid non-unique sequences [13]. Alternative 
enzymes and chemical digestions are one means to mitigate these issues and 
increase protein identifications and approach 100% sequence coverage [13]. 
While such adaptations are reported for PTM analysis and antibody sequencing, 
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only a handful of studies have employed multiple enzyme and/or chemical 
digestions for large scale proteomic analysis [14–16]. For example, Wiśniewski et 
al. combined multiple enzyme digestions with filter aided sample preparation 
(MED-FASP) to increase the proteome depth of HeLa cells over digestion with 
trypsin alone [12,17]. More recently, Bekker-Jensen et al. utilized trypsin, LysC, 
chymotrypsin and GluC digestions to report the highest protein identifications and 
greatest sequence coverage achieved in a mammalian cell line to date [5]. While 
these modifications are associated with increased sample handling, they provide 
additional sequence information for detecting species/proteoforms that are missed 
with standard tryptic digests [11]. 
In addition to sample preparation, ongoing advances in instrumentation hardware 
and software have resulted in significant improvements to the amount and quality 
of spectral data acquired. For instance, segmented quadrupoles on newer Orbitrap 
systems have reduced co-isolation of multiple precursors that are commonly 
encountered when working with complex samples. Impressively, current 
generation Orbitrap Fusion Tribrid mass spectrometers can theoretically achieve 
sequencing speeds of ~60Hz in parallel acquisition mode [18]. Until very recently, 
this potential was not realized due to limitations in assigning correct charge states 
of overlapping and/or low abundance precursors with the standard precursor 
detection algorithm. However, an Advanced Precursor Detection (APD) algorithm 
is now available which can handle these scenarios and maximize the number of 
MS/MS scans to 96% capacity up from 72% [18].  
The field of mass spectrometry-based proteomics is undergoing innovation at a 
staggering pace and it is an exciting time to witness these innovations. In the latest 
2017 report from the Human Proteome Project (HPP), highly stringent protein 
evidence was still missing from an estimated ~18% of the human proteome [19]. 
There is an ongoing effort to accelerate the identification of missing proteins such 
as that noted with olfactory receptors. In this section, I briefly touched on a few of 
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the many areas where sample preparation and data acquisition are having notable 
successes. In effect, a combination of the technologies and their iterations are 
needed to enable complete proteome coverage in future endeavors. 
6.3 Proteomic profiling enables classification of cancer 
subtypes 
Ovarian cancer remains a challenging disease to detect early, diagnose and treat. 
Genomic and histological studies have significantly improved our understanding of 
the mechanisms underlying EOC progression and pathology [20,21]. Mass 
spectrometry-based proteomics is a complementary approach to these techniques 
and is steadily being incorporated into ovarian cancer research [3,22]. In chapter 
3, we performed a global proteomics analysis on fresh frozen EC and HGSC 
tumour samples with the goal of identifying histospecific markers of EC. Using the 
SVM package ‘geNetClassifier’ in R, ~100 proteins were identified with high 
classification power for either EC or HGSC. Our proteomics dataset represents a 
significant contribution to the field of ovarian cancer research which is striving to 
improve patient management through better histopathological assessment. In 
agreement with other studies, TP53 and CDKN2A expression were upregulated in 
several HGSC tumours while PR was elevated in EC tumour samples [21]. To 
validate novel histotype specific markers for EC, we performed IHC for a subset of 
candidates on a large cohort of over 300 EC and HGSC tumour samples. IHC 
corroborated our proteomics findings however limited specificity or sensitivity 
hindered our ability to identify a high performing marker of EC. KIAA1324 was the 
best subtype specific marker of EC next to PR. IHC, although streamlined, remains 
a rate limiting, but necessary step for validation. Fortunately, we now have a 
database with matched staining information for these markers. We will use this 
information for multivariate analyses that may reveal a histotype specific signature, 
rather than a single marker, for detecting EC and correlating patient outcomes. 
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With regard to proteomic coverage, we achieved relatively good depth for 
unfractionated tumour samples analyzed on an Orbitrap Elite (~5600 entries after 
filtering). For a rough comparison, Hughes et al. quantified 8167 proteins (98.5% 
present in all samples) using TMT-labelled, HpH fractionated digests from FFPE 
tumour sections (CCC and HGSC) on an Orbitrap Fusion[3]. Although we 
anticipated an unfractionated approach would be sufficient to detect markers 
enriched in or exclusive to EC, it is possible that low abundance proteins were 
missed. Notably, WT1 is a transcription factor that is specific for HGSC which was 
absent from our proteomic dataset. We verified the presence of numerous nuclear 
proteins and transcription factors and therefore, insufficient extraction of this 
organelle was an unlikely factor. Rather, it is plausible that WT1 expression was 
below the limit of detection of our instrument when analyzing unfractionated 
samples. This observation is supported by previous work by Hughes et al. and 
Coscia et al. in which WT1 expression appears significantly lower than other 
HGSC markers including TP53 and CDKN2A. For example, in the study by Coscia 
et al., WT1 was absent in 19 of 30 cell lines analyzed with log2 LFQ intensity values, 
when present, ranging from ~20-25. TP53, on the other hand, was detected in 29 
out of 30 ovarian (cancer) cell lines with log2 LFQ values ranging from ~25-30. 
Using these values as a conservative estimate, the abundance of WT1 is likely 25 
or ~2 orders of magnitude lower than TP53.  Interrogation of our dataset revealed 
an average TP53 log2 LFQ value of 24.6 in the 3 out of 10 HGSC tumour samples 
it was present in. Accordingly, WT1 would be at or below the limit of detection (LFQ 
value of around 20). If low abundance markers are indeed required to improve 
discrimination of EOC subtypes, it is worthwhile to perform additional analysis on 
fractionated EC and HGSC tumours samples as the cost of instrument time. 
Multiplexing with tandem mass tags (TMT) can mitigate this issue but MS2 based 
quantification on Orbitrap Elite and Q Exactive systems is associated with 
interference in the low mass range, also known as ratio distortion [23]. MS3 based 
quantification, however, can improve quantification accuracy at the cost of 
sensitivity and sequencing speed [23]. Interestingly, an updated quantification 
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strategy based on complementary TMT (peptide) fragments (TMTc+) was recently 
reported [24]. Importantly, this approach is compatible with older generation 
Orbitrap instruments while maintaining the high sensitivity, accuracy and speed 
afforded by synchronous precursor selection (SPS) MS3-based quantification on 
newer Orbitrap Fusion Tribrid instruments [23,24].  
Advances in instrumentation and multiplexing are increasing the rate of proteomic 
profiling of tumours and cancer biopsies. Rapid in depth proteome coverage can 
be obtained within 1 day as demonstrated on recent state of the art Q Exactive HF 
[5]. It is probable that patient biopsies will one day be routinely profiled using 
proteomics.  Moreover, proteogenomics is a growing area of research that 
incorporates both genomics and proteomics [25]. While the field is still in its 
infancy, personalized protein sequence databases containing single amino acid 
variants (SAAVs) missing from publicly available repositories can be derived from 
whole genome, exome and RNA sequencing technologies. However, there are a 
number of challenges associated with generating, searching and integrating 
multiple ‘omic’ datasets. For instance, high quality spectral information may not 
exist in curated databases thereby necessitating the need for de novo peptide 
sequencing tools like Peaks® [26]. Moreover, iterative search strategies are 
required to minimize high FDRs associated with large search spaces involving six-
frame translations and potential SAAVs [25]. Tumours are also heterogeneous 
masses which may consisting of ~20% stromal and immune that further increases 
proteome complexity [27]. Laser capture microdissection combined with 
proteomics can help elucidate cancer- and stromal-specific factors but is manually 
intensive [28]. Unfortunately, we were unable to implement these strategies into 
our workflow given their significant technological barriers and ongoing 
development. Moving forward, advances in the field of proteogenomics will 
hopefully enable its accessibility for mainstream proteomic analysis of tumour 
biopsies. 
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6.4 Strategies for profiling cancer-derived biomarkers 
When detected early (stage I/II), the 5-year overall survival for patients with EOC 
patients is 70% or higher [29]. Unfortunately, most patients present with advanced 
disease (stage III/IV) for which overall survival is dismal [30]. CA-125 plus TVUS 
screening may reduce mortality by a small margin but is associated with a high 
ratio of unnecessary follow-up surgeries to confirm a positive diagnosis [31,32]. 
Non-invasive blood based biomarkers may one day improve early detection of 
ovarian cancer. However, unbiased biomarker discovery approaches are 
hampered by the capacity to detect low abundance tumour derived proteins in 
biological fluids [33]. In chapter 4, EV preparations from different bio-fluids 
(conditioned media, plasma and ascites) were characterized by LC-MS/MS as an 
alternative method for profiling potential plasma based biomarkers of malignant 
EOC. Our proteomics analysis revealed a substantial number of factors associated 
with malignant disease. Furthermore, this analysis extends beyond traditional 
biomarker discovery approaches which focus on soluble signalling factors and 
highlights the potential value in surveying all populations of EVs for detecting EOC. 
This dataset constitutes the most in depth proteome of ovarian cancer ascites EVs 
to date and is a significant contribution to the field of biomarker research.  
Although we extensively profiled and documented EV proteins associated with 
malignant EOC, according Pepe et al., this work encroaches on the first of 5 
phases of biomarker development, namely the pre-clinical exploratory phase. 
Therefore, to move towards the second phase of biomarker development – clinical 
assay and validation – we utilized a targeted PRM strategy as a proof-of-concept 
to determine the performance of EOC candidates in an independent cohort of 
plasma EVs. Notably, over a dozen candidates were found to harbour ROC-AUC 
values with similar or better performance than CA-125 for differentiating malignant 
from non-malignant plasma EVs. However, this approach can be further refined 
using isotopically labelled peptides for more accurate absolute quantification prior 
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to validation in larger patient cohorts (early versus late stage disease). While PRM 
assays may one day be used clinically, ELISAs may be better suited for detecting 
blood based markers in the near term. It remains to be confirmed whether 
membrane bound and intracellular EV markers can be readily detected in this 
format.  Rapid and robust EV purification strategies are also needed to overcome 
the limitations of ultracentrifugation (time and low/variable sample recovery). 
Interestingly, one group reported a technique known as PRotein Organic Solvent 
Precipitation (PROSPR) to selectively isolate EVs [34]. In this approach, soluble 
plasma proteins are precipitated in acetone while lipid containing vesicles remain 
in the organic phase [34]. PROSPR was shown to be superior over 
ultracentrifugation and therefore merits further interrogation in our hands.  
Once clinical assay development has been fully optimized, either using ELISAs or 
PRM assays, a substantial amount or work remains prior to clinical approval. This 
includes retrospective longitudinal studies, prospective screening studies and 
finally cancer control studies. However, TMT and advanced software detection 
algorithms can be implemented with PRM assays to facilitate high-throughput 
biomarker screening and validation in large case studies [35]. For example, Gygi’s 
group developed and applied TOMAHAQ (triggered by offset, multiplexed, 
accurate-mass, high- resolution, and absolute quantification) as a high-throughput 
screening tool for identifying molecular targets associated with drug sensitivity [35]. 
In this study, 69 target proteins (131 peptides) were monitored by TOMAHAQ in 
the entire panel of NCI-60 cell lines. Impressively, TOMAHAQ reliably quantified 
54 proteins in all cell lines (≥2 biological replicates) without fractionation in just 2 
days and revealed a novel role for the DNA damage response protein BAZ1B in 
predicting Doxorubicin sensitivity. TOMAHAQ was only recently developed and 
investigated using cell lines but should be applicable to monitoring biomarkers in 
biological fluids. 
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6.5 Cancer plasticity associated with NODAL signalling 
differentially regulates the breast cancer secretome and 
stromal cell recruitment 
In Chapters 3 and 4, I focused on proteomic characterization of clinical specimens. 
However, cancers are dynamic and plastic entities comprised of multiple cell types 
and extracellular factors within the TME. NODAL is one such embryonic 
morphogen which promotes metastatic phenotypes in cancer in part through 
regulating activities of cells within the TME [36,37]. In chapter 5, I combined 
proteomics with in vitro assays to test whether NODAL contributes directly or 
indirectly to stromal cell recruitment in breast cancer.  Proteomic analysis of 
conditioned media from MDA-MB-231 and SUM149 breast cancer cell lines 
revealed unpublished alterations in a subset of cytokines and chemokines 
following NODAL knockdown or overexpression. Surprisingly, NODAL regulated 
these factors in an agonistic and antagonistic manner depending on the breast 
cancer cell line and model. These opposing functions are not dissimilar to its family 
member TGF-β which also signals though SMAD2/3 and promotes malignant 
progression in some cancers but suppression in others [38]. Moreover, several 
reports have shown TGF-β signalling to positively or negatively regulate IL6, 
CXCL1, and CXCL8(IL8) levels in various cell lines [39–44]. Although we show 
that NODAL induces global shifts in several cytokines/chemokines, additional work 
is needed understand the underlying mechanisms of this regulation. For example, 
does SMAD2/3 transiently regulate gene expression or are epigenetic changes 
involved that may be more permanent? Co-immunoprecipitation (CHIP) 
sequencing and/or bisulfite sequencing of these promoters may reveal differences 
in histone methylation/acetylation and DNA methylation. Moreover, 
phosphoproteomics and affinity-purification mass spectrometry can identify 
downstream factors associated with canonical and non-canonical signalling events 
that may vary between cell types [45,46]. Although we utilized cell lines stably 
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expressing constitutively active NODAL shRNA and overexpression vectors, 
tetracycline inducible systems can aid in evaluating the dynamics NODAL 
induction/inhibition. NODAL signalling can also be robustly targeted with the small 
molecule inhibitor SB431542 however this drug also blocks TGF- β and ACTIVIN 
pathways due to inhibition of their cognate receptors (ALK4/5/7) [47]. 
NODAL has been previously shown induce endothelial tube formation indirectly by 
altering the secretion pro-angiogenic factors in breast cancer cells [36]. In this 
thesis, I investigated whether NODAL could act could act on stromal cells (directly 
or indirectly) to promote migration in vitro. MSC were sensitive to changes in the 
breast cancer secretome while HFFs were not. Conversely, recombinant human 
NODAL protein activated SMAD2/3 and ERK1/2 in HFFs, but not MSC, and was 
associated with increased migration, invasion and expression of CAF markers. We 
examined how NODAL indirectly regulates MSC migration by profiling cognate 
receptors and neutralizing IL6 in breast cancer CM. Our findings suggest that 
factors in addition to IL6 are driving MSC recruitment.  While the cognate receptors 
for CXCL1 and 8 (CXCR1/2) were not detected on MSC, these G-protein coupled 
receptors have been documented on other cell types in TME. For example CXCL8 
can signal to CXCR1/2 present on endothelial cells and transactivate VEGFR2 to 
increase vascular permeability and tube formation [48].  Alternatively, CXCL1 can 
signal to CXCR2 expressing myeoloid derived suppressor cells (MDSCs) and 
neutrophils which are important for fighting infection but are also implicated in 
cancer [49]. In a study by Swarnali et al., CXCL1 produced by mammary tumours 
promoted CD11b+Gr1+ myeloid cell recruitment. Reciprocal signalling to breast 
cancer cells via myeloid cell derived S100A8/9 was linked to increased tumour 
growth and metastasis. Along this line, cell type specific labeling using amino acid 
precursors (CTAP) may be useful to investigate reciprocal signalling events 
between NODAL expressing cancer cell lines and stromal cell types [50]. In 
addition to our in vitro work, we also attempted to trace MSC recruitment to breast 
cancer xenografts in vivo. However, we experienced significant issues with MSC 
241 
 
 
 
lodging in the lungs following tail vein injections and/or extremely low MSC 
frequencies in mammary fat pad tumours following intraperitoneal injections (data 
not shown). Thus, mice transplanted with labelled bone marrow cells may be 
required to sufficiently determine the effects of NODAL on MSC recruitment in 
breast cancer xenografts. 
In summary, NODAL promotes tumour growth in vivo and its expression is 
associated  disease progression in many human cancers including melanoma, 
breast cancer and prostate cancer [51–53]. Our proteomics and in vitro findings 
reveal an additional, unknown layer of complexity for NODAL in regulating 
inflammatory factors and stromal cell recruitment in breast cancer. Consequently, 
future NODAL targeted therapies may block its intrinsic and extrinsic tumourigenic 
activities while sparing healthy, non-transformed tissues. A recent study by 
Hendrix et al. detected NODAL expression in melanoma lesions of deceased 
patients prior to, and following, treatment with BRAF inhibitors targeting V600E or 
V600K mutations [54]. This observation suggests NODAL expressing cancer cells 
do not respond or acquire resistance to conventional therapy. However, inhibiting 
BRAF with Dabrafenib in combination with an anti-NODAL mAb in vivo significantly 
reduces lung metastasis of the human melanoma cell line A375SM-L1, compared 
to either monotherapy alone [54]. Collectively, NODAL regulates multiple 
phenotypes associated with cellular plasticity in embryonic and malignant settings 
and therefore synergistic or complementary approaches targeting NODAL may 
improve outcomes for cancer patients. 
6.6 Summary 
The realm of proteomics is providing exciting opportunities for interrogating cancer 
biology. In this thesis, I employed and demonstrated the capacity of MS-based 
proteomics for elucidating proteins important for defining cancer subtypes, 
detecting disease using bio-fluids, and regulating intercellular communication and 
cellular behaviours within TME. Advances in proteomic technologies are beginning 
242 
 
 
 
to bridge the gap between the laboratory and clinical settings and identify 
specialized treatment modalities for targeting not only cancer cells but the TME as 
a whole. 
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